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Insulin induced hypoglycaemia is a significant cause of morbidity and mortality in people 
with diabetes, and commonly limits tight glycaemic control.  An additional challenge is 
the loss of the normal counterregulatory response to hypoglycaemia over time in many 
patients, which reduces their ability to sense and respond to hypoglycaemia and can 
result in more frequent/severe hypoglycaemia.  In addition, failure of the 
counterregulatory response is accelerated by recurrent hypoglycaemia.  The 
mechanisms underlying this phenomenon remain incompletely understood, but one 
contributor is reduction of sympatho-adrenal responses to hypoglycaemia, originating in 
the central nervous system. 
Novel techniques including the use of genetically modified mice now allow more 
detailed investigation of neuronal subtype connectivity and responses to 
hypoglycaemia.  This thesis uses a mouse expressing Cre recombinase under the control 
of the corticotrophin releasing hormone (CRH) promoter to investigate the role of CRH 
PVN neurons in more detail.  CRH neurons of the PVN are well placed to influence 
responses to hypoglycaemia, as they receive inputs from multiple central and peripheral 
centres providing information on glycaemic and overall metabolic state, and have 
outputs via the pituitary and (as shown in this thesis) the sympathetic outflow centres of 
the brainstem and spinal cord.  In addition, data shown here presents the first evidence 
that a subset of CRH PVN neurons are able to directly sense changes in local glucose 
levels in the PVN, becoming activated when glucose levels fall.  This represents a novel 
glucose sensing population of the CNS, which may have an important role to play in 
modulating the counterregulatory response to hypoglycaemia.  Finally, data is presented 
of a model of recurrent hypoglycaemia resulting in an expansion of this glucose sensing 
CRH PVN population, which could represent a means by which these cells contribute to 
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Chapter 1 Introduction 
This thesis explores the role of corticotrophin hormone releasing (CRH) neurons of the 
paraventricular nucleus (PVN) in the context of their role in generating compensatory 
responses to hypoglycaemia and connections to autonomic outflow areas of the central 
nervous system.  This chapter will set out the background underpinning the experiments 
carried out during this thesis.  In particular, the clinical context of the work will be 
addressed.  The physiology and pathophysiology of responses to hypoglycaemia will 
then be outlined.  An overview of the role of the PVN and CRH neurons in particular will 
be presented, and the evidence for a role for CRH neurons in responses to 
hypoglycaemia will be assessed.  An outline of some of the specific techniques employed 
in the thesis follows, focussing particularly on more recently developed experimental 
techniques including targeted genetic modifications.  Following this review of the 
literature, the overall hypotheses and aims for this thesis will be presented. 
1.1 Glycaemic control is essential for health 
Glucose is essential for mammalian life, as the main fuel for respiration to provide 
energy for cells, and is obtained both directly from dietary intake and also synthesised 
from protein and fat.  Storage of glucose as glycogen provides a rapidly released store of 
glucose in times of scarcity, and further synthesis from fat and protein can also be 
initiated.  In health, the body maintains glucose levels within tight limits, with blood 
levels maintained at 4-5.9mmol/L in the pre-prandial state and less than 7.8mmol/L two 
hours after a meal.  Glucose is an essential fuel for the body, and particularly the brain, 
which has a very limited capacity to utilise alternative sources of energy.  The major 
regulatory hormones are insulin and glucagon released from the pancreas, with the 
sensitivity of peripheral tissues to insulin also playing an important role.  Insufficient 
insulin release and/or insulin resistance leads to failure of glucose homeostasis 
(resulting in diabetes mellitus), causing significant morbidity and mortality in affected 
individuals.  
The incidence of both type 1 diabetes (T1DM) and type 2 diabetes (T2DM) is increasing 
worldwide (Mathers and Loncar, 2006, Patterson et al., 2009).  The prevalence of 




diabetes in the UK in 2016-17 was almost 3.7 million (DiabetesUK, 2017) and is 
projected to rise above 5 million by 2025.  Prevalence is increasing even more rapidly in 
low and middle income countries.  The World Health Organisation predicts that diabetes 
will be the seventh leading cause of death worldwide by 2030 (Mathers and Loncar, 
2006).  
1.2 Hypoglycaemia- a common and significant complication of insulin 
administration in diabetes mellitus   
Since the landmark discovery of insulin by Banting and Best (1922), huge steps have 
been made in improving the care of diabetic patients (Tibaldi, 2012).  However, although 
insulin is life preserving, iatrogenic hypoglycaemia due to insulin remains an unresolved 
and significant adverse effect for many patients. Morbidity and mortality arising from 
hypoglycaemia is significant.  A UK study of patients aged 20-49 with T1DM ascribed 
18% (170/949) of male and 6% (57/949) of female deaths to severe hypoglycaemia over 
a 25 year period (Laing et al., 1999).  It is a greatly feared complication for many 
patients, and frequently limits the degree of glycaemic control which can be achieved, 
leading to increased risks of long term diabetic complications.  Whilst T1DM patients 
have always been at significant risk, the increasing use of insulin in T2DM (as well as the 
oral hypoglycaemic drugs- sulphonylureas and glinides), means that larger numbers of 
these patients are also at risk.   
Hypoglycaemia can be divided into mild and severe episodes, where mild events can be 
self-treated by the patient, and severe events require assistance to resolve.  Estimates of 
the incidence and prevalence of hypoglycaemic episodes in the literature vary widely 
depending on the method of data collection, the definitions used and the duration of 
the study.  In general, an annual prevalence of 30–40% and an annual incidence of 1.0–
1.7 episodes per diabetic patient per year are often quoted for T1DM (Frier, 2009).  In a 
subsequent review, Frier (2014) summarised multiple studies between 1990 and 2014 
examining the incidence of severe hypoglycaemia.  The incidence of events ranged from 
0.2-3.2 episodes per patient per year, with between 3 and 46% of patients being 
affected.  For patients with T2DM, the incidence was 0.1-0.7 events per patient per 
years and 3-25% of patients were affected.  It is important to realise that hypoglycaemic 




episodes are not spread evenly across the whole population of patients with diabetes; 
the majority of events are experienced by a subset of patients (for example, 5% of 
patients experienced 54% of events (Pedersen-Bjergaard et al., 2004)).  Hence any 
estimate of whole population incidence and prevalence will underestimate the effect on 
the lives of the individuals who do experience hypoglycaemic episodes (and 
overestimate it in the whole population).  
The UK hypoglycaemia study group is of particular interest as it compared different 
subgroups of both T1DM and T2DM patients with respect to duration of treatment and 
treatment modality.  Unsurprisingly, T1DM of longer duration (>15 years compared to 
<5 years) was associated with increased prevalence of hypoglycaemic events (3.2 vs 1.1) 
and a greater proportion of patients were affected (46% vs 22%).  This also held true for 
T2DM, with patients on insulin >5years experiencing 0.7 severe hypoglycaemic events 
per patient per year with 25% of patients affected, compared to 0.2 and 7% for those on 
insulin for <2 years.  Interestingly, sulphonylureas were also shown to cause a number of 
severe hypoglycaemic events in this study (0.1 events per patient per year, affecting 7% 
of patients) (U.K.HypoglycaemiaStudyGroup, 2007).  
Collecting data on mild episodes is often less reliable as these are poorly recalled, and 
may not be recognised on every occasion on which they occur.  Mild episodes have been 
reported as occurring around 1-2 times per week in T1DM and 0.3-0.7 times per week in 
insulin treated T2DM (Frier, 2014).  Continuous glucose monitoring studies can give a 
more accurate indication of the overall frequency of hypoglycaemic episodes.  Studies 
have revealed a much higher occurrence rate for nocturnal hypoglycaemic episodes 
than was previously recognised (Allen and Frier, 2003).  Continuous glucose monitoring 
is also of value in patients who are unable to detect hypoglycaemic episodes 
(hypoglycaemia unawareness), both to gain accurate information about frequency of 
hypoglycaemic events and to assist in avoiding hypoglycaemia (Choudhary et al., 2013). 
1.2.1 Risk factors for hypoglycaemia 
Duration of insulin treatment is a key risk factor for hypoglycaemia as described above 
(U.K.HypoglycaemiaStudyGroup, 2007).  Other risk factors include 




• Greater stringency of control of blood sugars 
• Extremes of age, both young and old  
• Cognitive impairment (Feil and Pogach, 2014) 
• Previous episodes of hypoglycaemia 
• Renal impairment 
• Hypoglycaemia unawareness and autonomic failure 
• Absence of c-peptide indicating absolute loss of pancreatic insulin 
(Morales and Schneider, 2014, Frier, 2014) 
 
The increasing incidence of diabetes and exogenous insulin use worldwide is certainly 
leading to increasing issues related to hypoglycaemia and its consequences. 
 
1.2.2 Sequelae of hypoglycaemia 
1.2.2.1 Physiological 
The effects of hypoglycaemia can be divided into those directly arising from the low 
blood sugar (neuroglycopenic symptoms and signs), and those resulting from the 
physiological response to hypoglycaemia (autonomic).  Neuroglycopenic symptoms 
include cognitive impairment, confusion, drowsiness, odd behaviours, seizures and loss 
of consciousness.  Autonomic effects include sweating, palpitations, shaking and hunger. 
Cardiac events are of particular concern with regard to morbidity and mortality.  In 
particular arrhythmias associated with hypoglycaemic episodes have been linked to 
‘dead in bed’ syndrome (Tattersall and Gill, 1991).  The mechanisms underlying this are 
thought to include a reduction of plasma potassium levels secondary to increased 
epinephrine levels.  ECG changes associated with hypoglycaemia include prolonged QT 
interval, which predisposes to tachyarrythmias which may be fatal (Robinson et al., 
2003).  ST and T wave changes, and symptoms of cardiac ischaemia have also been 
associated with hypoglycaemia (Desouza et al., 2003).  Furthermore, autonomic 
activation will increase the likelihood of tachycardia and hypertension, reducing 
coronary perfusion, and this may lead to ischaemia, especially in the context of pre-
existing coronary artery disease. 




Coma associated with hypoglycaemia is thought to occur in up to 25% of severe 
hypoglycaemic episodes (Frier, 2014).  Seizures and coma are fortunately fully reversible 
if treated promptly, and are not believed to be associated with longer term sequelae.  A 
lesser degree of acute cognitive impairment during the hypoglycaemic episode is more 
common and insidious.  This effect has been extensively studied.  In general, patients 
appear to suffer from reduced speed at performing tasks before accuracy is lost (Warren 
and Frier, 2005).  Multitasking and complex decision making are amongst the earliest 
domains to be affected.  It is important to note that full return of cognitive function may 
be delayed by up to an hour and a half after restoration of normoglycaemia (Zammitt et 
al., 2008).  In addition, with increasing age, the gap between onset of warning symptoms 
and onset of cognitive impairment narrows, and this can significantly impact on the 
ability of an individual to recognise and self-treat the episode (Matyka et al., 1997).  
Links have been made between hypoglycaemia and longer term impairment of cognitive 
function in the very young (<5 years) and the very elderly (Asvold et al., 2010, Feinkohl 
et al., 2014).  Deliberate insulin overdose or very protracted hypoglycaemia can result in 
irreversible neurological damage and death at any age. 
Other neurological sequelae, including impairment of normal vision, balance, and 
coordination can lead to falls and injuries and other accidents.  Drivers experiencing 
hypoglycaemia are of particular concern (Inkster and Frier, 2013). 
1.2.2.2 Psychological 
Fear of hypoglycaemia is a common issue for patients and their relatives and can 
significantly impact their ability to achieve good glycaemic control (Wild et al., 2007).  
Patients experiencing hypoglycaemic episodes tend to report poor quality of life, greater 
anxiety about their condition and poorer general health (Lundkvist et al., 2005, Alvarez-
Guisasola et al., 2010).  Hypoglycaemic episodes can also have a direct adverse effect on 
mood (McCrimmon et al., 1999). 
1.3 The normal physiological response to hypoglycaemia 
The normal counter-regulatory response to hypoglycaemia involves ceasing insulin 
secretion, release of glucagon, autonomic activation and cortisol and growth hormone 
secretion all leading to the liberation of glucose from tissues (Figure 1.1).  There is no 




direct glucose detection system mediating conscious awareness of hypoglycaemia.  
Awareness of hypoglycaemia is dependent on autonomic activation and the symptoms 
caused by this, and promotes food seeking.  These compensatory systems involve a 
significant degree of redundancy, which is protective in the event of failure of any single 
part of the physiological response. 
It is important to note that hypoglycaemia is only very rarely seen in healthy individuals 
in the absence of therapeutic insulin use.  Insulinoma is probably the most common 
example which would be found spontaneously (incidence 4 per million per year (Service 
et al., 1991)).  Other candidates in a healthy individual include drugs, factitious 
disorders, extreme exercise and ketosis (Service, 1995).  The physiological systems 
responding to insulin induced hypoglycaemia have therefore evolved to respond to 
slower falls in glucose, for example in the context of fasting, extreme exercise, starvation 
and severe infection, and are not necessarily best suited to responding to rapid falls in 







Figure 1.1 The counterregulatory response to hypoglycaemia 
As discussed in the text, these is considerable redundancy in the system, with the final effects of falling insulin, rising glucagon, cortisol, growth hormone 
and epinephrine/norepinephrine all leading to liberation of glucose from the liver, gluconeogenesis in liver and kidney, and reduced uptake in peripheral 
tissues.  Sympathetic autonomic activation, both cholinergic and adrenergic, also contributes to these effects.  Food seeking is triggered by the SNS and 
epinephrine release, but not by other mechanisms illustrated here.  




Patients become aware of hypoglycaemia due to sympathetic/adrenal activation 
(adrenergic-tachycardia, tremor, anxiety; cholinergic-sweating, paraesthesia, hunger) 
and seek food to restore glucose levels (Cryer, 2005, Towler et al., 1993).  In a study on 
healthy human volunteers, autonomic blockade reduced the hypoglycaemic symptoms 
experienced by 70%, suggesting that the first signs of hypoglycaemia awareness are via 
this pathway (Towler et al., 1993).   Interestingly, bilateral adrenalectomy does not 
abolish hypoglycaemia awareness due to autonomic symptoms, suggesting that the 
main pathway is neural rather than due to circulating epinephrine and norepinephrine 
(DeRosa and Cryer, 2004).  In the absence of a response from the sympathetic nervous 
system and/or epinephrine release from the adrenal medulla, patients lose their early 
warning of hypoglycaemia, until neuroglycopenic symptoms commence.   
The triggering of the various counterregulatory responses occurs at differing degrees of 
severity of hypoglycaemia, as illustrated in table 1.1.  The glucose values quoted are not 
absolute, but context dependent and subject to being reset.  For example, a subject with 
very poor glycaemic control may reset the values quoted to higher levels (Boyle et al., 
1988), and very tight glycaemic control can lower the glucose level at which 
counterregulation occurs (Amiel et al., 1988).  




Table 1.1: Triggers to counterregulatory hormone release adapted from Cryer (1997a) 
Blood glucose 
(mmol/L) for a  
healthy volunteer 
Compensatory mechanism Effects 





Glucagon levels start to rise in 
response to PSNS activation 
and loss of inhibition by 
glucose 
Increased glucose production- 
hepatic and renal 
Reduced uptake of glucose by 
insulin sensitive tissues- 
muscle, fat 
 
3.6-3.8 Increased glucagon secretion 
Sympathetic nervous system 
activation 
Epinephrine/norepinephrine 
secretion (act within minutes) 
 
Cortisol and growth hormone 
secretion (act over hours) 
Glycogenolysis, 
Gluconeogenesis- hepatic and 
renal 
Reduced uptake of glucose in 
periphery- muscle, fat 
Alternative fuel generation- 
ketones, alanine, glutamine 
 
 
Conscious awareness of 
symptoms from sympathetic 
activation promotes food 
seeking 
3 Early neuroglycopenic 
symptoms 
Food seeking 
2.6 Impaired cognition  Impairs ability to self-treat 
  




1.4 Pathophysiology of hypoglycaemia associated autonomic failure 
(HAAF) 
Recurrent episodes of hypoglycaemia can cause failure of the counter-regulatory 
response, defined as hypoglycaemia associated autonomic failure (McCrimmon, 2009).  
The ability of a diabetic patient to respond to hypoglycaemia is already, by definition, 
impaired due to their (absolute or relative) lack of endogenous insulin.  If the amount of 
insulin (absolute or relative) in the body is low, then there will be no benefit in 
attempting to reduce levels (floor effect), which impairs counter-regulation from the 
very beginning.  Subsequently, there is an incremental loss of the ability to release 
glucagon from the pancreas, which typically develops within 5 years of commencing 
insulin treatment in TIDM (Mokan et al., 1994).  The underlying cause of the loss of 
glucagon release remains somewhat unclear, but is thought to be related to the loss of 
local insulin signalling from the beta cells of the pancreas which tonically inhibits 
glucagon release from the alpha cells in health (Banarer et al., 2002, Cryer, 2005).  This 
leaves patients dependent on the remaining counterregulatory hormones, especially 
epinephrine and norepinephrine from the sympatho-adrenal system.  However, the 
sympatho-adrenal response is also impaired in many diabetic patients, especially with 
longer durations of disease (Cryer, 1997a, Cryer, 2005).  The reduction or loss of the 
sympatho-adrenal response to hypoglycaemia is functional rather than absolute, and is 
not directly linked to autonomic neuropathy per se.  It appears that the plasma glucose 
level for sympatho-adrenal activation is context dependent, and prior episodes of 
hypoglycaemia can reset the threshold to lower levels of plasma glucose (Amiel et al., 
1988, Dagogo-Jack et al., 1993). 
In summary, the hormonal profile of a patient with fully developed HAAF will exhibit 
absent or reduced insulin, glucagon, cortisol, growth hormone, epinephrine and 
norepinephrine responses to hypoglycaemia.  Such patients, with impairment of all the 
major counterregulatory systems will have both an inability to liberate glucose 
effectively from peripheral stores, and in addition lack of triggering of warning 
symptoms which would otherwise promote food intake and resolution of 
hypoglycaemia.  HAAF therefore puts patients at risk of severe and unpredictable 
episodes of hypoglycaemia.  A vicious cycle of worsening hypoglycaemic events can arise 




(Cryer, 2005).  This effect can be at least partially reversed by relaxation of glycaemic 
control, but this comes at a cost in the long term related to the complications of 
hyperglycaemia (Cryer et al., 2003, Dagogo-Jack et al., 1994, Leelarathna et al., 2013) 
The concept of HAAF was initially developed from studies in healthy volunteers.  A very 
small number of hypoglycaemic episodes (just one in some cases) are required to 
recreate the hormonal profile seen in HAAF (Heller and Cryer, 1991, Davis and Shamoon, 
1991).  Further work has expanded and placed this work in a clinical context.  The 
finding that recent episodes of hypoglycaemia alter the glycaemic threshold at which 
autonomic activation occurs (such that a lower glucose level is required for activation), 
and in addition reduce the glucose level at which patients are symptomatically aware of 
hypoglycaemia, is supportive of this hypothesis (Amiel et al., 1988).  In addition, the 
previously mentioned phenomenon of resolution of HAAF with scrupulous avoidance of 
hypoglycaemia is highly persuasive (Cryer, 2005).  These effects all appear to occur via 
the restoration of the sympatho-adrenal system because the glucagon responses are not 
restored in studies in diabetic patients (Cryer, 2001). 
1.5 Glucose sensing in the peripheral and central nervous system 
In order to effect a response to hypoglycaemia, low glucose levels must first be 
detected.  As for the effector pathways, there is a redundancy in the sensing system, 
with both peripheral and central sensing of glucose occurring.  Peripheral sensors almost 
all convey information to the central nervous system to engage motor responses.  It is 
likely that the sensing systems developed for different reasons, and are triggered in 
differing ways. 
1.5.1 Role of the peripheral glucose sensors 
1.5.1.1 Pancreas 
In a healthy individual, the pancreas is a key glucose sensor, with the beta cell long 
identified as the classical KATP mediated glucose sensing cell (Figure 1.2), responding to 
rises in glucose with increased secretion of insulin and to decreases in glucose with a fall 
in insulin release (Ashcroft and Rorsman, 2004).  However, due to beta cell loss, this 




system is impaired in all forms of diabetes, and absent in fully developed T1DM and long 
standing T2DM. 
The alpha cells of the pancreas, which are responsible for glucagon release during 
hypoglycaemia, are also thought to exhibit intrinsic glucose sensing.  Glucose inhibition 
of glucagon release has been suggested to be mediated by voltage inactivation of 
calcium channels during membrane depolarisation due to KATP channel closure when 
glucose levels rise (Walker et al., 2011).  However, mechanisms which are not intrinsic to 
alpha cells are probably of greater importance, in particular, sympatho-adrenal 
activation of the alpha cells is important for glucagon release during hypoglycaemia.  
The paracrine inhibitory effect of insulin is also of key importance to the glucagon 
response to hypoglycaemia, and as stated previously, the glucagon response is lost over 
time in diabetes mellitus patients (Banarer et al., 2002).  





Figure 1.2 KATP  channel dependent glucose sensing in pancreatic beta cell 
Glucose enters via GLUT-2 and is metabolised to produce ATP.  Increased levels of ATP 
close KATP channels, depolarising the cell.  Depolarisation opens voltage gated calcium 





















1.5.1.2 Hepatic portal vein 
The portal vein glucose sensors are also important in the detection of hypoglycaemia.  
Extensive animal work has demonstrated that perfusion of the hepatic portal vein with 
glucose during whole animal hypoglycaemia significantly decreases epinephrine and 
norepinephrine responses (42-73% suppression of epinephrine, 42-67% suppression in 
norepinephrine reported (Hevener et al., 1997, Donovan and Watts, 2014)).  This effect 
is even more pronounced when the superior mesenteric vein is included with 
suppression of 91% of epinephrine response reported (Saberi et al., 2008).  The 
converse experiment- perfusion of this system with low glucose in a euglycaemic animal, 
is able to elevate epinephrine and norepinephrine levels (Lamarche et al., 1996).  
Detection of low glucose appears to require GLUT-2 transport (Burcelin et al., 2000).  
Experiments perfusing the system with lactate and pyruvate have demonstrated that, 
similarly to the pancreatic beta cell, metabolism of glucose is necessary for glucose 
sensing in the portal system (Matveyenko and Donovan, 2006).  Sodium-glucose co-
transporters have also been demonstrated to be involved in the signalling of satiety by 
the portal vein glucose sensors, and have been suggested to be important for detection 
of small changes in glucose levels (<1mM) (Delaere et al., 2012).  SGLTs have not so far 
been investigated for a role in detection of hypoglycaemia.  The rate of fall of glucose 
has been shown to be of importance for portal glucose sensing.  In rats with ablation of 
the portal mesenteric sensors there was no response to a slow fall in glucose, whilst 
responses to a rapid fall were preserved (Saberi et al., 2008).  
The signalling pathway for hypoglycaemia from portal and mesenteric veins appears to 
be via spinal afferents, and not via the vagus nerve as originally thought (Fujita and 
Donovan, 2005, Fujita et al., 2007, Barja and Mathison, 1984).  The spinal afferents pass 
via the coeliac/superior mesenteric ganglia to the lower thoracic spinal cord (Barja and 
Mathison, 1984).  Signals are transmitted to the central nervous system via the nucleus 
of the solitary tract (Adachi et al., 1984) to the lateral hypothalamic area (Shimizu et al., 
1983). Vagal signalling does appear to play a role in glucose sensing from the hepatic 
portal vein, but it appears to be involved in signalling rises in glucose (Niijima, 1989). 




1.5.1.3 Carotid body glucose sensors 
The carotid body has been suggested as a potential further site of peripheral glucose 
sensing.  Studies in vitro in carotid body slices or cultured cells appear to demonstrate 
responses to low glucose (Nurse, 2005).  However, work in a whole carotid body 
preparation could not replicate this, and it has been suggested that low glucose in fact 
sensitises the response of the carotid body to CO2 (Bin-Jaliah et al., 2004).  In vivo 
studies have also proved inconclusive thus far and the role of the carotid body remains 
unclear. 
1.5.2 Role of the central glucose sensors 
The concept of the brain sensing glucose was first put forward in the 1950s (Mayer, 
1955).  Early work to establish the importance of the CNS in sensing glucose involved 
perfusion of the whole brain with glucose in a hypoglycaemic whole animal preparation.  
The counterregulatory response was decreased under these conditions (Biggers et al., 
1989).  Further infusion or microdialysis experiments targeting specific brain regions 
were also able to show effects on the whole animal response to hypoglycaemia, for 
example the infusion of 2-deoxyglucose to the ventromedial nucleus (VMN), which 
mimics hypoglycaemia, caused activation of the counterregulatory response (Borg et al., 
1995).  In contrast, application of glucose to the same area in a hypoglycaemic animal 
blunted counterregulation (Borg et al., 1997). 
When considering central glucose sensing, the importance of the blood brain barrier 
must be taken into account.  The microvasculature of the central nervous system is a 
significant barrier to almost all molecules which would otherwise freely pass between 
the blood and brain interstitium.  The blood brain barrier is protective as it prevents 
exposure of the brain to potential toxins, cytokines, drugs and infectious agents and in 
addition aids the maintenance of a more stable interstitial milieu compared to that of 
blood.  The structure of the endothelial cells of brain capillaries, with their tight 
junctions and additional contributions from pericytes, astrocytes and the basement 
membrane all create a barrier to free movement of the vast majority of molecules which 
would otherwise freely diffuse (Abbott et al., 2010).  The only molecules which pass 
freely by diffusion are small gaseous molecule (oxygen, carbon dioxide), and small 
lipophilic molecules which are not transported back into the blood by active transport 




(examples include caffeine and ethanol).  All other molecules, including water, ions and 
nutrients are transported or conducted via specific proteins and channels.  The major 
glucose transporter across the blood brain barrier is GLUT-1, with SGLT-1 also playing a 
role on the interstitial side of the endothelial cells (Patching, 2017).  Therefore most 
glucose is moved by facilitated diffusion down its concentration gradient (via GLUT1) 
with a small contribution from secondary active transport (SGLT1).  The glucose levels 
experienced by the majority of CNS cells is lower than those observed in the periphery, 
and subject to smaller variations when glucose in the blood increases or decreases 
(Silver and Erecinska, 1994b). 
In general, it is thought that most CNS glucose sensors must be able to sense changes in 
glucose levels which are observed in the CNS interstitium.  However, there are a few 
‘privileged’ areas of the brain in which the blood brain barrier is deficient.  In these 
regions, neurons may be exposed to blood glucose levels and so respond to a wider 
range of levels of glucose.  Such areas include the area postrema, the subfornical organ, 
and the median eminence.  In addition, some cells within the CNS are directly apposed 
to the ventricles, and therefore can respond to CSF glucose levels in a similar fashion.  
An example would be the tanycytes of the third ventricle (Frayling et al., 2011). 
Central glucose sensors are likely to be important for several different functions.  The 
brain is largely reliant on glucose as a metabolic fuel with a respiratory quotient very 
close to 1.0, and thus accounts for a large proportion of whole body glucose 
consumption (Cryer, 1997b).  In a fasted individual at rest, the brain uses around 60% of 
the total glucose consumed (Wasserman, 2009).  The ability of the brain to use fuels 
other than glucose is extremely limited.  Therefore it is likely that central glucose sensing 
is designed to act in a protective fashion for the brain to preserve its glucose supply.  In 
addition, the central nervous system plays an important role in many aspects of the 
counterregulatory response to hypoglycaemia as previously outlined in section 1.3.  
Finally, information about the overall metabolic status of the body is of importance in 
the longer term for a wide range of physiological functions, for example fertility (GnRH), 
thyroid function and circadian rhythms (Burdakov et al., 2005b). 





The hypothalamus was the first CNS area to be identified to contain glucose sensing cells 
(Oomura et al., 1969).  These neurons exhibited distinct responses to increases in 
glucose levels e.g. glucose-excited neurons increase their firing rate, while glucose 
inhibited neurons are silenced.  Glucose-sensing neurons have subsequently been 
identified in multiple distinct regions of the hypothalamus, including the arcuate and 
ventromedial nuclei (Kang et al., 2006, Kang et al., 2004), paraventricular hypothalamus 
(Melnick et al., 2011) and lateral hypothalamic area (Marston et al., 2011).  A degree of 
heterogeneity in what is defined as a glucose sensitive neuron exists, with criteria  for 
identification including changes in resting potential, action potential frequency, input 
resistance, calcium levels and combinations of these factors.  The glucose 
concentrations used also vary considerably between studies.  In some cases, the 
response observed appears to follow a dose response curve (Wang et al., 2004), in other 
cases only a binary response is reported (Melnick et al., 2011).  Plasticity has been 
reported in neuronal responses to glucose with changing environment, e.g. lowered 
glucose thresholds with recurrent hypoglycaemia in VMN (Song and Routh, 2006). 
The mechanisms underlying glucose sensing in the CNS are the subject of much interest.  
Parallels have been drawn between the pancreatic beta cell and glucose excited neurons 
(Ashford et al., 1990a, Ashford et al., 1990b).  The mechanisms underlying activation of 
some glucose inhibited neurons have been suggested to involve AMPK, cGMP, and 
chloride channels (Kang et al., 2004, Murphy et al., 2009a).  However, the genetic and 
molecular mechanisms determining the characteristics of the neuronal glucose-response 
phenotype remain incompletely understood despite extensive investigations.  Further 
discussion of specific glucose sensing mechanisms and neuronal subtypes will be 
addressed in Chapter 4, section 4.1.1 and 4.1.4 and Chapter 5, section 5.1. 
1.5.2.2 Hindbrain 
The hindbrain is the other major area which has been identified in the CNS as being 
important in sensing and responding to hypoglycaemia.  Early work established that the 
hindbrain can to some extent operate independently of the mid- and fore-brain, by 
demonstrating that a decerebrate rat preparation, which also removed the 
hypothalamus, can still mount an effective counterregulatory response to 




hypoglycaemia (DiRocco and Grill, 1979).  In addition, work by Ritter and colleagues, 
which involved microdialysis of multiple hypothalamic and hindbrain sites with 5-
thioglucose (which mimics hypoglycaemia in a similar fashion to 2-deoxyglucose), 
showed that hindbrain but not hypothalamic applications were effective in increasing 
glucose levels and eliciting feeding behaviours (Ritter et al., 2000). 
Glucose sensing neurons have been identified in the area postrema (Funahashi and 
Adachi, 1993), dorsal motor nucleus of the vagus (Kobashi and Adachi, 1995, Balfour et 
al., 2006), nucleus of the solitary tract (Balfour et al., 2006, Mimee and Ferguson, 2015) 
and lateral parabrachial nucleus (Flak et al., 2014, Garfield et al., 2014).  The precise role 
of each of these areas is not well understood.  However, recent work on the glucose 
sensitive neurons of the lateral parabrachial nucleus suggests that activation of a subset 
of these cells, which express cholecystokinin, can cause activation of the 
counterregulatory response (Garfield et al., 2014).  The rostral ventrolateral medulla 
(RVLM) has also been shown to play a role in activating the counterregulatory response 
(Ritter et al., 2001, Madden et al., 2006). 
1.5.2.3 Non neuronal cells as glucose sensors 
It is increasingly appreciated that the glial cells, astrocytes and other ‘support’ cells of 
the central nervous system also have important signalling roles to play (Araque et al., 
2001).  One clear example of this is the restoration of glucagon responses to 
hypoglycaemia in global GLUT-2 knock out mice which have had GLUT-2 re-expressed 
only in astrocytes (Marty et al., 2005).  The proposed mechanism involves metabolic 
coupling between these astrocytes and neurons in the NTS/DMX leading to restoration 
of the ability to sense hypoglycaemia in these regions and alter the autonomic outflow 
from NTS/DMX to the alpha cells of the pancreas.  Both astrocytes and tanycytes have 
been shown to express many of the key proteins implicated in glucose sensing, including 
GLUT-2, glucokinase, KATP channels and the sodium glucose co-transporter type 1 
(Steinbusch et al., 2015, Leloup et al., 2016).  Glucose sensing also has been 
demonstrated in tanycytes surrounding the third ventricle (Frayling et al., 2011) and in 
some astrocyte populations (Lee et al., 2016, McDougal et al., 2013).  Tanycytes 
represent an interesting population as they are situated in close apposition to the 
ventricular surface, and therefore access the CSF glucose levels, as opposed to that of 




the extracellular fluid.  These cells also have processes that extend into hypothalamic 
areas, creating potential anatomical sites for communication with neurons (Elizondo-
Vega et al., 2015).  The sweet taste receptor has recently been implicated in tanycyte 
glucose sensing (Benford et al., 2017). 
Potential mechanisms by which tanycytes could communicate with neurons include ATP 
release to act on P2Y receptors (Frayling et al., 2011) and lactate, which can be taken up 
by neurons using monocarboxylate transporter 2 (Elizondo-Vega et al., 2015, 
Weightman Potter et al., 2018).  The lactate shuttle hypothesis, which suggests that 
astrocytes supply lactate to neurons, both as a fuel and as a means of signalling energy 
status, is a long established theory for astrocytic signalling (Pellerin and Magistretti, 
1994).  In addition, other peptides, for example the endozapines have also been 
suggested as signalling molecules mediating glucose signalling between astrocytes and 
neurons (Tonon et al., 2013). 
1.6 Putative mechanisms underlying HAAF 
1.6.1 Loss of hypoglycaemia awareness 
As discussed in section 1.3, awareness of hypoglycaemia appears to derive largely from 
neurogenic symptoms secondary to cholinergic and adrenergic signalling by the SNS.  
The evidence for this comes from studies in healthy volunteers.  The early symptoms of 
hypoglycaemia were all suggestive of SNS activation (Towler et al., 1993).  Adrenergic 
blockade alone using phentolamine and propranolol did not alter symptoms.  Pan-
autonomic blockade using phentolamine, propranolol and atropine reduced the 
hypoglycaemic symptoms experienced by 70% (Towler et al., 1993).  The remaining 
hypoglycaemic symptoms may, therefore, be due to neuroglycopenia, but could also be 
residual SNS symptoms due to incomplete blockade.  In a further study, evidence that 
the main pathway is due to activation of the sympathetic nervous system rather than 
due to circulating epinephrine and norepinephrine is presented, as patients with prior 
bilateral adrenalectomy can still demonstrate hypoglycaemia awareness due to 
neurogenic symptoms (DeRosa and Cryer, 2004). 




1.6.2 Reduced counterregulatory response to hypoglycaemia 
The reasons underlying loss of the insulin and glucagon responses to hypoglycaemia 
have already been covered in section 1.4.  The mechanisms which underlie the failure of 
the sympatho-adrenal, cortisol and growth hormone response are much less well 
understood.  Whilst a range of mechanisms have been proposed, no single hypothesis 
has yet emerged with compelling evidence. 
1.6.2.1 CNS versus peripheral mechanisms 
Given that the effector response is mediated by the CNS for both the sympatho-adrenal 
and cortisol responses to HAAF, it is clear that the CNS must play some role in failure of 
these aspects of the counterregulatory response.  However, it is possible that the main 
point of failure could be downstream of these effectors.  Interest has focused on the 
possible role of the adrenal medulla, with reports of reduced epinephrine stores (De 
Galan et al., 2004), and reduced levels of mRNA for key enzymes involved in epinephrine 
synthesis (tyrosine hydroxylase and phenylethanolamine N -methyltransferase (Inouye 
et al., 2005)) after hypoglycaemia, which could result in the observed reduction in 
epinephrine release.  However, it is also entirely possible that all of these effects could 
be due to reduced activation of the adrenal medulla per se, rather than the cause of the 
observed effects.  This hypothesis cannot explain the observed reductions in 
sympathetic neural activation or cortisol levels.  Overall, it seems more likely that a 
change within the CNS is responsible for the change in thresholds observed during 
failure of sympatho-adrenal and cortisol counterregulatory responses. 
1.6.2.2 Systemic cortisol elevations as potential causative agents in HAAF 
A further hypothesis that has been advanced is that the rise in systemic cortisol which is 
observed during hypoglycaemia drives the subsequent development of HAAF.  This is 
based upon the finding that cortisol infusion or stimulation of endogenous cortisol with 
infused ACTH can reduce the sympatho-adrenal response to subsequent hypoglycaemia 
(Davis et al., 1996).  Infusion of a1-24ACTH to stimulate a cortisol rise has a similar effect 
(McGregor et al., 2002).  In addition, patients with primary adrenocortical failure do not 
appear to develop HAAF (Davis et al., 1997). 




However, the levels of cortisol which were required to cause the observed effects have 
been called into question as being rather higher than observed during cortisol rises due 
to hypoglycaemia (32-45µg/dL (cortisol or ACTH infusion) versus 26µg/dL 
(hypoglycaemia)).  When healthy volunteers received cortisol infusions designed to 
reproduce levels comparable to those measured during hypoglycaemia, there was no 
effect on the sympatho-adrenal response to subsequent hypoglycaemia (Raju et al., 
2003).  However, this study actually infused cortisol at rather higher levels than 
originally planned, achieving peak concentrations of ~31 and ~34µg/dL in 2 sets of 
infusions, and in many ways is therefore comparable to Davis et al. (1996) where the 
peak plasma concentration of cortisol was 33µg/dL.  There were differences between 
studies with regard to the rapidity of infusion of cortisol and indeed the speed at which 
hypoglycaemia was induced (both more rapid in the Davis study), which might 
contribute to the observed differences.  
Further evidence that contradicts this hypothesis relates to sleep and hypoglycaemia.  It 
is recognised that hypoglycaemia during sleep contributes to development of HAAF, and 
it is also known that cortisol responses to hypoglycaemia in sleep are blunted (Cryer, 
2005, Cryer, 2004). 
1.6.2.3 Increased endogenous beta endorphins 
Beta endorphins are known to be released in response to stressful stimuli (Nakao et al., 
1979).  Investigations in both healthy volunteers (Caprio et al., 1991, Vele et al., 2011) 
and patients with type 1 diabetes (Caprio et al., 1991, Leu et al., 2009) have shown 
amelioration of HAAF following delivery of naloxone (opioid antagonist) during a prior 
episode of hypoglycaemia.  This suggests that the development of some components of 
HAAF could be mediated by an opioid related mechanism.  However, a study using 
naltrexone (a longer acting, orally delivered opioid antagonist) alongside an initial  
episode of hypoglycaemia caused only a modest increase in epinephrine response to 
subsequent hypoglycaemia and no effect on other hormones (Naik et al., 2017).  Work 
by Carey and colleagues (2017) examined the effect of an infusion of morphine (or saline 
control) on day 1 on the response to a stepped hypoglycaemic clamp on day 2.  They 
report a 30% reduction in the epinephrine response to hypoglycaemia after morphine 
compared to a saline infusion, and a reduction in hypoglycaemia symptoms score.  There 




was no difference in the glucagon or norepinephrine response between the 2 groups in 
this study.  Taken together, these data are suggestive of a contributory role of opioids in 
the development of HAAF. 
It is not clear from these studies whether opioids acting centrally or peripherally are 
responsible for the observed effects, or what the underlying mechanism might be.  
Peripherally, the adrenal medulla secretes beta endorphin as well as 
epinephrine/norepinephrine (Cheng et al., 2001).  Infusion of beta endorphin in 
streptozotocin induced diabetic rats has been shown to directly increase peripheral 
glucose uptake and reduce hepatic gluconeogenesis, which would exacerbate 
hypoglycaemia (Cheng et al., 2002).  A negative feedback action of beta endorphin to 
reduce epinephrine release from the adrenal medulla has also been proposed 
(Dermitzaki et al., 2001).  However, there was no change in beta endorphin levels during 
naloxone infusion in the studies above, which does not support a negative feedback role 
(Leu et al., 2009, Vele et al., 2011, McCrimmon, 2011).  In addition, morphine infusion 
had no direct effect on glucose levels and effects were only observed during subsequent 
hypoglycaemia (Carey et al., 2017). 
With regard to the CNS, naloxone and morphine both readily cross the blood brain 
barrier.  Opioid receptors have been reported to be expressed widely in both the 
hindbrain and hypothalamus (Zhang et al., 1996, Zheng et al., 2005, Mansour et al., 
1994).  Neurons in the VMN are inhibited by opioids (Zhang et al., 1996). In addition, 
Suda and colleagues report a reduction in CRH mRNA expression and ACTH secretion in 
response to hypoglycaemia, when beta endorphin is delivered i.c.v (Suda et al., 1992).  
Further studies are needed to better identify potential mechanisms by which opioids 
could act centrally at these and other sites in the context of HAAF. 
1.6.2.4 Increased availability of glucose or alternative fuels in the brain 
A further alternative hypothesis is that prior episodes of hypoglycaemia alter glucose 
uptake to the central nervous system, making transport more efficient and/or increasing 
glycogen stores.  This would improve the glucose supply to the brain, which would 
improve energy supplies in the face of future hypoglycaemia, but would also reduce the 
threshold for sympatho-adrenal activation.  It is known that long term hypoglycaemia in 




rats (days rather than hours) results in increased GLUT-1 (glucose transporter) 
expression in cells of the blood-brain barrier (Kumagai et al., 1995).  Preserved glucose 
uptake to the brain in the face of prolonged, between meal, hypoglycaemia has been 
reported in healthy volunteers and type 1 diabetics (Boyle et al., 1995, Boyle et al., 
1994).  In these studies, whole brain glucose uptake was calculated from the 
arteriovenous difference across the brain and cerebral blood flow using the Ketty 
Schmidt method.  However, this evidence does not appear to translate to the acute 
episodes of hypoglycaemia experienced in diabetic patients.  Glucose uptake imaging 
studies using radiolabelled PET and acute hypoglycaemia have not so far proven 
supportive of this theory, at least when global uptake of glucose is examined (Segel et 
al., 2001, de Vries et al., 2003).  It is possible that regional changes in glucose uptake 
could still play a role, but this has not yet been shown. 
Alternative fuels for the brain include lactate and acetate (De Feyter et al., 2013, Mason 
et al., 2006).  The concept of the astrocyte-neuron lactate shuttle has been described 
(Pellerin and Magistretti, 2012), with metabolism of glucose to lactate taking place in 
astrocytes, which then make lactate available to neurons for ongoing metabolism.  
Boumezbeur and colleagues (2010) showed that approximately 10% of the brain’s 
metabolic needs could be provided by lactate.  Infusion of lactate was observed to cause 
attenuation of counterregulatory responses and hypoglycaemic awareness in healthy 
volunteers and patients with type 1 diabetes (Veneman et al., 1994, Maran et al., 2000).  
A period of exercise to increase lactate levels followed by a hypoglycaemic clamp 
resulted in increased lactate uptake and oxidation by the brain in type 1 diabetic 
patients with impaired hypoglycaemia awareness when compared to healthy controls 
and patients with type 1 diabetes who did not have impaired hypoglycaemia awareness 
(Wiegers et al., 2017).  In an earlier study on patients with type 1 diabetes, De Feyter et 
al. (2013) found that lactate uptake was increased during hypoglycaemia 5-fold in 
subjects with type 1 diabetes compared to control subjects, but without increased 
oxidation.  It is thought that increased use of lactate as a fuel source for the brain can be 
protective in hypoglycaemic conditions, but can also impair the ability of the brain to 
sense and respond to hypoglycaemia. 




Glycogen stores have been shown to increase in the CNS following hypoglycaemia, and 
‘glycogen supercompensation’ has been suggested as a further mediator of reduced 
counterregulation and delayed detection of hypoglycaemia.  Astrocytes are the main 
source of glycogen within the brain (Brown, 2004), and it is thought that metabolism to 
lactate within astrocytes may provide fuel to neurons when glucose levels fall.  Choi et al 
(2003) induced hypoglycaemia in anaesthetised rats and measured brain glycogen 
levels.  They showed that glycogen fell during hypoglycaemia, but during the recovery 
phase glycogen levels were higher than those measured prior to the hypoglycaemic 
event, i.e supercompensation.  Suh et al. (2007) showed that increased levels of 
glycogen in astrocytes of rats resulted in increased neuronal survival following 
hypoglycaemia.  Therefore, increased availability of glycogen due to supercompensation 
after hypoglycaemia could contribute to HAAF.  However, the total available glycogen 
store in the CNS is still very small compared to liver or muscle, and increased glycogen 
levels return to baseline well before resolution of HAAF is observed (Herzog et al., 2008). 
1.6.2.5 Changes in metabolism/glucose sensing within the CNS 
The overall concept is that alterations in the ability of small groups of glucose sensitive 
neurons to sense and respond to hypoglycaemia could contribute to failure of the 
sympatho-adrenal and other counterregulatory responses.  Table 1.2 summarises some 
of the potential contributors.  Multiple mechanisms are likely to contribute to this 
system.  This is a broad topic, and there is limited evidence for any single mechanism 
operating in isolation.  Much of the work has focused on the ventromedial nucleus of 
the hypothalamus (VMN), but it is clear that this is not the only region of the CNS which 
contributes to the counterregulatory response.  Other regions which have been 
implicated in counter-regulation, and could showed altered responsiveness contributing 
to HAAF include the parabrachial nucleus, lateral hypothalamus, paraventricular 
nucleus, arcuate nucleus, and indeed the portal and mesenteric vein glucose sensors 
(Beall et al., 2012a, Cryer, 2005)  




Table 1.2 Putative mechanisms causing changes in metabolism/glucose sensing in the 
CNS 
Mechanism References 
Globally in CNS 
Reduced insulin signalling 
Increased GABA release 
Increased circulating CRH levels  
 
(Fisher SJ, 2005) 
(Klement et al., 2014)  
(Flanagan et al., 2003) 
VMN 
Increased glucokinase activity 
Reduced AMPK activity 
KATP channel closure 
  
Urocortin release  
 
 
(Dunn-Meynell et al., 2002, Routh, 2003) 
(McCrimmon et al., 2004)  
(Evans et al., 2004, McCrimmon et al., 2005, 
McCrimmon et al., 2004) 
((McCrimmon et al., 2006, McCrimmon RJ, 
2005))  
PVN 
Reduced PVN activation 
 
(Sanders and Ritter, 2000, Evans et al., 2001, 
Evans et al., 2003) 
VNM ventromedial nucleus, KATP ATP sensitive potassium channel  
  




1.7 The hypothalamus as a key player in the integration of glycaemic 
control 
Significant elements of the response to hypoglycaemia are mediated via the central 
nervous system, (CNS), which integrates peripheral and central information about 
physiological state (Beall et al., 2012a).  Indeed, the first clues that the brain is important 
for whole body glucose levels were presented over 160 years ago, when Bernard 
stimulated the floor of the 4th ventricle and observed a rise in blood glucose (Bernard 
and Tripier, 1858).  As discussed in the review by Watts and Donovan (2010), the 
classical view of a sensory, integrative and output system can be applied to the glucose 
homeostatic system, but is a significant simplification of the actual process.  Any one 
anatomical region may exhibit overlapping functions- for example the lateral 
hypothalamus receives inputs from peripheral glucose sensors, contains directly glucose 
sensing cells, has outflow to autonomic areas of the brainstem and also contains 
gonadotrophin releasing hormone (GnRH) neurons which release GnRH into the 
pituitary portal circulation and alter their output depending on metabolic context. 
Multiple nuclei of the hypothalamus have been identified as playing a role in the 
response to hypoglycaemia.  Figure 1.3 summarises the major connections and roles 
ascribed to various hypothalamic nuclei in this context.  Glucose sensing populations 
within the hypothalamus include the arcuate, VMN, LH and possibly the PVN as 
previously mentioned in section 1.6.2.5.  In addition to the ability of these nuclei to 
respond to changes in glucose, their response can also be modulated by sensing and 
responding to other signals indicating the overall status of the body, with examples 
including insulin, ghrelin, leptin, free fatty acids, oestrogen and androgens and 
angiotensin (Canabal et al., 2007b, Jordan et al., 2010, Santiago et al., 2016, Roland and 
Moenter, 2011).  





Figure 1.3 Elements of the hypothalamic network sensing and responding to glucose.  
Adapted from Watts and Donovan (2010) 
Several nuclei have more than one function.  The PVN also has a role in activation of the 
hypothalamo-pituitary axis leading to glucocorticoid rises. 
LH Lateral hypothalamic area, ARC Arcuate nucleus, VMN Ventromedial nucleus, DMN 


















However, much of what we know is incomplete.  A major challenge is that in many 
cases, neuronal subtyping within the hypothalamus does not readily identify populations 
with single functions.  For example, consider the pro-opiomelanocortin (POMC) and 
agouti related peptide/neuropeptide Y (AgRP/NPY) neurons within the arcuate nucleus, 
one of the better characterised areas of the hypothalamus.  The generally accepted 
roles of these neurons are related to control of food intake and energy expenditure, 
with AgRP/NPY neurons being activated when food/energy stores are less available, 
promoting food seeking and reducing energy expenditure via projections to the PVN, 
whilst POMC neurons are activated when energy stores and food are abundant, 
opposing these effects.  However, some NPY neurons in the ARC have been shown to be 
inhibited by glucose, but by no means all (Murphy et al., 2009b).  In addition, not all 
POMC neurons project to the PVN, which is thought to be their main site of action to 
mediate food intake and energy expenditure (King and Hentges, 2011). 
The hypothalamus contains a wide range of specialised cell types, often spatially 
intermingled, and their anatomical location and connectivity is not precisely conserved 
between species.  In addition, much previous work has relied on immunohistochemistry 
to identify neuronal subtypes and try to connect structure and function.  Technical 
advances over the last 10-15 years have greatly increased the ability to dissect out 
different subsets of neurons in vitro and in vivo and this has improved the 
understanding of this complex anatomical area.   
1.8 The paraventricular nucleus- more than just an effector nucleus 
The PVN is situated dorsally within the medial hypothalamus, on either side of the third 
ventricle.  It is best known for its role at the apex of the hypothalamo-pituitary axis, with 
large numbers of neurons projecting to both the anterior and posterior pituitary 
originating here.  It is an area with multiple roles, including regulation of stress 
responses, body temperature, circadian rhythms, food intake and energy expenditure.  
Historically the PVN was largely thought to be an output (effector) nucleus, responsible 
for enacting motor responses subsequent to integration of signals in other areas of the 
brain. 




With regard to its outflow, the classical pathway from the PVN is to the median 
eminence, with major projections to both posterior and anterior pituitary.  The PVN also 
has a significant outflow to autonomic areas of the brainstem, and also receives 
significant inputs from multiple brainstem areas.  This reciprocal innervation places it in 
a key position with regard to coordination of autonomic and hypophyseal outflow 
(Hosoya et al., 1991, Geerling et al., 2010, Sawchenko and Swanson, 1985, Saper et al., 
1976).  The output effects of the different divisions of the PVN are summarised in Figure 
1.4.  The classical view of the PVN was that its functions were compartmentalised, in 
particular by neuronal subtype, and that there was relatively little cross talk between 







Figure 1.4 Schematic to illustrate the major outputs of the PVN 
TH Thyrotropin releasing hormone, CRH corticotropin releasing hormone, TRH thyroid releasing hormone, ACTH adrenocorticotrophin releasing hormone, 




Release of neurotransmitters into 
portal circulation at median 
eminence
Neurotransmitters trigger release
from anterior pituitary 
TRH ACTH Inhibits GH
Magnocellular
Pre-autonomic
Hormones released directly from terminals in
posterior pituitary
Wide variety of signalling 
peptides, projecting to 










1.8.1 Neuronal subtypes in the PVN 
The PVN contains specialised neuronal subtypes (Figure 1.4).  Broadly, neurons can be 
classified as magnocellular or parvocellular, based on their morphology and projection 
patterns.  Magnocellular neurons are larger, contain oxytocin or vasopressin, and 
project to the posterior pituitary where they release these hormones directly into the 
circulation to act peripherally.  Parvocellular neurons are smaller, contain CRH, 
thyrothropin releasing hormone or somatostatin, and project to the median eminence 
where they release peptides into the hypophyseal portal circulation, causing release of 
downstream hormones (ACTH, TRH) from the anterior pituitary gland into the 
bloodstream.  While this partitioned cell class model has stood the test of time there is 
evidence for a degree of overlap between cell types and co-expression of signalling 
molecules in some cases.  Perhaps the clearest example of this is the co-release of 
vasopressin and CRH from parvocellular CRH neurons after acute stressful stimuli 
(Swanson et al., 1986, Sawchenko and Swanson, 1985). 
 A third group of pre-autonomic neurons has also been identified within the PVN.  These 
were initially identified by neuronal tracing studies, demonstrating 1) that not all PVN 
neurons project to the median eminence (Simmons and Swanson, 2009, Swanson et al., 
1983, Sawchenko and Swanson, 1982), and 2) that retrograde tracing from the 
brainstem identifies a subgroup of neurons situated caudally in the PVN (Geerling et al., 
2010, Biag et al., 2012).  In addition, pre-autonomic neurons exhibit a characteristic 
electrophysiological profile, at least in rat studies (Luther et al., 2002, Tasker and Dudek, 
1991).  Pre-autonomic neurons identified by neuronal tracing studies express a wide 
range of neurotransmitters including oxytocin, vasopressin, 5HT, dopamine, TRH, CRH 
and enkephalins, as well as glutamate (Sawchenko and Swanson, 1982, Biag et al., 2012, 
Simmons and Swanson, 2009, Zhao et al., 2017).  With regard to GABA, one paper used 
retrograde tracing, either with fluorogold from the thoracic spinal cord, or GFP tagged 
herpes simplex virus from the adrenal medulla, with additional GABA 
immunohistochemistry, but was unable to show any evidence of GABA expression in 
pre-autonomic PVN neurons (Watkins et al., 2009). 
In the rat, neuronal subtypes are clearly anatomically delineated on the basis of their 
size, morphology and peptide expression, and up to 10 subdivisions of the rat PVN have 





been described (Simmons and Swanson, 2009).  However, this is not the case in the 
mouse, where a much higher degree of intermingling of neuronal subtypes occurs (Biag 
et al., 2012).  The human PVN appears to exhibit a degree of homology with the rat PVN, 
albeit with a smaller number of subdivisions being identified (Koutcherov et al., 2000).  
The overall topography of the human PVN is also somewhat different to that in rodents, 
largely due to the fornix which compresses the anterior PVN into a more vertical 
structure, with a significant caudal extension behind the fornix. 
1.8.2 Overall connectivity of the PVN 
The PVN receives inputs from a very wide range of structures, both local and distant.  
From within the hypothalamus, significant inputs are received from the VMN, ARC, LH, 
DMN and preoptic area (Larsen et al., 1994).  Projections are also received from 
brainstem nuclei; from the NTS (in particular the C2/A2 catecholaminergic group), the 
ventral medulla, as well as the parabrachial nucleus, the periaqueductal grey and the 
raphe nuclei (Cunningham and Sawchenko, 1988, Sawchenko et al., 1983, Krukoff et al., 
1993, Floyd et al., 1996).  In addition, the lamina terminalis group of nuclei, which lies 
outside the blood brain barrier, has significant connections to the PVN, including from 
the subfornical organ, the median pre-optic nucleus and the vascular organ of the 
lamina terminalis (Sawchenko and Swanson, 1983).  The forebrain, notably the 
hippocampus, prefrontal cortex and amygdala also provide some inputs to the PVN, but 
these are largely indirect, via the bed nucleus of the stria terminalis or the brainstem 
(Sawchenko and Swanson, 1983). 
Traditionally, the roles of different areas of the PVN were thought to be segregated, and 
this was partly due to the very clear sub-divisions of the PVN observed in the rat.  
However, it is increasingly clear that this view of the PVN should be modified, with more 
recent work expanding the concept of its role to include the collation of multiple inputs 
and balancing information to effect a coordinated output.  Overall, the PVN is of key 
importance to effect homeostatic responses, and this is known to involve activation of 
multiple outflows in a coordinated manner.  For example, consider the response to 
acute severe haemorrhage.  Release of vasopressin from the posterior pituitary, ACTH 
from the anterior pituitary, catecholamines from the adrenal medulla and loss of 
sympathetic vasoconstriction all occur simultaneously (Schadt and Ludbrook, 1991).  





Given the close proximity of the magnocellular, parvocellular and pre-autonomic parts 
of the PVN, it seems likely that cross talk is occurring between these areas (the 
alternative being segregated inputs targeted to each individual output region).  
Signalling via dendrites within the PVN has been suggested as likely to contribute to co-
ordinating responses (van den Pol, 1982, Rho and Swanson, 1989, Herman et al., 2003, 
Stern, 2015).  Paracrine signalling may also play a role, for example, both nitric oxide and 
CO have been shown to be released within the PVN and to alter neuropeptide release 
(Rivier, 2001, Rivier, 2002).  The PVN has also been shown to have an important role in 
feeding back upon itself, with a shell of inhibitory terminals and GABAergic interneurons 
surrounding the more closely packed cell bodies in the main PVN (Biag et al., 2012, 
Roland and Sawchenko, 1993).  Indeed, many inputs to the PVN have been shown to 
synapse onto this shell, rather than entering the body of the PVN, and this has been 
suggested as an important gating mechanism for altering PVN neuronal activity (Herman 
et al., 2003). 
1.8.3 Glucose homeostasis and the PVN 
The PVN is reported to have important roles maintaining glucose homeostasis (Hill, 
2012).  Connections to both the pituitary axis and the autonomic system are well 
established, and these are two systems that are key for counter-regulation (Herman et 
al., 2003, Hosoya et al., 1991).  The PVN has an established role in the regulation of 
appetite and energy homeostasis, with inputs from the POMC and AgRP neurons of the 
ARC, as well as other well established centres signalling the availability of food and 
energy status.  In terms of PVN outflows, autonomic projections provide routes by which 
the PVN can potentially communicate with organs including the pancreas, liver, stomach 
and adipose tissue, and in addition, via the neuro-hypophyseal route, cortisol and 
thyroid hormone both play important roles in adaptation of metabolic state to the 
environment. 
With specific regard to the response to hypoglycaemia, the PVN is recognised as having 
a role to play.  Hypoglycaemia is a trigger of the stress response, and the PVN is a key 
component of the generic response to any stressor, as opposed to specifically 
responding to hypoglycaemia per se.  PVN neurons are activated by systemic 
hypoglycaemia as evidenced by cfos expression (Evans et al., 2001, Al-Noori et al., 2008) 





and PVN inactivation using lignocaine causes defective counter-regulation (Evans et al., 
2003).  The specific potential of CRH neurons as effectors of the counterregulatory 
response to hypoglycaemia will be discussed in more detail in the next section. 
1.9 CRH neurons 
1.9.1  Identification of CRH and early studies 
The concept of substances arising in the brain which could stimulate the release of 
hormones from the pituitary gland had existed since the 1930s, and a focus on the 
hypothalamus as the source of such substances was developed by, amongst others, 
Geoffrey Harris in the 1950s (Harris, 1955).  Validation of this concept came with the 
identification of TRH in 1969 by Guilleman and colleagues (Burgus 1969).  However, it 
was not until 1981 that Wylie Vale and colleagues identified a 41 amino acid peptide 
responsible for simulating secretion of ACTH- namely CRH (Vale et al., 1981).  The 
development of the CRH antibody and subsequent immunohistochemical studies 
revealed the dense group of CRH neurons within the paraventricular nucleus as the apex 
of the HPA axis signalling cortisol release (Bloom et al., 1982), as well as a much wider 
network of CRH neurons throughout the brain (Swanson et al., 1983). 
It is clear from immunohistochemical studies that CRH neurons are not confined to the 
PVN, although that is an area with one of the highest densities of CRH neurons.  Other 
areas with significant concentrations of CRH neurons include the central amygdala, bed 
nucleus of the stria terminalis, Barrington’s nucleus and inferior olivary complex 
(Swanson et al., 1983).  Many of the areas in which CRH neurons are found have been 
implicated in responses to stress.  In addition, small CRH-positive GABAergic 
interneurons are found scattered throughout the cortex (Taniguchi et al., 2011).  These 
additional CRH expressing areas have not been implicated in glucose sensing and will not 
be considered further in this introduction. 
1.9.2 CRH PVN neuron anatomy and physiology 
There are thought to be approximately 2000 CRH neurons in the PVN in the rat 
(Swanson et al., 1983).  CRH neurons are concentrated in the PVN, and in particular in 
the parvocellular part, with at least 90% of CRH neurons being reported to be found in 





this region in mice (Biag et al., 2012).  Rat and mouse anatomy are not identical, with 
CRH neurons being found in more dorsal and lateral part of the parvocellular PVN in the 
mouse compared to the rat.  Additional CRH neurons have been reported in more 
posterior areas, and some have been demonstrated to be pre-autonomic (Sawchenko, 
1987b). 
CRH neurons of the PVN can co-express a range of additional neurotransmitters, 
including glutamate, vasopressin, enkephalins, CCK and angiotensin II (Sawchenko et al., 
1984b, Sawchenko et al., 1984a, Dabrowska et al., 2013).  Basal CRH levels exhibit 
circadian rhythms, and are driven by inputs from the suprachiasmatic nucleus (Ixart et 
al., 1993).  The level of CRH mRNA within PVN neurons is relatively high, and so 
variations in CRH levels in the portal circulation are likely to be due to variation in 
release, rather than transcription (Watts et al., 2004).  Indeed, CRH mRNA levels rise at 
times of low ACTH levels, and this is likely to be due to the need to replace CRH peptide 
already released from pools at terminals (Watts et al., 2004).  Acutely stressful stimuli 
cause rapid rises in CRH release from CRH neurons over minutes, followed by an 
increase in CRH translation and transcription over the next 2 hours.  This response 
appears to be attenuated in some forms of chronic stress, such as cold or restraint 
(Grissom and Bhatnagar, 2009, Kant et al., 1983, Keim and Sigg, 1976).  However, many 
other stressors show no attenuation with repeated application, for example foot 
shock(Kant et al., 1983, Grissom and Bhatnagar, 2009).  Chronic stress has been shown 
to increase the responsiveness of CRH neurons to a different stressor, regardless of the 
response to the chronic stimulus, suggesting sensitisation and plasticity in CRH 
responses (Herman and Cullinan, 1997). 
Interestingly, evidence has also been presented that responses to CRH in the brain are 
different for an acute infusion of CRH compared to chronic or repeated exposure.  In 
particular, whilst cortisol, epinephrine and norepinephrine release are all stimulated by 
acute exogenous CRH administration, longer term administration tends to reduce 
responsiveness (Cunningham et al., 1988, Flanagan et al., 2003).  This effect is not 
thought to be via the HPA axis, as ACTH or corticosterone infusion had the opposite 
effect to CRH infusion (Flanagan et al., 2003).  In addition, CRH infusion intravenously 
was still able to cause an acute rise in ACTH and cortisol in animals after chronic CRH 





infusion intracerebroventricularly (i.c.v) had caused attenuation of the normal response, 
again suggesting a central mechanism of action (Cunningham et al., 1988). 
Inputs to the CRH PVN neurons are diverse.  Table 1.3 is a summary of known inputs.  In 
addition, it is not entirely clear where such inputs are targeted in all cases.  For example, 
the BNST neurons are primarily GABAergic, but a proportion of BNST effects on CRH 
neurons are excitatory.  This is thought to be mediated by BNST synapses onto 
GABAergic interneurons in the shell surrounding the PVN.  It is also thought that the 
mediators of responses observed from many neurons identified by neuropeptide 
expression are in fact GABA or glutamate which are co-released or indeed released 
independently from terminals. 
Table 1.3: Identified neurotransmitter phenotypes of neurons signalling to CRH neurons 
of the PVN, and their effects (derived from Herman et al. (2003) and Aguilera and Liu 
(2012)) 
 
Nuclei Neurotransmitters Effect 
All hypothalamic nuclei 




Inhibitory via GABAA 
Excitatory 
ARC AgRP, NPY, CART, aMSH Can all cause CRH release 
PVN CRH, oxytocin, vasopressin Inhibitory 














Excitatory via a1 
Possible indirect 
inhibitory effect via b 
Excitatory 





Excitatory via  a2 
Possible indirect 
inhibitory effect via b 
Raphe 5HT Excitatory, direct and via 
interneurons 
PBN Glutamate Excitatory 





In addition to neuronal inputs CRH neurons can also respond to a range of signals from 
the periphery conveyed via the PVN microvasculature (substances that can cross the 
blood brain barrier, e.g. steroids and cytokines) or via signals from circumventricular 
organs, particularly the subfornical organ and  organum vasculosum of the lamina 
terminalis, where the blood brain barrier is deficient.  Circulating plasma levels of 
glucocorticoids, sex steroids, cytokines, angiotensin II, prolactin and leptin have all been 
shown to modulate CRH neuronal responsiveness (Aguilera and Liu, 2012). 
1.9.3 Evidence for specific involvement of CRH PVN neurons in responses to 
hypoglycaemia and development of HAAF 
CRH expressing neurons in the PVN project to the median eminence (Swanson et al., 
1983) and also connect with autonomic areas (Simmons and Swanson, 2009, 
Sawchenko, 1987b).  They are therefore a key element of the hypothalamic-pituitary-
adrenal axis and the sympatho-adrenal outflow, important components of the 
counterregulatory response to hypoglycaemia.  Data in rats show that the transcription 
factor DfosB accumulates in the PVN in recurrent hypoglycaemia and this is co-localised 
with corticotrophin releasing hormone (CRH) (Al-Noori et al., 2008).  DfosB is a member 
of the immediate early gene family, which includes cfos and is thought to exhibit raised 
levels following neuronal activation (McClung et al., 2004).  Acute i.c.v infusion of CRH in 
the rat results in hyperglycaemia with increases in epinephrine, norepinephrine and 
glucagon.  Adrenalectomy and hypophysectomy do not prevent this effect, suggesting 
that it is mediated via the sympathetic nervous system (Brown et al., 1982). 
CRH activation as part of the counter-regulatory response would be expected to reduce 
the requirement for exogenous glucose as it liberates glucose from tissues.  Therefore it 
is interesting to examine the effect of CRH knockout on responses to a hypoglycaemic 
insulin clamp- it would be expected that CRH KO mice would have a higher requirement 
for exogenous glucose.  Jacobson and colleagues (2006b) examined the effect of 
hypoglycaemia on CRH knockout mice.  They found that CRH KO mice did indeed have 
higher glucose requirements in response to the initial hypoglycaemic event, and that 
this was unchanged during a second hypoglycaemic challenge.  In comparison, WT mice 
showed an increase in glucose requirements only after previous exposure to 





hypoglycaemia.  This might imply that failure of activation of CRH neurons contributes to 
HAAF. 
However, the effects were complex and difficult to interpret, in particular as CRH KO 
mice have a very different basal hormonal profile when compared to WT mice, with 
extremely low levels of corticosterone, lower levels of insulin and increased levels of 
norepinephrine.  This makes interpretation of the responses to hypoglycaemia 
challenging.  The profile of all the hormones measured (epinephrine, norepinephrine, 
glucagon and corticosterone) were comparable in CRH KO mice to WT once the changes 
in basal levels were considered, and suggested that CRH KO mice can still exhibit 
elements of HAAF.  The basal levels of corticosterone are dramatically reduced in a CRH 
knockout mouse throughout development, and it is likely that the development of other 
elements of the counterregulatory response were also affected by CRH KO.  Candidates 
include effects on glycogen storage and insulin sensitivity related to long term deficits in 
corticosterone levels and in addition alteration of the sympatho-adrenal response acting 
via neuronal synaptic transmission rather than mass release of 
epinephrine/norepinephrine.   
Davis et al. carried out studies in healthy human volunteers as mentioned in section 
1.6.2.2, which showed that cortisol infusion can reproduce the effect of prior 
hypoglycaemia in generating a HAAF hormonal profile on exposure to subsequent 
hypoglycaemia (Davis et al., 1996).  A further study showed that patients with primary 
adrenocortical failure were not able to develop HAAF (Davis et al., 1997).   
Work by Flanagan and colleagues (2003), using a rat model of hypoglycaemia, expanded 
and developed this line of enquiry.  They found that prior CRH infusion or insulin 
induced hypoglycaemia could both elicit a hormonal profile consistent with HAAF on 
subsequent induction of hypoglycaemia.  However, this was not true of either 
antecedent ACTH or corticosterone infusion, so the results appear somewhat conflicting.  
Persuasively, the addition of a CRH receptor antagonist (antalarmin) to CRH infusion 
abolished the HAAF like effect seen on subsequent insulin-induced hypoglycaemia.  An 
explanation that would account for all of the results would be that the effect is 





mediated by CRH acting on CRH type 1 receptors via sympatho-adrenal outflow, rather 
than via the HPA axis. 
Overall, the evidence suggests an effect related to CRH, perhaps mediated primarily via 
the sympatho-adrenal response rather than the HPA axis.  Unpicking the effects of 
different groups of CRH neurons, in particular the pre-autonomic versus the 
neuroendocrine populations has been a significant barrier to further investigation of this 
area. 
1.9.4 Challenges to the study of CRH neurons 
A major limitation to the study of CRH neurons has been the difficulties in identifying 
this specific neuronal subtype amongst the wide range of different neurons present in 
the PVN.  As a result of this, previous studies have not been able to demonstrate that 
CRH neurons are necessary and sufficient to mediate counterregulation, or indeed to 
demonstrate definitively whether CRH neurons of the PVN are glucose sensing.  
Although immunocytochemistry was effective in fixed tissues, there was no readily 
available method to identify or isolate these neurons in live cells.  Essentially, many 
studies were carried out which could only identify CRH neurons after the event, either 
by immunohistochemistry or using single cell PCR.  The advent of genetically modified 
mice, and in particular the use of the Cre-loxP system has revolutionised the study of 
neuronal subtypes in all parts of the brain, and this is certainly true for CRH neurons 
(McLellan et al., 2017, Albanese et al., 2002). 
1.10 Development of techniques allowing neuronal subtyping 
1.10.1 Genetically modified rodent models 
The CRH KO mouse has already been mentioned, and indeed knock out mice were the 
earliest genetically modified mice used to examine the effect of individual neuronal 
subtypes.  This provided valuable information about functionality in some cases, for 
example, the POMC knock out mouse was hyperphagic and obese (Coll et al., 2004).  
However, in many cases the effects were unpredictable, due to compensation during 
development, and also because the knockout affected the whole animal.  More precise 
techniques were therefore required. 





The use of genetic modification to label cell subtypes of interest with reporter proteins 
(often fluorescent), has been of enormous value in opening up new possibilities for 
investigation of specific cell types, in particular in the central nervous system, where it 
has often proved impossible to identify subtypes in living cells by other means.  The 
additional flexibility conveyed by conditional targeting systems, which will be discussed 
in more detail below, has further enabled studies in this area. 
1.10.1.1 Transgenic versus knock in genetically modified mice 
Initial genetic modifications to allow identification of specific neuronal subtypes 
involved injection of DNA into the male pronucleus of a fertilised egg to introduce the 
DNA encoding the desired protein into the genome.  This generates a transgenic mouse, 
with random incorporation of the genetic material into the genome, at an unknown 
number of sites (from one to many).  Construction of larger bacterial and yeast artificial 
chromosomes (BACs and YACs), allowed more complex DNA constructs to be introduced 
in a similar manner.  This methodology is simple and effective, but can be unreliable.  
Three main problems were observed.  Firstly, the presumed promotor sequence 
included in the transgene construct was not always comprehensive, as upstream 
promotor effects can extend a much longer distance away from the gene of interest 
than was initially appreciated.  This could lead to patterns of expression that differed 
from the endogenous gene of interest.  Secondly, the random incorporation of the 
construct into the genome could result in its integration at sites with either very high or 
very low levels of transcription, and this could circumvent the specificity of the 
promotor sequence included in the construct, leading to off target effects or indeed 
under-reporting.  Finally, the presence of an unknown number of copies of the same 
construct makes spontaneous recombination events more likely, and this could result in 
genetic instability in the genetically modified mouse line, most commonly with loss of 
the introduced DNA, but also potentially disruption of other genes (producing an 
unintended phenotype unrelated to the introduced transgene). 
Gene targeting techniques, initially developed to produce knockout mice by excising 
specific sections of the genome, were subsequently expanded to generate knock in 
mice, with new genetic material being introduced at a specific point in the genome.  This 
method targets a specific sequence of genetic material to introduce the DNA of interest 





into embryonic stem (ES) cells.  Although the desired insertion event occurs at very low 
frequency, successful insertion can be screened for by including a gene conveying 
antibiotic resistance in the DNA to be inserted.  Only ES cells with successful DNA 
insertion will grow in the presence of the drug, and these can then be inserted into early 
embryos to produce chimeric mice.  Subsequent breeding of the chimeric mice will 
produce mice with the desired mutation expressed in all cells (Doyle et al., 2012).  This 
method results in targeted mutations at a single known point in the genome.  This is 
advantageous as, for example, genes can be inserted directly downstream of the 
promotor of interest, allowing near identical control of the endogenous gene and the 
new genetic material.  All of the mice used in this thesis were developed using the knock 
in technique. 
1.10.2 Cre-loxP and FLP-FRT systems 
The development of the Cre-loxP and FLP-FRT systems was complimentary to the 
development of knock in or transgenic mice, as it allowed significantly more flexibility in 
the use of the same mouse line for a wide variety of purposes (Albanese et al., 2002).  
These techniques exploit the ability of enzymes from bacterial phages (Cre recombinase) 
or eukaryotes including yeasts (FLP) to edit their genomes, targeting excision and 
recombination events to specific short DNA sequences designated loxP and FRT 
respectively.  The enzyme will have no effect on the cell until the relevant DNA sequence 
is present.  Therefore, two mutations are required to generate an effect in any one cell.  
The first is the expression of the enzyme, usually under the control of a specific 
promoter (Figure 1.5A).  The CRH Cre mouse used throughout this thesis expresses Cre 
recombinase under the control of the endogenous CRH promotor and is referred to as 
the CRH-ires-Cre mouse (Taniguchi et al., 2011).  The second mutation is a DNA 
sequence of interest, flanked by the targeting sequences required by the enzyme (LoxP 
for Cre recombinase, FRT for FLP).  This could be a fluorescent reporter gene, a section 
of DNA to be excised or indeed a functional gene to be expressed such as an ion channel 
(Figure 1.5B, 1.6).  Only when the enzyme and the relevant DNA targeting sequences are 
both present in the same cell will recombination occur and the effect of the second 
mutation be observed.    






Figure 1.5 Illustration of Cre-loxP system 
A Cre recombinase enzyme is expressed under the control of the desired promoter 
B A reporter protein with a loxP flanked STOP codon preceding it is introduced, either 
via a viral vector or crossing a Cre mouse line with a floxed reporter mouse line.  In cells 
expressing Cre recombinase, the DNA between the loxP sites is excised, removing the 









A Cre recombinase expressing knockin mouse
inserted into 3' untranslated
region of gene of interest





























Figure 1.6 Illustration of Double floxed Inverse Orientation (DIO) version of the loxP 
system 
A Cre recombinase is expressed under the control of the desired promoter 
B The reporter protein is engineered to be in reverse orientation, such that it will not be 
transcribed, flanked by two sets of loxP sequences, in pairs. Cre recombinase will firstly 
reverse the orientation of the DNA between one pair of loxP sequences.  It will then 
excise DNA to remove 2 loxP sites, leaving the reporter DNA intact and now in the 









A Cre recombinase expressing knockin mouse
inserted into 3' untranslated
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The introduction of conditionality in this fashion allows a wide range of genetic effects 
to be produced in a cell specific manner, without needing to specifically generate a new 
transgenic or knock in mouse line in each case.  In this thesis, two loxP ‘reporter’ mouse 
lines are crossed with the CRH-ires-Cre mice, to produce mice expressing TdTomato 
(Madisen et al., 2010) or GCaMP6f (Madisen et al., 2015).  An alternative method of 
introducing loxP targeted DNA is to use a viral vector containing a loxP flanked reporter 
protein to express the reporter protein only in Cre recombinase expressing neurons, and 
only in the anatomical area targeted by the virus (Figure 1.6) (Wang et al., 1996, 
Albanese et al., 2002).  The utility of the Cre-lox system to allow investigation of specific 
neuronal subtypes has been of great value in allowing more detailed investigation of the 
CNS.  Development of repositories of genetically modified mouse lines, for example 
Jackson Laboratories, such that they are commercially available, has improved access to 
a wide range of GM lines for the use of the whole scientific community. 
The range of reporter or effector genes which can be activated using Cre-recombinase is 
very broad, and encompasses a wide range of techniques, as briefly summarised below. 
Simple fluorescent reporter genes for identification of neuronal subtypes in vivo and in 
vitro are perhaps the most widely used.  Neuroanatomy can be elucidated without the 
need for complex immunohistochemical techniques, especially where the peptide of 
interest is expressed at low levels.  This also removes the need for pharmacological 
treatments such as colchicine, previously used to increase sensitivity of staining for 
neuropeptides such as CRH in neuronal somata by inhibiting microtubule transport of 
such neuropeptides to terminals for release.  Additionally, by introducing the reporter 
gene via a viral vector, or using a time locked gene (tamoxifen or tetracycline dependent 
as well as Cre recombinase dependent), still greater precision can be achieved in which 
neurons are identified.  This technique minimises the effects of changes in patterns of 
gene expression during development.  The choice of viral vector can also allow tracing of 
neuronal projections both anterograde and retrograde; this topic will be discussed in 
more detail in section 3.1.6.  Pre identification of neurons of interest can also direct 
functional investigation, for example using electrophysiology.  The molecular profiles of 
specific neuronal subtypes could also be investigated, for example using fluorescence 
activated cell sorting followed by quantitative PCR. 





Genetically encoded calcium indicators (and indeed voltage indicators) can be expressed 
in specific neuronal subtypes for non-invasive, functional imaging of neuronal activation, 
in vitro and in vivo (Paredes et al., 2008).  Technical advances in imaging such as 
gradient refraction index lenses and 2-photon microscopy have increased the breadth of 
application of these techniques. 
Finally, the fields of optogenetics and pharmacogenetics allow investigation of the 
effects of functional activation or inhibition of specific neuronal populations, either in 
vitro, or in a whole animal model (Fenno et al., 2011, Sternson and Roth, 2014).  This 
ability to target specific populations in the context of well characterised mouse models 
of disease has greatly increased the precision with which experiments can be designed 
and carried out. 
1.11 Summary 
This introductory chapter has outlined the clinical context underpinning this thesis; in 
particular the increasing incidence and prevalence of diabetes mellitus worldwide, and 
associated with this the increasing frequency of hypoglycaemia associated autonomic 
failure due to insulin use.  In order to better understand the potential causes of HAAF, a 
better understanding of the physiological and pathophysiological response to 
hypoglycaemia is required.  A summary of the known physiological response to 
hypoglycaemia has been presented, and it is clear from this that the loss of the 
sympatho-adrenal response to hypoglycaemia is key to the development of HAAF in 
diabetic patients.  Having outlined some of the potential mechanisms underlying the 
development of HAAF a wide range of potential avenues present themselves for further 
investigation. 
Focusing in on the CRH neurons of the PVN, it is clear that there are a number of known 
features of this neuronal population which makes them an attractive target for a 
potential role in the development of HAAF.  In particular, the role of these neurons at 
the top of both the hypothalamo-pituitary-adrenal axis and their potential pre-
autonomic connections to the brainstem situate them such that they can influence both 
aspects of the sympatho-adrenal response to hypoglycaemia.  Those experiments 
involving infusions of CRH with observed alterations in the response to hypoglycaemia 





are also suggestive of an important role for these neurons.  Currently, there are some 
important gaps in the knowledge of this system, and recent technical developments now  
allow these questions to be effectively addressed. 
• The specific targets of CRH PVN pre-autonomic neurons have not been fully 
described, and would provide valuable indications of the potential effector 
targets of CRH PVN neurons in the brainstem, in particular the sympathetic 
outflow 
• Glucose sensing has been described in PVN putative pre-autonomic neurons in 
the rat, but not at physiological glucose levels, and glucose sensing in CRH PVN 
neurons has not been investigated  
• Whilst the PVN as a whole has been shown to be activated by hypoglycaemia as 
evidenced by cfos, this has not been investigated for CRH neurons, particularly 
in the mouse. 
• Models of recurrent hypoglycaemia and HAAF in the mouse are currently still 
being optimised, and would be of great value in further investigating the role of 
neuronal subtypes in development of HAAF using the wide range of GM mice 
available.  
• The availability of mice expressing Cre recombinase under the control of a wide 
range of specific promoters facilitates the investigation of neuronal subtypes 
including CRH 
• Cre dependent reporter genes including simple fluorescent proteins and 
genetically encoded calcium indicators allow investigation of both the anatomy 
and function of specific neurons, especially when combined with differing 
methods of introducing these genes  
This thesis will therefore aim to use the CRH-ires-Cre mouse in combination with floxed 
reporter mice (TdTomato and GCaMP6f) and viral vectors including floxed mCherry to 
investigate the neuroanatomy and glucose responsiveness of the CRH PVN neurons.  The 
hypotheses and aims are outlined in detail below.  






CRH PVN neurons: 
• make direct connections to autonomic areas of the brainstem 
o including the nucleus of the solitary tract, dorsal motor nucleus of the 
vagus and ventrolateral medulla 
• are intrinsically glucose sensing 
• include a subpopulation that are activated by hypoglycaemia 




• Use anterograde and retrograde viral tracing techniques to investigate the 
autonomic areas of the brainstem which have direct synaptic connections from 
CRH PVN neurons 
• Use electrophysiology and calcium imaging to seek evidence of glucose sensing 
in CRH PVN neurons 
• Investigate whether glucose sensing in the PVN requires metabolism of glucose 
• Use a mouse model of single hypoglycaemia and cfos immunohistochemistry to 
demonstrate neuronal activation of CRH PVN neurons by hypoglycaemia 
• Develop a mouse model of recurrent hypoglycaemia, seek evidence of HAAF as 
indicated by corticosterone and glucagon levels, and examine the effect of 
recurrent hypoglycaemia on glucose sensing 











Chapter 2 Methods 
This chapter describes in detail the methods used for data collection and analysis 
throughout this thesis, including relevant negative and positive controls.  Specific 
experiments using the methods described are outlined in the relevant sections.  
Overall the thesis chapters contain data from experiments using: 
• All chapters contain data collected using genetically modified mice. 
• Chapter 3 uses injection of viral vectors for neuronal tracing and 
immunohistochemistry/microscopy. 
• Chapters 4 and 5 use in vitro slice preparations for electrophysiology and 
calcium imaging. 
• Chapter 6 uses in vivo mouse models of hypoglycaemia, immunohistochemistry 
(IHC), radioimmunoassays (RIA) and calcium imaging. 
 
2.1 Genetically modified mice 
The mouse lines chosen for use in this thesis were based on an examination of the 
literature to find what had been used successfully in the past.  Several strains of mice 
have been developed to identify CRH neurons, some using direct expression of a 
reporter protein under the control of the CRH promoter (Alon et al., 2009), and others 
using the Cre-lox system (Taniguchi et al., 2011).  The Cre-lox mouse was preferred for 
two main reasons.  Firstly, it recapitulates the known expression pattern for CRH 
neurons more accurately than some other strains (Chen et al., 2015). Secondly, the use 
of Cre recombinase increased the flexibility of the system, as genes with different 
functions could be introduced into CRH neurons, either by crossing with floxed mouse 
strains or using floxed viral vectors. 
The CRH-ires-Cre mouse used throughout this thesis expresses Cre recombinase under 
the control of the endogenous CRH promotor, as illustrated in Figure 2.1A (Taniguchi et 
al., 2011).  Two loxP mouse lines are crossed with the CRH-ires-Cre mice, to produce 
mice expressing TdTomato (Madisen et al., 2010) or GCaMP6f (Madisen et al., 2015) 





specifically in CRH neurons (Figure 2.1B, C).  TdTomato was chosen on the basis that it is 
a very bright fluorescent protein which does not in general require amplification using 
immunohistochemistry, and has previously been combined successfully with the CRH-
ires-Cre mouse strain (Wamsteeker Cusulin et al., 2013).  GCaMP6f is a genetically 
encoded calcium indicator (GECI) with rapid kinetics and good signal to noise ratio.  
More detailed discussion of GECIs can be found in Chapter 4, section 4.2. 
Mice from genetically modified lines were obtained from Jackson Laboratories as shown 
in Table 2.1.  The experiments performed in each chapter and which mouse strain was 
used is summarised in Table 2.2. 
Mice were maintained on a 12-h light/dark cycle with temperature and humidity control 
and free access to water and mouse chow.  Studies were carried out in accordance with 







Table 2.1: Genetically modified mouse lines used in this thesis 
Name Jax ref. Promoter What expressed Hetero or 
homozygous 
Used for 
CRH-ires-Cre 012704 Endogenous 
CRH promoter 
Cre Recombinase in CRH expressing neurons Homozygous Founder line breeding, for F1 
crosses 
CRH-ires-Cre used with viral 
vectors for neuronal tracing TdTomato 007914 ROSA 
promoter 
Conditional expression of TdTomato (Floxed stop 
codon before TdTomato gene) 
Homozygous 
GCaMP6f 028865 ROSA 
promoter 
Conditional expression of GCaMP6f (Floxed stop 
codon before GCaMP6f gene) 
Heterozygous 
CRH x Td n/a See above TdTomato, potentially in all neurons which ever 
expressed CRH at any developmental point.  Cre 
recombinase in any neurons in which CRH is 
currently expressed 
Heterozygous Identify CRH neurons by 
TdTomato (red) fluorescence 
for IHC, ISH and 
electrophysiology 
CRH x GCaMP6f n/a See above GCaMP6f in all neurons which ever expressed CRH at 
any developmental point.  Cre recombinase in any 
neurons in which CRH is currently being expressed 
Heterozygous for 
both genes 
Calcium imaging in CRH neurons 
CRH x GCaMP6f x Td n/a See above TdTomato and GCaMP6f in all neurons which ever 
expressed CRH at any developmental point.  Cre 
recombinase in any neurons in which CRH is 
currently being expressed 
Heterozygous for 
all 3 genes 
Calcium imaging with pre-
identification of CRH neurons 
using TdTomato 
All mice are bred on background strain C57Bl6J   





Figure 2.1 Diagrams to illustrate the genetic modifications introduced in the 3 mouse 
strains used in this thesis 
Introduced elements in blue/purple, native elements in pink, CRH corticotropin releasing 
hormone, IRES- internal ribosome entry site, PolyA- to maintain stability of transcribed 
mRNA, CAG promoter- a Cytomegalovirus early enhancer element/chicken beta-
actin/rabbit beta-globin hybrid promoter, loxP- target sites for Cre recombinase to act 
on, STOP- a sequence containing STOP codons in all three reading frames, WPRE- 




promoter CRH gene IRES
Cre
recombinase PolyA
A CRH IRES Cre mouse inserted into 3' untranslated





















inserted between exons 1 and 2 of the Gt(ROSA)26Sor locus
C GCaMP6 mouse
Figure 1.4 Diagrams to illustrate the genetic modifications introduced in the 3 mouse
strains used in t is thesis
Introduced elements in blue/purple, native elements in pink.
CRH corticotropin releasing hormone
IRES- internal ribosome entry site
PolyA- to maintain stability of transcribed mRNA
CAG promoter- a Cytomegalovirus early nhancer element/chicken beta-actin/rabbit
beta-globin hybrid promoter
loxP- target sites for Cre recombinase to act on
STOP- a sequence containing STOP codons in all three reading frames
WPRE- woodchuck hepatitis virus post-transcriptional regulatory element to enhance
mRNA transcript stability




Table 2.2 Overall characteristics of mice used for each experiment 
Chapter Experiment Mouse line Sex Age 
(weeks) 
3 Anterograde tract tracing 
Retrograde tract tracing 
In situ hybridisation 
CRH x Td 
CHR-ires-Cre 









CRH x Td 
CRH x GCaMP6f x Td 







5 Calcium imaging CRH x GCaMP6f Female 6-12  
6 IHC (cfos) 
RIA (glucagon, cortisol) 
Calcium imaging 
CRH x Td 
C57Bl6J 









Mice were genotyped by polymerase chain reaction analysis from DNA extracted from 
ear notches.  DNA was extracted from the ear notch using 30µl of 0.2mM EDTA/25mM 
NaOH solution, heated to 98°C for 30minutes, followed by physical disruption of tissue 
by pipetting.  The digestion was neutralised using 30µl 40mM TrisHCl, pH7.4. 
The DNA obtained from this method was input to a master mix for PCR (Table 2.3): 
Table 2.3 PCR master mix 
 Volume (µl) for one reaction tube 
10X PCR buffer 2 
Deoxynucleotides 2 
Primers (100mmol each)  1 x number of primers 
rTaq 0.2 
DNA  1 
  
To total volume with distilled water 20 
rTaq, 10X PCR buffer and deoxynucleotides supplied as a kit R001A, TaKaRa Taq™ 
(Takara BIO, USA) 
Table 2.4 contains a summary of the primers used in each case.  PCR programs are 
summarised in table 2.5.  




Table 2.4 Primer details for each mouse strain genotyped 











Mut 468bp  
WT 676bp  
CAC GAG CAG 
GCT GCG GCT 
AAC 
CTT ACA CAT 
TTC GTC CTA 
GCC 
CAA TGT ATC 
TTA TCA TGT 
CTG GAT CC 







AAG GGA GCT 
GCA GTG GAG 
TA 
CCC AAA ATC 
TGT GGG AAG 
TC 
CTG TTC CTG 
TAC GGC ATG 
G 
GGC ATT AAA 





AAG GGA GCT 
GCA GTG GAG 
TA 
CCG AAA ATC 
TGT GGG AAG 
TC 
ACG AGT CGG 
ATC TCC CTT 
TG 




Primers obtained from Eurofins (UK) 
 



























































Each cycle (shaded boxes) performed 35 times for each reaction 
 
The PCR product was pipetted into a 2% agar gel with 0.01% ethidium bromide in TAE 
buffer (40mMTris, 20mM acetic acid and 1mM EDTA) and electrophoresed to allow 
identification of bands of interest.  Example gels are shown in Figure 2.2  





Figure 2.2 PCR results for CRH Cre, TdTomato and GCaMP6f genotyping 
Left hand lane is a 1kb ladder in all gels 
A CRH Cre PCR-results for 3 mice shown.  PCR for wild type (WT) and mutant (Mut) 
bands are carried out separately such that there are 2 lanes for each mouse genotyped, 
left lane is WT band, right lane is CRH Cre band.  Mouse A is a WT, B is homozygous for 
CRH Cre and C is heterozygous (Het).  Mutant band is 469bp, wild type 676bp.   
B TdTomato- results for 3 mice as for CRH, Mut band 196bp, WT 297bp.  Here, a 
multiplex PCR was run, so bands are visible in a single lane 
C GCaMP6f, genotyping a litter of 6 mice, of which 2 are heterozygous for GCaMP6f 























A- WT B- Mut C- Het




bands run as multiplex
GCaMP6 PCR
bands run as multiplex
1kB A    B    C    D    E    F




As most breeding strategies used homozygous parents, routine genotyping was not 
required once the colonies were established.  The exception was the CRH x GCaMP6f 
line, which used a heterozygous GCaMP6f parent, and therefore genotyping of all 
offspring for GcaMP6f was required to identify offspring with the desired mutation.  The 
reason for using a heterozygous GCaMP6f parent was two-fold- firstly this was 
expedient for obtaining litters with the relevant mutation rapidly, as homozygous 
GCaMP6f animals were not initially available.  Secondly, there is evidence that some 
homozygous GCaMP strains have a tendency to epileptiform activity (Steinmetz et al., 
2017).  There were no obvious behavioural or physiological phenotypes in any of the 
mouse lines maintained for this study.  CRH-ires-Cre homozygous mice in general had 
smaller litters than observed in the TdTomato strain or crosses between strains. 
2.3 Viral vectors 
For retrograde tracing studies, a canine adenovirus type 2 expressing GFP under the 
CMV promoter (CAV-CMV-eGFP) was obtained from E. Kremer (Institut de Génétique 
Moléculaire de Montpellier, CNRS-Universities of Montpellier I and II, Montpellier, 
France.)(Bru et al., 2010).  The titre was 4.8X1012particles/ml.  The virus was not diluted 
for injection into the brain.  This virus was used for retrograde tracing of neurons 
projecting to the nucleus of the solitary tract (NTS) from the PVN.  Virus was injected 
into the NTS of CRH x TdTomato mice where it will be taken up into any axonal 
terminals, dendrites and soma.  CAV-2 viruses specifically transduce neurons, and not 
glial cells (Junyent and Kremer, 2015).  This means that distant neurons with projections 
to the NTS will be transduced, resulting in GFP signal in the soma of these neurons (in 
this case the PVN).  Local cell bodies will also be transduced, as will cells projecting to 
the NTS from other areas.  The genetic modifications introduced using this virus are 
summarised in Figure 2.3B. 
Adeno-associated viral vector (serotype 2), DIO-mCherry (AAV_DIO-mCherry) was 
obtained from Carolina Vector Core Services (originator Karl Deisseroth lab, 
Stanford,USA, now available (plasmid#20297) via Addgene, MA, USA)(Cerritelli et al., 
2016). The titre was 6X1012particles/ml, the virus was not diluted for injection.  The 
genetic modifications included in the virus are summarised in Figure 2.3A.  This vector 




was used for anterograde tracing, and does not travel retrogradely.  It was injected into 
the PVN of CRH-ires-Cre mice to express mCherry only in CRH neurons, and only in the 
anatomical area targeted by the virus. 
Both viruses were used in the autonomic tracing experiments in chapter 3.  In addition, 
the CAV-CMV-eGFP virus was injected into some mice used in chapter 4 for 
electrophysiology.  





Figure 2.3 Diagrams to illustrate the genetic modifications introduced in the 2 viruses 
used in this thesis 
AAV- adeno associated virus, CAV- canine adeno virus, EF-1α- human elongation factor 
1-alpha is a constitutive promoter which can be used to drive ectopic gene expression, 
LoxP or lox2722- target sequences for Cre recombinase, DIO- Double-floxed Inverse 
Orientation-two sets of loxP sequence are inserted, cre recombinase will firstly switch 
the orientation of the DNA between loxP-loxP or lox2722-lox2722 and then excise one 
set of loxP to leave DNA in the correct orientation for transcription and translation, 
mCherry- fluorescent red protein, ChR2- channel rhodopsin; a light activated ion channel 
(not used functionally in this thesis), WPRE- woodchuck hepatitis virus post-
transcriptional regulatory element to enhance, mRNA transcript stability, PolyA- to 
maintain stability of transcribed mRNA, CMV promoter- human cytomegalovirus early 
promoter; causes high levels of transient downstream gene expression, eGFP- enhanced 































2.4 Surgery – stereotaxic vector injections 
Mice were anesthetized with intraperitoneal ketamine (70mg/kg, Vetalar; Pharmacia) 
and medetomidine (0.5mg/kg, Domitor; Pfizer) until loss of the hindpaw withdrawal 
reflex.  The area to be operated on was shaved and cleaned with iodine.  Lacrilube was 
applied to the corneas to prevent drying.  The animal was placed in a stereotaxic frame 
(David Kopf Instruments, CA, USA) and core temperature was maintained using a heat 
pad. Aseptic surgical techniques were used throughout. 
Injections were made using a micropipette pulled to ~20µm diameter tip, using a 
vertical puller (Harvard Apparatus, UK).  2 types of microcapillary glass were used.  For 
NTS injections, microcapillary glass with 1µL calibration was used (P0549, Sigma, USA).  
For PVN injection, microcapillary glass with external diameter 1.14mm, internal 
diameter 0.53mm, was used (3-000-203-G/X, Drummond Scientific, USA).  The pipette 
was attached to two different systems.  Experiments involving injection of virus into the 
NTS used a 25µL Hamilton syringe (Hamilton, UK) in a Genie RS232 pump (Kent Scientific 
Corp, Torrington, CT USA), attached via polyethylene tubing to the pipette using 
polyethylene silicon tubing.  Polyethylene silicon tubing expands in ethyl ether and then 
contracts to form a tight seal around the connections once removed from the solvent.  
Experiments injecting virus into the PVN used a syringe injector system directly 
connected to the pipette (Nano-W Wireless capillary nanoinjector, Neurostar, 
Germany).  In both cases, the tubing and micropipette were firstly filled with mineral oil, 
and virus then back filled into the pipette tip.  Injections were made at a rate of 
0.2µl/min, with the pipette being kept in place for one minute after each injection 
before moving to the next point of injection. 
2.4.1 NTS injection 
The head was flexed by means of inverting the bite bar and gently pushing the end of 
the bite bar against the animal’s snout.  An incision was made over the occiput 
extending to the nape of the neck.  Muscles were removed from their attachments to 
the occiput.  A 27G needle was used to incise the dura (atlanto-occipital membrane) to 
enable visualisation of calamus scriptorius (caudal tip of area postrema) on the dorsal 
surface of the medulla.  The most caudal point of calamus scriptorius was identified and 




used as a reference point to delineate the midline and rostro-caudal targeting of 
injections. 
Stereotaxic injections of CAV-CMV-eGFP were made into the nucleus of the solitary 
tract/dorsal motor nucleus of the vagus using a similar approach to that described in 
(Cerritelli et al., 2016).  Vector injections were made unilaterally at the following 
coordinates:  From the reference of calamus scriptorius, lateral 0.2 mm, 0.3–1.0 mm 
deep from brain surface with a 35° rostral angulation. 3 viral injections (210 nL) at 
0.35mm intervals were performed (1.0mm, 0.65mm, 0.3mm).  Bilateral NTS injections 
were performed for mice used subsequently for electrophysiological recordings.  
Muscles and skin were sutured in two layers, and antibacterial powder applied to the 
wound. 
2.4.2 PVN Injection 
An incision was made over the dorsum of the skull, bregma was identified and used to 
delineate the midline and rostro-caudal targeting of injections.  A burr hole was drilled 
unilaterally allowing access at the following coordinates:  bregma -0.94mm, 1mm lateral, 
for injection from a pipette with 10˚ angle from vertical, aiming towards the midline in a 
coronal plane, 4.5-5.1mm deep.  A total of 4 injections (100nl) were performed at 
0.2mm intervals (5.1mm, 4.9mm, 4.7mm, 4.5mm).  The skin was then sutured, and 
wound powder applied. 
A vertical approach at 0.2mm lateral was initially employed (bregma -0.94mm, lateral 
0.2mm, 5.1mm deep), but it proved difficult to avoid the central sinus and resultant 
bleeding (and also the 3rd ventricle), and therefore the 10˚ angle and more lateral entry 
point were used subsequently. 
2.4.3 Recovery from surgery 
At the end of stereotaxic surgery, anaesthesia was reversed with atipamezole 
(Antisedan, 1mg/kg, i.p; Pfizer) and buprenorphine was given for pain relief (Temgesic, 
0.1mg/kg, s.c; Schering-Plough). Animals typically showed a rapid functional recovery 
from anaesthesia and surgery.  Welfare scoring was used to monitor animal’s recovery. 




2.5 Solutions and chemicals 
All chemicals used in this thesis were obtained from Sigma, UK unless otherwise stated. 
2.6 Tissue Fixation and imaging 
These techniques were used as follows: 
• This chapter uses ISH to validate CRH x Td mice as identifying CRH neurons 
• Chapter 3 uses immunohistochemistry to amplify transfected viral fluorescence- 
eGFP and mCherry, double immunohistochemistry to label autonomic neuronal 
subtypes in addition to mCherry. 
• Chapter 6 uses immunohistochemistry for cfos and oxytocin.  
 
2.6.1 Solutions 
Solutions used for tissue fixation and immunohistochemistry were as summarised in 
table 2.6 
Table 2.6 Solutions used for tissue fixation and immunohistochemistry 
Solution Abbreviation Volume Solvent Solutes pH 
10% neutral 
buffered formalin 
N/A- purchased ready to use 
0.1M Phosphate 
buffer 








buffer with azide 




buffer with 0.3% 
triton X-100 






Mice were terminally anesthetized with intraperitoneal injection of pentobarbitone 
(100mg/kg) and perfused trans-cardially with 25 ml of 10% neutral buffered formalin.  
Brains were removed, stored in the same fixative for 12 hours at 4°C and then immersed 




in 20% sucrose in PB, pH 7.4, at 4°C overnight for cryoprotection prior to cutting on a 
freezing microtome. 
2.6.2.2 Slice preparation 
Coronal sections of brain, brainstem and spinal cord were cut of 30μm thickness into 1:4 
equal series on a freezing microtome.  Sagittal sections were cut of 30μm thickness into 
1:3 equal series in the same manner.  Sections were stored at 4°C in PB azide for use in 
the next 2 weeks, or at -20°C in a cryoprotectant solution (2:3:5 glycerol:ethylene 
glycol:PB) for long term storage. 
2.6.3 Immunohistochemistry: 
2.6.3.1 Free floating sections 
This method was used for the majority of immunohistochemistry experiments. 
Sections were washed 3 times for 10 minutes, in PB (6 times if taken from storage in 
cryoprotectant).  Sections were then incubated in 50% ethanol in distilled H2O for 30 
minutes to permeabilise cell membranes and facilitate antibody entry into cells.  They 
were subsequently incubated overnight at room temperature in primary antibody in PBT 
and 3% donkey serum (NDS).  After washing 3 times in PB, sections were incubated in 
secondary antibody in PBT plus NDS 2% for 3 hours at room temperature.  Brain sections 
were mounted onto electrostatically charged slides (Superfrost plus slides, Menzel-
Glaser, Fisher Scientific, UK) using fluorsave medium (FluorSave, Merck Millipore, 
Germany) and stored at 4°C.  See tables 2 and 3 for antibodies and concentrations used. 
2.6.3.2 On slide immunohistochemistry 
This was performed for parasagittal brainstem sections. 
Sections were mounted immediately after cutting onto electrostatically charged slides 
and dried overnight (or in an oven at 30°C for 2 hours).  3 washes of the slides with PB 
were performed, and they were subsequently blocked for 30 minutes in 5% normal 
donkey serum in PBT.  Primary antibody in PBT and 5% donkey serum was added and 
left overnight at room temperature.  After washing in PB, slides were incubated in 
secondary antibody in PBT plus NDS 2% for 4 hours at room temperature.  Slides were 




then washed 3 times and cover-slipped using fluorsave mounting medium before 
viewing/for storage at 4°C.  The same antibody concentrations were used as for free 
floating immunohistochemistry. 
2.6.3.3 DAPI counterstaining 
In some cases, DAPI (2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride) at 
1:10,000 was applied to stain nuclei at the end of the IHC process.  5 minutes of 
incubation at room temperature was used.  Sections were then washed and  
mounted/cover-slipped as described above. 
2.6.3.4 Double immunohistochemistry 
Where 2 antibodies were employed, both primaries were added to the slices at the 
same time in the concentrations described in table 2.  Both secondaries were also added 
at the same time at the concentrations described in table 3.  Care was taken in the 
choice of primary and secondary antibodies to avoid cross reactions. 
2.6.3.5 Controls and need for amplification of native fluorescence 
Primary antibody was omitted from negative control slides during 
immunohistochemistry, for example during cfos staining to test the specificity of any 
fluorescence.  Most antibodies used in this study have been widely validated by the 
group in previous work, and therefore positive controls were not repeated (Cerritelli et 
al., 2016, Hickey et al., 2014, Li et al., 2016).  The antibodies which had not been 
previously validated by the group were the rabbit anti oxytocin antibody (T4084 
Peninsula) and the sheep anti tyrosine hydroxylase antibody (Millipore). 
The oxytocin antibody has been previously used in a range of publications including 
(Mecawi et al., 2011, Sutton et al., 2014, Griffin et al., 2010).  Immunoreactivity was not 
observed in oxytocin knock out mice or following a pre-absorption control (Griffin et al., 
2010).  The distribution of positive signal in the PVN was as previously reported for 
oxytocin neurons. 
The tyrosine hydroxylase antibody was observed in areas known to have tyrosine 
hydroxylase activity, including locus coeruleus, A1/C1 and A2/C2.  This antibody was 




validated by the manufacturer using Western blotting, and reported to have positive 
staining in corpus striatum and adrenal medulla, but not liver.  It has been reported in a 
range of publications including (Koblinger et al., 2014, Tsai et al., 2014). 
The fluorescence signal from native TdTomato was very bright and was not enhanced 
using IHC at any point in the data presented here.  IHC was performed to enhance 
intrinsic fluorescence from mCherry and eGFP where viral vectors were used for 
neuronal tracing.  This was particularly of value for highlighting axonal terminals, which 







Table 2.7 Primary antibodies used in this thesis 
 
Table 2.8: Secondary antibodies used in this thesis 
Antigen Raised in  Concentration used Company Name/ catalogue no Poly or monoclonal 
Green Fluorescent Protein Chicken 1:5000 Abcam AB13970 Polyclonal 
mCherry Goat 1:2000 Biovision 5993-100 Polyclonal 
Choline Acetyltransferase (ChAT) Goat 1:200 Chemicon AB144P Polyclonal 
Tryptophan Hydroxylase (TrH) Mouse 1:300 Sigma T0678 Monoclonal 
Tyrosine Hydroxylase (TH) Sheep 1:1000 Millipore AB1542 Polyclonal 
cfos Rabbit 1:200 Santa Cruz Sc-52 Polyclonal 
cfos Goat 1:200 Santa Cruz Sc-52g Polyclonal 
Oxytocin Rabbit 1:2500 Peninsula T-4084 Polyclonal 
Anti- Raised in  Concentration used Company Name/ catalogue no Alexa 
Chicken Donkey 1:1000 Jackson 703-545-155 488 
Sheep Donkey 1:200 Jackson 713-545-003 488 
Goat Donkey 1:1000 Molecular Probes A11055 488 
Rabbit Donkey 1:500 Life technologies A21207 594 
Goat Donkey 1:1000 Invitrogen A11055 594 
Rabbit Donkey 1:1000 Abcam Ab175651 405 
Mouse Goat 1:1000 Life technologies A11001 488 
Rabbit Goat 1:1000 Invitrogen A11012 594 
Chapter 2 Methods 
66 
 
2.6.4 In situ hybridization for validation of the CRH x Td mouse. 
2.6.4.1 Rationale for experiment 
As discussed in the introduction, using a Cre-lox system with a genetically modified 
reporter mouse line to identify a neuronal subtype, in this case CRH neurons, is in 
principle a simple, reliable and repeatable system.  The major concern is that some 
neurons may have expressed CRH in development and no longer do so, but remain 
fluorescent as they have activated transcription of the gene for the fluorescent reporter 
protein (Schmidt-Supprian and Rajewsky, 2007).  The gold standard for validation would 
be IHC for CRH and TdTomato protein, which has been reported by two different groups 
for this mouse line.  Wamsteeker et al. (2013) have previously characterised the CRH x 
Td mouse line and report that 80.5+/-1.1% of PVH TdTomato neurons stain positive for 
CRH after colchicine treatment (2013).  Chen et al. (2015) report even better co-
localisation, without the use of colchicine (93.3 +/-1.2% of TdTomato neurons stain for 
CRH).  Colchicine has been widely used in the past to allow visualization of CRH (as well 
as many other neuropeptides) in cell bodies (Rho and Swanson, 1989, Sawchenko and 
Swanson, 1985, Sawchenko et al., 1984a), due to its inhibition of microtubules, 
preventing axonal transport (Paulson and McClure, 1975).  The possibility of repeating 
CRH IHC in-house was investigated, however it was anticipated that without colchicine 
treatment results would be unreliable at best, as the sensitivity of CRH IHC in this 
instance is greatly reduced (Prof S. Lightman, personal communication). 
Therefore an alternative approach, using ISH, was used to examine co-localisation of 
CRH and TdTomato mRNA.  The main area of interest for this thesis is CRH expression in 
the PVN, therefore PVN CRH and TdTomato expression was examined in this region and 
adjacent territories. 
2.6.4.2 Method 
The RNAscope® _2.0 Assay kit (Wang et al., 2012)(ACD-Biotechne, USA) was used for in 
situ hybridization, according to the manufacturer’s instructions (Protocols 320535 and 
320393). 
As the native TdTomato fluorescence is exceptionally strong, some experiments were 
carried out with the aim of preserving this fluorescence and only probing for CRH mRNA.  
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Pretreatment 4 involved proteases, and this step was shortened on the manufacturers 
advice to try to preserve TdTomato.  A further series used the standard protocol with 
fluorescent probes for both TdTomato and CRH mRNA. 
Briefly, 2 CRH x Td mice were perfused with 4% paraformaldehyde (otherwise treated as 
for all mice undergoing perfusion), and tissue post-fixed in 4% paraformaldehyde 
overnight.  A further 24 hours of incubation in 20% sucrose in PB then followed.  22μm 
slices in a 1:4 equal series through the PVN were obtained as before on a freezing 
microtome.  4 series were mounted onto superfrost plus slides and dried. 
Pretreat 2 (Antigen retrieval) was applied at a low boil, after which 2 washes in distilled 
water were carried out, followed by a wash in 100% ethanol.  The slides were then dried 
overnight.  Pretreat 4 (Protease reagent) was applied for different lengths of time, as 
there was a possibility of preserving the native TdTomato fluorescence with a shorter 
treatment, which would mean that only one probe (for CRH mRNA) would be needed.  
The standard duration of 30 minutes was used for the multiplex CRH and TdTomato ISH 
and for controls.  Incubation with pretreat 4 was performed at 40°C, and 2 washes in 
distilled water followed.  
Table 2.9 summarises the timings of pretreat 4 and the experiments performed.  
Table 2.9 Tissue used for ISH 
CRH probe only 
(to compare with native 
TdTomato fluorescence) 






1 series for short pretreat 
4 protocol (10minutes) 
 
1 series for longer pretreat 
4 protocol (20minutes) 
1 series, standard pretreat 
4 protocol (30 minutes) 
1 series shared, standard pretreat 
4 protocol (30 minutes) 
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Probes and amplification treatments were then applied as summarised below: 
• Probes applied for 2 hours at 40°C 
• Wash 2X 2minutes in kit Wash Buffer 
• Apply AMP 1-FL solution for 30 minutes at 40°C 
• Wash 2X 2minutes in kit Wash Buffer 
• Apply AMP 2-FL solution for 15 minutes at 40°C 
• Wash 2X 2minutes in kit Wash Buffer 
• Apply AMP 3-FL solution for 30 minutes at 40°C 
• Wash 2X 2minutes in kit Wash Buffer 
• Apply AMP 4-FL solution for 15 minutes at 40°C 
• Wash 2X 2minutes in kit Wash Buffer 
• Apply kit DAPI for 30 seconds at room temperature 
• Mount and coverslip 
• Stored at 4°C 
 
2.6.4.3 Results and conclusion 
The CRH TdTomato multiplex slides resulted in clear, bright co-localisation of red 
(TdTomato) and green (CRH) fluorescence (Figure 2.4). 
Quality control (Figure 2.5A) 
• the negative control probe was negative  
• the positive control probe revealed scattered fluorescent puncta throughout the 
section 
 
This suggests that the assay was performing as expected by the manufacturer, and that 
there is a low likelihood of false positive/negative signal.  




Figure 2.4 Results from multiplex ISH show co-localisation of CRH and TdTomato mRNA 
in the PVN 
A Low power image of PVN after multiplex ISH, with DAPI (blue), TdTomato (red) and 
CRH (green). White square shows location of higher power images shown to right.  
Arrows indicate co-localisation of mRNA 
B Diagrammatic representation of co-localisation for cells counted in 2 separate animals.  

















Figure 2.5 In situ hybridisation controls and comparison of probes 
Ai Positive and negative control probes, ii zoomed in 
Bi CRH probe (green) with partially preserved native TdTomato protein fluorescence 
(red). 
ii Multiplex with CRH (green) and TdTomato (red) probes showing much clearer 
TdTomato signal. 
Zoomed in images shown below main images.  White square=zoomed in area, 3V=3rd 
ventricle  
Ai





CRH probe Native TdTomato CRH probe TdTomato probe
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The slides in which native TdTomato fluorescence were to be preserved did not 
successfully preserve signal in either pre-treatment condition (only one shown).  The 
fluorescence was much reduced compared to freshly mounted sections.  Therefore as 
multiplex images were much clearer they were used for interpretation (Figure 2.5B 
shows comparison). 
In sections from both of the mice, co-localisation of CRH mRNA (green fluorescence) and 
TdTomato mRNA (red fluorescence) was observed in most neurons visualised in the PVN 
(Figure 2.5).  87.5% and 80.3% of TdTomato neurons co-expressed CRH in the 2 animals. 
This approach has now been published for these mice, (Harris et al., 2014), available as 
part of the Allen Mouse Brain Connectivity Atlas and the data presented here falls 
broadly in line with that report.  The large majority of the TdTomato neurons seen in 
CRH x Td mice in the PVN are indeed CRH expressing neurons. A small number of false 
positive and negatives were observed.  These cells may indeed express both CRH and 
TdTomato mRNA, but at levels which are not sufficient to be detected by IHC.  
Alternatively, these neurons may have expressed CRH at some point in their 
development, but not currently (false positives). 
To be even more confident that all neurons identified were currently expressing CRH, an 
alternative strategy, for example, using injections of a Cre dependent viral vector in a 
CRH-Cre mouse could be used.  Indeed, this strategy is employed for neuronal tracing 
studies (see chapter 3). 
2.6.5 Microscopy and image processing 
2.6.5.1 Conventional light microscopy 
Histological sections were initially viewed on a Zeiss Axioskop 2 microscope 
(Oberkochen, Germany) and images captured using an AxioCam (Zeiss, UK) and the 
Axiovision 4.7 software (Zeiss, UK), using X10 and X20 objectives.  The light source was a 
pE-2 LED excitation system (Cool LED, UK).  Excitation and emission spectra are 
summarised in table 6. 
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Table 2.10 Axioskop excitation and emission wavelengths 
Fluorophore/colour Excitation LED Filter sets nm 
mCherry or TdTomato/Red 565nm Excitation 560/40 
Dichroic 585 
Emission 630/75 
eGFP / Green 490nm Filter cube #10 (Zeiss) 
DAPI / Blue 365nm Filter cube #02 (Zeiss) 
 
Tile scanning was performed using a widefield Leica DM1600 inverted epifluorescence 
microscope in the Wolfson Bioimaging facility.  The camera was a Leica DFC365FX 
monochrome CCD.  Images were acquired using a 20x objective with NA 0.4.  The filter 
sets were as follows: 
Table 2.11 DM1600 excitation and emission wavelengths 
Fluorophore/colour Filter sets nm 
mCherry or TdTomato/Red Excitation 560/40 
Dichroic 595 
Emission 645/76 
eGFP/Green Excitation 480/40 
Dichroic 505 
Emission 527/30 




2.6.5.2 Confocal scanning microscopy 
Confocal imaging was also carried out on some sections for confirmation of co-
localisation.  A Leica SP5-AOBS confocal scanning microscope (Leica, UK) was used 
(Wolfson Bioimaging facility).  eGFP or Alexa488 (green) was imaged using a 100mW 
Argon laser, whilst TdTomato, mCherry or Alexa 594 (red) used a 2mW HeNe 594nm 
laser.  A line average of 2 was used to reduce noise.  Z stacks 0.5μm apart were obtained 
using the x40 oil immersion objective (NA 1.25), or x20 oil objective (NA 0.7) for analysis 
of co-localisation in cell bodies.  Individual z planes were examined for evidence of co-
localisation of red and green pixels.  Where the confocal microscope is used, this is 
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stated in the figure legend.  All other images were generated by conventional 
microscopy. 
Software for image acquisition on all Wolfson Bioimaging microscopes was Leica-LASX. 
2.6.5.3 Image processing and analysis 
All files were saved in the .TIFF format and processed using FIJI software (Version 1.0 
(Schneider et al., 2012, Schindelin et al., 2012)).  All comparative images taken from a 
single experiment were acquired with the same exposure times and using identical filter 
and laser settings where applicable.  Any adjustments to brightness and contrast from 
within FIJI were also applied to all comparable images. 
Quantitative analysis of cell bodies largely involved manual counting of all visualised 
cells in a defined area.  A particle counting plugin provided by FIJI was used to quantify 
cfos expression in the PVN from 20X widefield images.  For this, thresholding was first 
performed using the Otsu algorithm.  The thresholded, binarized image was processed 
by the FIJI particle counter.  The same parameters were applied to all images counted in 
this way. 
Mapping of mCherry fibres was performed after amplification of the signal using 
immunohistochemistry.  Images were captured using the widefield tile scanning 
microscope and a X20 objective.  The density of labelled fibres was assigned a value of 0, 
+, ++, +++, ++++ (from zero to maximal expression as observed in the NTS) for each area 
of interest and mapped onto the mouse brain atlas (Franklin and Paxinos, 2007) as 
colour coded shading.  Quantification of fibre density was performed comparing the 
DMN, NTS and hypoglossal nuclei in the same slice in 3 mice.  2 parasagittal sections 
were imaged for each mouse, at lateral 0.04 and 0.24mm from the midline.  6 
100x100micron boxes were placed evenly rostral to caudal within each nucleus and fibre 
counts determined within each box.  Fibres were only counted if they were clearly linear 
structures, with length at least 5µm.  Puncta were not counted for this analysis.  These 
values were then summed for each mouse. 
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2.7 In vitro hypothalamic slicing and recording 
These methods were employed throughout chapters 4 and 5 
2.7.1 PVN Slices 
Hypothalamic slices were prepared from mice at 6-12weeks, which were schedule 1 
culled by cervical dislocation followed by decapitation.  The brain was removed and 
bathed in ice-cold artificial CSF (aCSF, see below).  A coronal block containing the 
hypothalamus was glued to the vibratome stage, caudal surface down, and 300μm thick 
coronal slices were cut using a vibratome (Dosaka LinearslicePro 7; DSK, Japan) in cold 
(4°C) aCSF.  Slices were incubated at 37°C in carbogenated aCSF for 20 minutes to 
remove/reduce dead surface cells.  Slices were then kept at room temperature in 
carbogenated aCSF for at least 1 hour before recording. 
2.7.2 Electrophysiology 
Slices were transferred into the recording chamber of an upright fluorescence 
microscope (Eclipse E600FA, Nikon, Japan), superfused with aCSF containing the 
following (mM): NaCl 127, KH2PO4 1.2, KCl 1.9, NaHCO3 26, MgCl2 1.3, CaCl2 2.4, and d-
Glucose 10, saturated with 95% O2/5% CO2, pH 7.3, 36.5°C at a rate of 2–3ml/min.  aCSF 
containing lower glucose (2.5mM and 0.5mM) used mannitol substitution to 
compensate osmolarity (300-310mosm).  Patch pipettes (4–7 MΩ) were pulled from 
borosilicate glass (GC120, Harvard Apparatus, UK) and filled with internal solution 
containing the following (mM): K-gluconate 140, KCl 10, Na-HEPES 10, NaATP 2, EGTA 1, 
KOH 4, Sucrose 4.  All membrane potentials were corrected for junction potential of 15 
mV. 
Fluorescent CRH neurons (TdTomato) were firstly identified using epifluorescent 
illumination and then the soma identified using DIC contrast with a 40X water 
immersion objective (Nikon, Japan, NA 0.8).  A MP225 manipulator (Sutter, CA, USA) was 
used to manoeuvre the patch pipette to the cells.  Recordings were made in current-
clamp mode in the whole cell configuration.  Current pulses were injected to examine 
the current-voltage and current-spike frequency relationships (Multiclamp 700A 
amplifier; Molecular Devices).  The signal was filtered at 3 kHz, digitized at 10 kHz 
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(micro1401, Cambridge Electronic Design, UK), and stored using Spike 2 software 
(Cambridge Electronic Design, UK). 
The threshold for action potential discharge was determined as the point at which the 
rate of change of membrane potential exceeded 7.5 V/s and all spike parameters were 
measured with reference to this point (using a custom Spike2 script). 
2.7.3 Calcium imaging 
Calcium imaging experiments used hypothalamic slices prepared from CRH x GCaMP6f 
mice (cutting protocol as above).  Slices were transferred into the recording chamber of 
the 2-photon microscope (Prairie Technologies) and perfused with aCSF as for 
electrophysiology.  A 16X water immersion objective (NA=0.8, Nikon) was used 
throughout.  Fluorescent CRH neurons expressing native GCaMP6f (and in some cases 
additional native TdTomato) were identified in the PVN using direct epifluorescence 
(LED) prior to switching to 2-photon mode.  GCaMP6f was excited using a tuneable 
Ti:Sapphire pulsed laser (~100 fs pulse width, MaiTai HP, SpectraPhysics) at 940nm, and 
a XY plane was delineated containing a hemi-PVN to one side of the third ventricle.  The 
depth of field of view in focus was 1-2µm.  The zoom required to encompass a hemi PVN 
ranged from 1 to 1.6X.  Data was collected using PrairieView acquisition software at a 
rate of between 0.4 and 0.5Hz (slight variation due to differences in zoom used altering 
the time taken to acquire each image).  Resolution was 1024 X 1024 pixels, and data was 
collected using a high sensitivity photon detector (GAASP PMT) and a GFP filter at 
525/70nm, with a dichroic at 565nm.  The TdTomato filter, where used, was 595/50nm.  
File sizes were around 2-3GB for an experiment lasting 20minutes.  Longer recording 
times were avoided as they were prone to data loss due to errors in processing and 
conversion of files at the end of acquisition.  For this reason, in most cases the recording 
was split into 2 parts (each of 20minutes) to allow experiments lasting ~40minutes to be 
carried out. 
As discussed in the introduction, the fluorescence signal from GCaMP6f at basal levels of 
calcium is low- which is an advantage of the dye in terms of dynamic range.  However, 
this made it impossible to confidently localise the non-activated CRH cells in the slice in 
any experiments.  In order to clearly identify all the GCaMP6f cells which were present in 
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the slice, aCSF with 40mM potassium was applied at the end of each experiment, 
depolarising cells and raising their calcium levels, making all of the CRH neurons 
fluoresce. 






All drugs were obtained from Tocris (Biotechne) 
 
2.8 Pipeline for processing of calcium imaging data 
All initial analysis was performed in FIJI 
• Data saved as .tiff uploaded to FIJI.  Image series, (typically 1200 images for one 
experiment) concatenated to make a single file using FIJI. 
• Registration to align all images and correct for movement in xy carried out using 
the template matching plugin (FIJI, (Tseng et al., 2012)).  The region of interest 
to register outlined as a rectangular region encompassing PVN. 
• Maximum projection over time and standard deviation of images over time 
generated in FIJI. 
• Regions of interest drawn manually using these maximum projection images to 
identify cells, many of which only became visible for short periods or during 
application of high potassium. 
• Background subtraction process applied to the registered file with using the FIJI 
standard background subtraction process, with a 50-pixel rolling ball.  This is a 
widely used method to remove uneven background signal.  Objects smaller than 
the ball (here 50 pixels, ~22microns, which is approximately 2 times the size of a 
neuronal soma) are counted as foreground and preserved. 






1078 1mM 500nM 
D-AP5 0106 50mM 50µM 
CNQX 1045 10mM 10mµM 
Picrotoxin 1128 50mM (DMSO) 100µM 
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• FIJI Multimeasure function applied to subtracted image series to generate a 
mean pixel value for each region of interest for each image in the series.  Result 
saved as .csv 
• Imported into Matlab for next steps in analysis. 
• Convert data into DF/Fo format for each ROI, where the baseline (Fo) is the 
mean of the lowest 5% of values for that ROI, as measured over the entire time 
series. 
 
A visual example of the effect of registration and background subtraction is provided in 
Figure 2.6 
• Data thresholding (see also figure 2.7). 
o For glucose excited cells (GE), find mean and standard deviation of 
baseline DF/Fo (last 100s (50 values) before change to low glucose 
solution). 
o Find mean of final 100s (50 values) in low glucose solution (response).  If 
response  >3SD below baseline mean, consider as GE. 
o Exclude if falling baseline (and no sign of a washout), no response to K, 
or random events visible in trace. 
o For glucose inhibited cells (GI), plot mean of baseline DF/Fo+3SD.  If > 2 
values above this line in low glucose period, consider as candidate GI 
cell.  Then exclude as above, in particular, if spontaneous activity at the 
same level or greater is seen in the control period. 
 
2.8.1 Measuring size of response to low glucose in GE cells 
These cells exhibited a relatively consistent profile of response, examples of which are 
shown in Figure 2.7.  The size of response was assessed using the raw fluorescence data.  
This was preferred to the DF/Fo as it compared the absolute change in fluorescence, 
rather than the relative change.  The relative change is highly useful for identifying 
events within a single trace, but less so when comparing responses between different 
cells as it is dependent on the maximum and minimum observed responses within a 
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trace, which are not consistent between cells.  A rolling mean with a timeframe of 40 
seconds (20 images) was calculated in Matlab.  From this, the highest value in the 
timeframe prior to change of solution (x) and the lowest value during the response 
period at the end of perfusion with low glucose solution (y) were obtained using peak 
and trough functions in Matlab.  Peak and trough levels were preferred to simply fixing a 
time point to measure the response, as not every trace showed a maximum or minimum 
at the same time point, leading to underestimates of the size of response in some cells.  
The normalised value x-y/x was then calculated.  See Figure 2.8 for a visual summary. 
2.8.2 Measuring size of response to low glucose in GI cells 
The profiles of the responses in these cells was much more heterogenous both within 
and between experimental conditions (Figure 2.9).  The combination of some spiking 
cells and others with slower response profiles was a challenge, as a mean or peak 
measurement as used for GE cells did not accurately represent all of the data.  Area 
under the curve was also unsatisfactory as spiking cells were not well represented.  The 
method which seemed best able to detect both spiking and slow rising responses was a 
measure of the amount of time spent with calcium levels >3standard deviations above 
the mean of the baseline (with the maximum possible time set as 450seconds).  A 
maximum time was set as there is a small amount of variation in the duration of time it 
takes to capture one image, depending on the degree of zoom, and this standardised all 
of the data to include the same number of data points.  Having plotted a series of mean 
GI response traces to assess the time course of GI responses, the response period was 
measured from +100 images (~200s) after onset of low glucose to +300 images (~600s), 
as this contained the maximal response in most cells.  See Figure 2.9 for a visual 
summary of this measure. 
  




Figure 2.6 Effects of processing in FIJI on calcium images 
A Projection of maximum fluorescence over time using raw images (with false colour).  
Note 'smearing' of cell outlines due to movement in xy over time 
B Same projection after application of the template matching registration algorithm.  xy 
movement largely corrected 
C Same projection after background subtraction.  
A B C
Figure 2.6 Effects of processing in FIJI on calcium images
A Proection of maximum fluorescence over time using raw images (with false colour). 
Note 'smearing' of cell outlines due to movement in xy over time
B Same projection after application of the template matching registraion algorithm.  
xy movement largely corrected
C Same projection after background subtraction. 




Figure 2.7 Data processing pipeline for calcium imaging data 
A GE 
B GI  
1.Calculate mean and standard deviation 
of baseline (last 50 values before 
change to low glucose solution)
2.Calculate mean of final 50 values in 
low glucose solution (response)
If response >3SD below baseline mean, 
consider as GE.  
Exclude if falling baseline, no response 











1.Plot mean  of baseline +3SD.
If >2 values fall above this line in 
low glucose period, consider as GI.  



















Figure 2.8 Illustrating calculation of effect size for GE cells 
A Example of GE cell, normalised trace. 
B Cell from A redrawn using i) raw data, ii) following application of moving mean  
blue shaded area=period from which mean for baseline (peak) is obtained, green shaded 
area=period from which mean for response (trough) is obtained. Normalised value 
calculated as (y-x)/x 
C Data for a set of GE cells obtained as illustrated in B. Example cell shows where Cell 1 

























































































Figure 2.9 Illustrating calculation of effect size for GI cells 
A 2 examples of GI cells, normalised traces, one slow rising, one spiking. 
B Cells from A redrawn, blue shaded area=area to obtain mean and standard deviation 
for baseline, red shaded area=area to obtain number of points greater than 3 standard 
deviations above the mean of the baseline. 
C Data for a set of GI cells including these examples. Example cell shows where cells 














































Figure 2.9 Illustrating calculation of effect size for GI cells
A 2 examples of GI cells, normalised traces, one slow rising, one spiking.
B Cells from A redrawn, blue shaded area=area to obtain mean and standard deviation for baseline, 
red shaded area=area to obtain number of points greater than 3standard deviations above the 
mean of the baseline.  
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2.9 Hypoglycaemic models 
Please see Chapter 6 section 6.1 for a detailed discussion of models of hypoglycaemia 
and HAAF in human, rat and mouse studies. 
2.9.1 Mouse model of single hypoglycaemia  
After acclimatization to handling and daily i.p injection (with saline 50µl per day for 7 
days), mice were injected with short acting insulin i.p (2.5U/kg, Humulin S, Lilly, USA) 
and confirmed to have blood glucose <4mmol/L at 30 minutes from a tail tip blood 
sample using a handheld glucometer (Onetouch, Lifescan, UK). A control group received 
saline injections in place of insulin. 
Following the completion of the protocol, mice were terminally anaesthetised and 
perfused/fixed as described in section 2.6.2.1 for immunohistochemistry. 
2.9.2 Mouse model of recurrent hypoglycaemia 
Mice fasted for 2 hours, and then were injected i.p with rapid acting insulin (2U/kg, 
Lispro (Humalog), Lilly, USA).  Fasting was used in this protocol as it allowed a lower 
insulin dose to be used, but with reliable development of hypoglycaemia.  The insulin 
used here is more rapid acting than that used for single hypoglycaemia, with the aim of 
achieving rapid development of hypoglycaemia at lower dose, followed by reliable 
recovery.  Mice were confirmed to have blood glucose <4mmol/L, 30 minutes after each 
i.p injection using a handheld glucometer (Onetouch, Lifescan, UK). This was repeated a 
total of 4 times over a 48 hour period.  Figure 2.10 is a summary.  Control groups 
received saline injections in place of insulin (CT), or saline followed by a final single 
insulin injection (SH). 
Following the completion of the protocol, mice were either terminally anaesthetised and 
decapitated for collection of truncal blood for radioimmunoassays, or kept until the 
following day to obtain brain slices for calcium imaging.  
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                               Day 1                                                 Day 2 
                              10am                   3pm                      10am                  3pm 
 
Figure 2.10 Injection schedule for mice in 3 groups  




These assays were used in chapter 6. 
2.10.1 Truncal blood collection 
Samples for use in RIAs were collected onto ice from truncal blood, with 0.5M EDTA, 
100µL/mL added to prevent clotting and 1mg/mL aprotinin, 50µL/mL added to inhibit 
protease activity.  Plasma was obtained by centrifuging samples for 15minutes at 
3000rpm at 4 ˚C and collecting the supernatant into 100µL aliquots.  These were stored 
at -80˚C. 
2.10.2 Glucagon RIA 
2.10.2.1 Experimental procedure 
A glucagon RIA kit (GL-32K, Merck Millipore, Germany) was used according to the 
manufacturer’s instructions.  The kit uses iodine-125 as the tracer, with gamma 
radiation measured using a gamma counter (NE1600, Nuclear Enterprises, Edinburgh 
UK).  This is a competitive binding assay, using a known, limited concentration of 
glucagon antibody to bind an unknown amount of glucagon in the sample, which is in 
competition with a quantity of radioactive tracer glucagon.  As the amount of glucagon 
present in the unknown sample increases, the amount of radioactive tracer bound 
glucagon which can bind to the antibody will decrease and thus the gamma radiation 
count will decrease. 
C57Bl6 st rain, CRHXAi95D
Male (for RIA) Female (for calcium  im aging)
6-12 weeks
Day 1 Single cage
Fast
Wait  2 hours
Tail t ip for baseline blood glucose
IP insulin 2U/kg (or saline 4µl/g)
Wait  30 m inutes
Tail t ip for blood glucose
Refeed
Recover for 2 hours
If < 2m m ol, IP 20%
glucose 3µl/g
Day 2 As day 1 Tem inal anaesthesia
and collect  blood for
RIA
Day 3 Term inal anaesthesia and remove brain




Insulin Insulin Insulin Insulin
InsulinSaline Saline Saline
Saline Saline Saline Saline
Figure 3.10 Recurrent hypoglycaemia protocol
A Scheme of work over 3 days
B Table to show IP injections recieved by recurrent hypoglycaemia (RH), single hypoglycaemia
(SH) and control (CT) mice respectively
B
A
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Briefly, a standard curve was prepared using serial dilution of glucagon (400pg/mL) 
supplied in the kit to obtain standards of 25, 50, 100, 200 and 400pg/mL.  Standards, 
quality controls and samples were all pipetted in duplicate.  50µL of each sample was 
used rather than the 100µL samples suggested in the assay.  This was because all of the 
mice had undergone some degree of fasting, and the SH and RH mice were all 
hypoglycaemic at the time of blood collecting.  Therefore, many of the glucagon levels 
were expected to read higher than the fed or baseline range. 
• Each tube was incubated with 100µL glucagon antibody at 4˚C overnight. 
• 100µL glucagon I-125 tracer was then added to each tube and incubated at 4˚C 
overnight. 
• Precipitating reagent was then added for 20minutes, after which each tube was 
vortexed at 2000xg for 20 minutes at 4°C. 
• The supernatant was then decanted and discarded and the remaining 
radioactivity in the pellet counted using a gamma counter. 
2.10.2.2 Analysis 
A number of definitions were assigned: 
Total binding:  maximum possible binding of tracer to antibody. Tubes containing 
glucagon antibody, tracer and no sample or standard. 
Non-specific binding: Count due to binding of tracer to substances other than the 
antibody- e.g. interior of assay tube, assay buffer.  Tubes where glucagon tracer with no 
antibody was added. 
The mean count was calculated for each duplicated pair of results.  The count reflecting 
non-specific binding was subtracted from all other results. 
The % total binding was then calculated for each standard and each sample as follows: 
(Sample or standard/Total binding)x100 
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The standard curve % total binding was plotted against the known standard 
concentrations and the line of best fit determined. 
 
Figure 2.11 Standard curve and line of best fit for glucagon assay. 
 
Internal quality controls were then calculated from the line of best fit equation as 
follows: 
QC1 48.9pg/mL at start of assay, 58.2pg/mL at end (acceptable range 35-73pg/mL) 
QC2 106.8pg/mL (acceptable range 98-205pg/mL) 
The assay was therefore accepted as valid. 
The results for the samples were calculated and corrected for a dilution factor of 2 (50µL 
input rather than 100µL).  The normal fasting range is 50-150pg/mL.  The values 
obtained for samples from the RH protocol ranged from 43.8 to 693.8pg/mL. 
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2.10.3 Corticosterone RIA 
This assay was kindly carried out by Mrs Yvonne Kershaw in the Dorothy Hodgkin 
building according to their standard protocol for corticosterone assays.  This is a 
competitive binding RIA using corticosterone bound I-125. 
Solutions: 
• B Buffer 7.3g Tri-sodium citrate [HOC(COONa)(CH2COONa)2], 6.9g 
Sodium dihydrogen orthophosphate [NaH2PO4], 1g BSA in 1L H2O, pH 3 
with HCl 
• Charcoal solution 0.5g Dextran T70, 5g Charcoal in 1L B Buffer 
• Tracer I-125 Corticosterone (cat no IRC-123 Izotop, Institute of Isotopes, 
Hungary), diluted to give 3500-4000 CPMs per 50µL 
• Antibody Donation from Gabor Makara, Hungary, diluted 1:50 
• Stock standard (10ng/100µL), serially diluted with 100µL of B buffer 
(C2505, Sigma, UK) 
• Quality controls QC20 & QC100 (Sigma, UK) 
 
Construct the assay as shown below (all volumes are in µL) 
Table 2.13 Corticosterone RIA construction 
Tube no. Description B Buffer Sample Ab Tracer 
1-3 Total (T) 0 0 0 50 
4-6 B0 100 0 0 50 
7-28 Standards 100 0 50 50 
29 QC20 0 100 50 50 
30 QC100 0 100 50 50 
31-174 Samples 50 50 50 50 
 
• Shake/vortex for ~5 seconds 
• Incubate overnight at 4°C  
• Add 500µl of charcoal solution to each tube except T (totals) and gently 
shake/vortex. 
• Centrifuge for 15 minutes at 4000RPM and 4oC 
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• Aspirate off supernatant immediately 
• Count tubes using gamma counter.  
Data was provided in the form of the raw counts, standard curve and final calculated 
values.  Quality controls were in range according to the acceptable limits used routinely 
by the lab. 
2.11 Statistical analysis:  
Data were analysed in GraphPad Prism.  A D’Agostino-Pearson omnibus normality test 
was used to test for normal distribution of data.  Results are displayed as mean ± 
standard error unless otherwise stated.  Comparison of normally distributed groups of 
data is performed using Student's t-test or one way ANOVA with Sidak’s multiple 
comparisons test for parametric data.  Non-normally distributed data is analysed using 
Mann-Whitney or Kruskal Wallis with Dunn’s multiple comparisons and displayed as 
median ± interquartile range (IQR).  Categorical data is analysed using Chi-square.  The 
statistical tests used in each case are described in detail in the relevant results chapter 
and/or figure legend.  
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Chapter 3 CRH neurons in the paraventricular hypothalamus 
project widely to autonomic areas of the brainstem 
3.1 Introduction 
Projections to autonomic areas of the brainstem from CRH neurons are an important 
alternative means by which these neurons could effect responses to hypoglycaemia, by 
activation of neurons contributing to sympathetic outflow.  This chapter firstly discusses 
what is known about the projections of CRH PVN neurons to destinations other than the 
median eminence and pituitary gland.  Reports from non-neuronal subtype specific 
studies of PVN projections are also presented.  Most work examining projections from 
the PVN and indeed CRH neurons has been carried out in rats, and the differences 
between mouse and rat PVN anatomy is briefly discussed.  The advantages of viral 
vector neuronal tracing techniques for more detailed study of neuroanatomy are 
considered.  Results are then presented for retrograde and anterograde tracing 
experiments to demonstrate projections from CRH PVN neurons to specific autonomic 
brainstem areas. 
3.1.1 Initial identification of CRH neurons and early tracing experiments (rat) 
Following the identification of CRH expressing neurons by Bloom and colleagues (1982) 
further work identified a wide range of other sites where CRH positive cells and their 
projections could be found (Swanson et al., 1983).  Adrenalectomy and colchicine were 
both shown to increase CRH signal, colchicine throughout the brain, adrenalectomy 
solely in cells of the PVN.  However, it was difficult at that time to unpick which groups 
of neurons were projecting to which areas, as immunohistochemistry could only 
determine whether a cell body or terminal expressed CRH, but not where terminals 
originated.  In addition, not all axons were visible under these conditions. 
A large body of early work was performed in rats.  In particular Swanson et al. (1983) 
and Simmonds and Swanson (2009) extensively investigated PVN neuronal populations 
and their projections.  These studies used injection of fast blue into the bloodstream to 
identify neuroendocrine neurons, which will stain positive for fast blue as their terminals 
lie in the median eminence, which is outside the blood brain barrier.  This has been 
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shown to identify at least 98% of neuroendocrine neurons (Markakis and Swanson, 
1997).  Non-neuroendocrine cells will not stain positive as they have no direct 
connection to the circulatory system.  Simmons and Swanson (2009) largely focussed on 
identifying the anatomical location of different neuronal subtypes within the PVN.  They 
show that fewer than 1:10 CRH neurons are non-neuroendocrine, and that in the rat 
these neurons are scattered rostro-caudally throughout the PVN, although interestingly 
they do not appear within the central core of the neuroendocrine CRH population.  The 
earliest demonstration of CRH neurons projecting to the brainstem and spinal cord was 
performed by Sawchenko (1987b).  Fast blue dye was injected into the area 
postrema/NTS/DMX of a group of rats, and a second set of experiments injected fast 
blue into the thoracic spinal cord.  The fixed brains were then stained for both 
vasopressin and CRH and examined for colocalization with fast blue in cell soma in the 
PVN.  Colchicine was used in a subgroup of animals and was shown to be required to 
allow identification of CRH neurons.  In both the brainstem and spinally injected animals, 
CRH colocalization was demonstrated with fast blue, indicating a population of CRH 
neurons projecting to the brainstem and spinal cord.  Sawchenko suggested that around 
5.5% of the CRH neurons of the PVN could be pre-autonomic.  This pre-autonomic 
population has frequently been disregarded when considering the CRH neuronal 
population.  However, given that there are thought to be 2000 CRH neurons in rat PVN, 
even 5-10% of this number would still represent around 100-200 neurons. 
In addition to examining the location of different neuronal subtypes within the PVN, 
further work has examined the projections of neurons of the PVN to brainstem centres.  
Projections of neurons in the PVN to brainstem autonomic areas have been widely 
described in the rat, with areas including NTS, DMX, RVLM, locus coeruleus, and nucleus 
ambiguus (Swanson et al., 1987, Sawchenko and Swanson, 1982, Swanson et al., 1986).  
These are all important contributors to sympathetic outflow, and a CRH projection to 
these areas would certainly be a potential means to modulate SNS activation.  A 
particularly detailed and comprehensive study was performed by Geerling et al. (2010) 
which used phaseolus vulgaris leucoagglutinin (PHAL) injected into the PVN as an 
anterograde tracer to identify a wide range of PVN terminals in the areas summarised in 
table 3.1.  This work was all performed examining the projections of all neurons, rather 
than describing what the individual neuronal subtypes do (i.e. CRH).  The most extensive 
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projection to the brainstem of PVN terminals, observed in the majority of reported 
studies, is the nucleus of the solitary tract, a significant autonomic relay area. 
Table 3.1 PVN Projection targets in the brainstem courtesy of Geerling et al. (2010) 
Midbrain Ventral tegmental area 
Edinger-Westphal nucleus 
Ventrolateral periaqueductal gray matter 
Reticular formation 
Pedunculopontine tegmental nucleus 
Dorsal raphe nucleus 
Dorsal pons Pre-locus coeruleus 
Viscerosensory subregions of the 
parabrachial nucleus. 
Ventral medulla Superior salivatory nucleus 
Retrotrapezoid nucleus 
Compact and external formations of the 
nucleus ambiguous 
A1 and caudal C1 catecholamine neurons 
Caudal pressor area  
Dorsal Medulla Medial nucleus of the solitary tract 
(including A2 neurons)  
Dorsal vagal nucleus 
Area postrema 
 
3.1.2 CRH specific projections to autonomic areas of the brainstem 
Whilst the reports presented thus far provide evidence that some CRH neurons are 
indeed pre-autonomic, the destination of these autonomic projections had not been 
extensively investigated in detail, and until very recently no studies had been carried out 
in the mouse.  Indeed, in many cases all that can really be stated with confidence is that 
these neurons are not projecting to the median eminence.  More recent retrograde 
studies have demonstrated some further specific CRH connections via the brainstem.  
Work by Stanley and colleagues using pseudorabies virus injections in mice 
demonstrated connections from white adipose tissue and the liver to the PVN, possibly 
via the DMX and pontine reticular nucleus (Stanley et al., 2010).  Co-localisation was 
demonstrated with both oxytocin and CRH.  A similar study by Jansen et al. (1995) used 
pseudorabies viral tracing in rats to demonstrate a connection between the stellate 
ganglion and the PVN, with 5% of the neurons identified reported to express CRH.  
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However, in both cases the study could not specifically identify the CRH pathway to the 
brainstem, as it was a multi-synaptic tracing study carried out over time. 
3.1.3 Anatomy of the PVN in the mouse 
Whilst PVN neuroanatomy has been extensively investigated in the rat, much less work 
has been done in the mouse.  Similar cell groups and functions are ascribed to the PVN, 
but it is clear that even at a superficial level, there are significant differences in the 
neuroanatomy of the two species.  Whilst the rat PVN exhibits closely packed neurons, 
and a clear delineation between magnocellular and parvocellular compartments, in the 
mouse the neuronal subtypes are much more mixed, and the limits of the rostral and 
caudal PVN are much less easy to delineate using Nissl staining (Biag et al., 2012).  One 
publication which sought to address this examined neuropeptide expression and 
autonomic projections in the mouse PVN (Biag et al., 2012).  They examined the 
distribution of neuronal subtypes within the PVN using fast blue and fluorogold in a 
similar fashion to that described above using fast blue in the rat.  In addition to labelling 
neurons with projections to the median eminence, they also injected labels into the 
spinal cord and DMX/NTS to identify neurons projecting to brainstem autonomic 
centres.  It is clear that the majority of pre-autonomic neurons identified in this study 
are located caudally within the PVN.  The minority which are more rostral are present 
along the ventral border of the PVN.  Biag and colleagues did not go on to examine 
whether any of their pre-autonomic neurons expressed neuropeptides other than 
oxytocin and vasopressin. 
3.1.4 Colchicine treatment to facilitate neuropeptide immunohistochemistry 
One of the challenges of identifying CRH neurons in all the work described above has 
been the need for colchicine treatment in most IHC studies, to retain CRH in cell somata 
and allow their identification.  This problem is not limited to CRH neurons and affects a 
large number of peptidergic neuronal subtypes.  Colchicine acts to inhibit microtubule 
activity, preventing transport of neuropeptides to terminals and therefore concentrating 
them in the cell somata (Paulson and McClure, 1975).  Colchicine treatment is in itself a 
stressful experience for the animal, and we know that such stress can alter 
neuropeptide expression in the PVN (Swanson et al., 1986).  In addition, colchicine has 
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been observed to alter neuronal morphology (Rho and Swanson, 1989, Berkenbosch and 
Tilders, 1988). 
3.1.5 CRH neuronal subtype specific investigation 
Genetic modification ± viral tracing techniques have enabled the use of reporter 
molecules in mice to visualize CRH neurons without the need for colchicine treatment 
(Wamsteeker Cusulin et al., 2013, Alon et al., 2009, Taniguchi et al., 2011).  These gene-
reporter systems have been validated using fluorogold and CRH in the PVN, showing 
that the fluorescently labelled neurons do indeed express CRH.  The evidence for this 
and an in-house validation using ISH are covered in detail in Chapter 2, section 2.6.4. 
3.1.6 Advantages of viral tracing techniques 
The advent of viral vectors carrying reporter proteins has allowed investigation of 
neuroanatomy with greater precision and sensitivity than earlier techniques (Kantor et 
al., 2014).  In particular, use of the cre-lox system makes it possible to examine the 
connections made by a specific sub-population of neurons, delineated in time, space and 
by their neuronal subtype marker.  The choice of viral vector allows tracing to be carried 
out in an anterograde or retrograde direction or indeed across multiple synapses.  A 
wide range of viral subtypes have been used for research purposes (Nassi et al., 2015).  
Some commonly used viral vectors used in the CNS are summarised in table 3.2.  Of 
note, the choice of vector can determine whether the virus transduces cell soma at the 
injection site, axon terminals, or both.  This will affect whether anterograde or 
retrograde tracing is carried out.  In addition, some viruses can replicate and cross 
synapses.    
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Table 3.2 Properties of various viral vectors used for gene transduction into the CNS 
(Kantor et al., 2014, Bru et al., 2010, Nassi et al., 2015) 










Not integrated at 
high levels, stable 







































e.g. rabies virus 
 
ssRNA ~12kb  
NB cannot use 
Cre/FRT as no DNA 
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The viral vectors used in this chapter were chosen to allow anterograde tracing (AAV2 
vector) and retrograde tracing (CAV2 vector), without any trans-synaptic travel.  This will 
identify primary neurons only. 
The use of a viral vector in combination with the Cre-lox system is especially attractive 
as it removes any concerns regarding transient expression of Cre recombinase during 
development (Padilla et al., 2012).  Only neurons expressing Cre recombinase at the 
time of viral injection will be able to recombine a floxed vector and lead to the 
expression of a reporter protein.  In addition, the use of a reporter protein allows clear 
visualisation of a neuron and its processes without the use of inhibitors of protein 
trafficking such as colchicine. 
Potential disadvantages include problems that are experienced with any use of the Cre-
recombinase system.  Off target Cre-recombinase expression in the mouse line can 
occur, and the vector itself can exhibit non-specific or leaky expression.  In addition, 
problems with inbred mouse strains can arise.  A further issue could be considered to be 
that the reporter protein is not expressed or trafficked under the same regulatory 
elements as the native protein of interest.  This may lead to over or under amplification 
of signal compared to the native protein.  However, in general, these issues are 
outweighed by the benefits of a highly sensitive system. 
3.1.7 Evidence from electrophysiological studies with subsequent neuronal 
subtyping 
Neuronal populations in the rat PVN can be identified by their electrophysiological 
properties as either neuro-secretory, pre-autonomic, or magnocellular (Luther et al., 
2002).  Pre-autonomic neurons of the PVN have been shown to exhibit a distinct profile 
in response to a depolarising current step, with low threshold spiking and t-type calcium 
currents.  Having identified the different cell types electrophysiologically, the peptide 
profile of putative pre-autonomic neurons was then identified using IHC after the 
recording (Melnick et al., 2007).  Almost half of the PVN neuro-secretory neurons 
(47/95) were found to be positive for CRH.  Interestingly, 35/74 pre-autonomic neurons, 
thought to project to the brainstem, were also found to contain CRH.  This is a higher 
proportion than might have been expected from the previous neuroanatomical studies.  
Chapter 3 CRH neurons in the paraventricular hypothalamus project widely to 
autonomic areas of the brainstem 
96 
 
Differences could be explained by the differing methods of identifying pre-autonomic 
neurons, or indeed by a bias towards patch clamping CRH neurons compared to other 
neuronal subtypes. 
3.2 Hypotheses 
• A specific subpopulation of CRH neurons arising in the PVN will target brainstem 
autonomic areas 




• Use retrograde tracing from the brainstem to investigate the anatomy of pre-
autonomic CRH cell bodies in the PVN 
• Use anterograde tracing from the PVN to delineate and describe the projections 
of CRH PVN neurons 
 
3.4 Results 
3.4.1 TdTomato fluorescence was readily observed in sections from CRH x Td 
mice  
The mice used in the experiments described in this chapter were CRH x Td and CRH-ires-
Cre.  CRH x Td mice were generated by crossing CRH-ires-Cre males with TdTomato 
females.  Expression of TdTomato in areas previously reported to express CRH (including 
the PVN, median eminence, amygdala, bed nucleus of the stria terminalis, Barrington’s 
nucleus and scattered cortical interneurons) was observed on fluorescent microscopy 
(Figure 3.1).  No amplification of the native TdTomato signal was needed to enable 
visualisation of presumed CRH neurons.  
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Figure 3.1 TdTomato expression in sections from a CRH x Tdtomato mouse in areas 
known to express CRH 
A PVN and median eminence, merged images with DAPI and TdTomato 
B Central amygdala and bed nucleus of the stria terminalis 
3V Third ventricle, CEA- central amygdala, BLA- basolateral amygdaloid nucleus, AC 
anterior commissure, BNST- bed nucleus of the stria terminalis  
Figure 3.1 TdTomato expression in sections from a CRH x Tdtomato mouse in areas known
to express CRH
A PVN and median eminence, merged images with DAPI and TdTomato
B Central amygdala and bed nucleus of the stria terminalis
3V Third ventricle, CEA- central amygdala, BLA- basolateral amygdaloid nucleus, AC anterior
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3.4.2 Anterograde tracing 
3.4.2.1 Injection sites 
8 homozygous CRH-ires-Cre mice were unilaterally injected with AAV_DIO-mCherry 
adenovirus to the mid PVN (see Methods section 2.3 for details of this virus).  Mouse 
characteristics are summarised in table 3.3 
Table 3.3 Characteristics of mice having injections of AAV_DIO-mCherry to PVN 














42624 M 6 2 Coronal Transverse n/a 
42623 M 6 2 Coronal Transverse n/a 
41067 F 6 2 Coronal Transverse n/a 
43825 F 11 4 Coronal Parasagittal n/a 
43824 F 11 4 Coronal Parasagittal n/a 
43823 F 11 4 Coronal Parasagittal n/a 
45937 F 10 4 Parasagittal Parasagittal Transverse 
47832 M 12 4 Parasagittal Parasagittal Transverse 
 
Transduction at the site of injection was confirmed in all 8 mice by histology and 
microscopy of the injection site.  Examples of injection sites from sections cut coronally 
and parasagittally are shown in Figure 3.2. 
There is a small amount of spread across the midline to transduce cell somata visible in 
some transverse sections, but the injection was largely confined to a unilateral site. 
Longer incubation following injection appeared to result in more readily visible terminals 
in the brainstem, but did not greatly affect the number of cells visibly transduced in 
PVN.  No differences in the numbers of transduced cells or projection patterns were 
observed between males and females.  
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Figure 3.2 Injection sites in the PVN 
A CRH-Cre mice were injected with AAV-DIO mCherry to the PVN.  Diagram shows the 
planned coordinates 
B Example of viral transduction within PVN, coronal slices.  Immunohistochemistry used 
to enhance mCherry fluorescence. Red; Alexa 594 in CRH neurons expressing mCherry.  
Blue; DAPI 
C Further example as above but sliced parasagitally. 
3V- third ventricle 
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3.4.2.2 Localised projections 
The main projection within the hypothalamus was to median eminence, as illustrated in 
figure 3.3A.  The tracts ending in the median eminence passed laterally and then 
medially around the periphery of the hypothalamus. 
Sparse terminals were observed in other areas of the hypothalamus.  Very few terminals 
were observed in the arcuate nucleus (Figure 3.3A).  The VMN received a moderate 
innervation whilst the DMN and lateral hypothalamus were sparsely innervated (Figure 
3.3B). 
3.4.2.3 CRH neuronal axonal tracts to brainstem 
Two major tracts were observed running from the CRH PVN neurons and descending to 
brainstem.  The first runs below the fornix and then into the PAG before entering the 
brainstem and travelling laterally to join the more ventral tract.  The second runs more 
laterally into the ventral medulla.  These pathways are illustrated in figure 3.4.  Very few 
fibres were observed to travel to other areas, in particular no major forebrain 
projections were identified in the cortex, amygdala, BNST or hippocampus. 
3.4.2.4 CRH neuronal terminals in the midbrain 
Terminals with varicosities as well as fibres of passage were observed within the PAG 
(Figure 3.5 A,B).  A similar picture was observed for the ventral tegmental area (Figure 
3.5 C). 
3.4.2.5 Terminals in the pons 
The locus coeruleus received sparse innervation, with terminals more readily visible in 
the adjacent medial and lateral areas (pre-locus coeruleus) (Figure 3.6A).  The 
parabrachial nucleus, both the medial and lateral parts, received moderate inputs from 
CRH terminals (Figure 3.6 A and B).  The dorsal raphe also received sparse innervation 
(Figure 3.7).  
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Figure 3.3 Local projections of CRH neurons within the PVN 
A Dense projection to median eminence compared to absence of fibres in arcuate 
nucleus. Red; Alexa 594 enhanced CRH-Cre mCherry fibres. Blue; DAPI 
B Moderate density of fibres seen in VMN and sparse fibres in DMN when compared to 
median eminence in sagittal sections  
ME- median eminence, ARC- arcuate nucleus, VMN- ventromedial nucleus, DMN- 
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Figure 3.4 Two main tracts of CRH fibres projecting from PVN to mid and hindbrain 
A Diagram and widefield image to illustrate both periventricular and ventromedial tracts 
running close to midline in a sagittal section. Red; Alexa 594 enhanced mCherry in CRH 
neurons. Blue; DAPI 
B Fibres running in the periventricular tract. 











Figure 3.4 Two main tracts of CRH fibres projecting from PVH to mid and hindbrain
A Diagram anfd widefield image to illustrate both periventricular and ventromedial
tracts running close to midline in a sagittal section. Red; Alexa 594 enhanced mcherry
in CRH neurons. Blue; DAPI
B Fibres running in the periventricular tract.
C Fibres running trough the ventral tegmental area in the ventromedial tract.
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Figure 3.5 Fibres from CRH PVN neurons in the periaqueductal grey and ventral 
tegmental area. 
A Images to show lateralisation of fibres in the mid brain- fibres visible in left 
ventrolateral PAG (i), not in right (ii).  Fibres indicated by arrows 
B Sagittal section showing fibres running in ventrolateral PAG (white arrows) 
C Sagittal section showing fibres in the VTA, some fibres of passage and others with 
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Figure 3.6 Projections to locus coeruleus and parabrachial nucleus 
CRH PVN fibres were observed in lateral and medial parabrachial nuclei, very limited 
evidence of fibres in locus coeruleus 
A Sagittal section showing CRH PVN fibres in PBN (i), with limited puncta of uncertain 
significance in the LC (ii). 
B Transverse section showing CRH PVN fibres in both the lateral and medial parabrachial 
nuclei (white arrows) 
  
PBN
RED Alexa 594 enhanced mcherry in CRH PVN neurons
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Figure 3.7 CRH PVN fibres in the dorsal raphe 
Green neurons are stained for TrH to identify serotoninergic neurons of the dorsal 
raphe.  Red is mCherry from CRH PVN fibres 
A Transverse section 
B Sagittal section.  Inset schematic to show location of dorsal raphe (DRaphe, orange) 
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3.4.2.6 Terminals in the medulla 
The nucleus of the solitary tract received the densest innervation from CRH neuronal 
terminals, the dorsal motor nucleus of the vagus received a moderate input whilst the 
hypoglossal nucleus received few or no terminals (Figure 3.8).  It was possible to 
quantitate innervation to these three structures as they were all visible in the same 
images, and the results are summarised in figure 3.9.  Fibres were only counted if they 
were clearly linear structures, >5µm long.  More detail regarding quantification can be 
found in methods section 2.6.5.3. 
CRH terminals with varicosities were observed in close apposition to A2 cell bodies in 
the NTS, and similarly varicosities in close apposition to cholinergic neuronal cell bodies 
were observed in the DMX (Figure 3.10). 
Moderate innervation was observed in the ventral raphe (Figure 3.11) and the RVLM 
(Figure 3.12).  The nucleus ambiguus received a very sparse innervation, although more 
terminals were seen in the area around the NAmb, which includes the C1/A1 neurons 
(Figure 3.12).  
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Figure 3.8 CRH PVN fibres in NTS and DMX 
A Transverse section with CHAT staining to identify cholinergic neurons of the DMX. 
CRH fibres clearly visible in NTS and DMX (white arrows) 










RED Alexa 594 enhanced
mcherry in CRH neurons
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Figure 3.9 Quantification of terminals in the nucleus of the solitary tract, dorsal motor 
nucleus of the vagus and hypoglossal nucleus 
A Terminal counts are higher in the DMX and NTS compared to the HG.  Data shown as 
mean ± SEM.  One way ANOVA with multiple comparisons, p=0.0092. NTS vs HG 95% CI 
4.6-24.0 (**), DMX vs HG 95% CI 1.3-20.7 (*), NTS vs DMX 95% CI -6.3-13 (ns).  
B Comparison of terminal counts at 6 levels rostral to caudal along a longitudinal section 
of i) NTS and ii) DMX, with superimposed lines of best fit.  No significant trend in 
regression for NTS (R square= 0.075).  Significant trend to increased terminal counts in 
more caudal areas for DMX (R square=0.23)  
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Figure 3.10 CRH PVN fibres in close proximity to autonomic neuronal cell bodies in the 
brainstem 
A Confocal images of an A2 neuron within the NTS, with CRH fibres in close proximity.   
1-5 are sequential z planes at 0.5micron intervals.  MAX is a maximal projection of entire 
21 slice z stack 
B Confocal images of a cholinergic neuron within the DMX with closely apposed CRH 
fibre.  Details as for A  
















Figure 3.10 CRH PVN fibres in close proximity to autonomic neuronal cell bodies in the brainstem
A Confocal images of an A2 neuron within the NTS, with CRH fibres in close proximity.  
1-5 are sequential z planes at 0.5micron intervals.  MAX is a maximal projection of entire 21 slice 
z stack
B Confocal images of a cholinergic neuron within the DMN with closely apposed CRH fibre.  
Details as for A.
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Figure 3.11 CRH PVN fibres within the ventral raphe 
Green neurons are stained for TrH to identify serotoninergic neurons of the ventral 
raphe 
Inset diagram top right to illustrate anatomical location of ventral raphe (orange, VR) 3V 
third ventricle, 4V fourth ventricle 
Left panel- transverse section 
Right panel- parasagittal section. 
CRH PVN fibres indicated by white arrows  
Figure 3.10 CRH PVN fibres within the ventral raphe
Green neurons are stained for TrH to identify serotinergic neurons of the ventral raphe
A Transverse section
B Sagittal section.
CRH PVN fibres indicted by white rrows
4V
3V VR
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Figure 3.12 Sparse CRH PVN fibres around the nucleus ambiguus, with relative sparing 
of the compact NA 
A Sagittal section showing CHAT positive neurons within the NAmb and more ventrally 
C1 in green, and CRH PVN fibres in red.  CRH PVN fibres are largely seen running 
longitudinally. 
B Transverse section through NAmb showing fibres in the surrounding areas, likely 
C1/A1/RVLM, but sparing the compact part of the NAmb  
NANA
A B
Figure 3.11 Sparse CRH PVN fibres around the nucleus ambiguus, with relative sparing 
of the compact NA
A Sagittal section showing CHAT positive neurons within the NA and more ventrally C1 in green, 
and CRH PVN fibres in red.  CRH PVN fibres are largely seen running longitudinally.
B Transverse section through NA showing fibres in the surrounding areas, likely C1/A1/RVLM, but sparing the
compact part of the NA
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Table 3.4 Summary of CRH innervation density 
 Nucleus Fibre density 










Dorsal pons Locus coeruleus 
Pre-locus coeruleus 
Medial parabrachial nucleus 





Ventral medulla Nucleus ambiguus 
Compact 
external 











Dorsal medulla Nucleus of the solitary tract 
(including A2 neurons)  





A map of these projections is contained in Figure 3.13   
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Figure 3.13 Map to illustrate relative density of innervation of various autonomic areas 
by CRH PVN neurons 
4V; Fourth Ventricle, VLPAG; ventrolateral periaqueductal gray, DRaphe; dorsal raphe, 
NTS; Nucleus of the solitary tract, DMX; dorsal motor nucleus of the vagus, VRaphe; 
ventral raphe, VTA; ventral tegmental area, MPBN; medial parabrachial nucleus, C1/A1; 
C1/A1 catecholaminergic neurons, LPBN; lateral parabrachial nucleus, NAmb; nucleus 



















Figure 3.12 Map to illustrate relative density of innervation of various autonomic areas 
by CRH PVN neurons
4V; Fourth Ventrical, VLPAG; ventrolateral periaqueductal gray, DRaphe; doral raphe, NTS;
Nucleus of the solitary tract, DMN; dorsal motor nucleus of the vagus, VRaphe; ventral 
raphe, VTA; ventral tegmental area, MPBN; medial parabrachail nucleus, C1/A1; C1/A1 
chatecholaminergic neurons, LPBN; lateral parabrac hial nucleus, NA; nucleus ambiguus
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3.4.2.7 Spinal cord projections 
Coronal spinal cord sections from mid thoracic cord showed evidence of a tract running 
in the lateral funiculus, and terminal varicosities in the region of the sympathetic 
preganglionic cell bodies as identified by CHAT positive staining (Figure 3.14).  
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Figure 3.14 Projections of CRH PVN neurons to sympathetic pre-ganglionic neurons of 
the mid thoracic spinal cord 
A Diagram of transverse section of mid thoracic spinal cord to show location of 
sympathetic pre ganglionic neurons (SPNs) and location of images. 
B Maximal projections of a 21 plane z stack from confocal microscopy to show (i) fibres 
running in the tracts of the lateral fasiculus, (ii) fibres apposing SPNs and (iii) fibres 
extending from SPNs towards the central canal.  Arrows in white indicate fibres 
C Control area- CHAT positive neurons from the ventral horn with no CRH fibres seen 
D CRH PVN fibres in close proximity to CHAT stained SPNs. 5 sequential z planes at 
0.5micron intervals.  MAX is the projection of the entire 21 plane z stack.  White arrows 
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3.4.3 Retrograde tracing of pre-autonomic neurons projecting to the NTS/DMX 
The NTS/DMX was chosen as the best site for injections for retrograde tracing because it 
was the site of the densest projections and has previously been shown to be a target of 
the PVN.  Successful targeting of CAV-CMV-eGFP viral injection to the NTS/DMX was 
confirmed in 4 animals with IHC for eGFP (Figure 3.15).  Their characteristics are 
summarised in table 3.5.  This virus primarily acts as a retrograde tracer, but does also 
transduce neurons locally and the reporter protein (eGFP) fills the cell projection tree.  
CAV viruses do not cross synapses.  The CMV promoter is a non-specific promoter, so 
will express eGFP in all transfected neurons. 
Table 3.5 Characteristics of mice having injections of CAV-CMV-eGFP to NTS/DMX 











C F 11 2 Transverse Transverse 
D F 11 2 Transverse Transverse 
E F 11 3.5 Transverse Transverse 
G F 11 3.5 Transverse Transverse 
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Figure 3.15 Injection site in NTS/DMX 
Top: Injection schematic 

















Figure 3.14 Injection site in NTS/DMN
A Injection schematic
B Injection site and local projections to contralateral NTS and ventral raphe
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3.4.3.1 eGFP positive cell bodies in the hypothalamus 
eGFP cell bodies (retrograde) and fibres (anterograde fills) were identified in the PVN, 
indicating that the PVN both projects to and receives projections from the NTS/DMX, as 
previously reported (Biag et al., 2012).  eGFP positive cell bodies are retrogradely 
transduced cells sending fibres to the NTS/DMX.  Cell bodies were seen in the caudal 
PVN, LH and Zona incerta (ZI) which connects PVN and LH (Figure 3.16 and table 3.6).  
This corresponds with previous reports of the locations of pre-autonomic neurons within 
the PVN in mice (Biag et al., 2012).  38.6% of the pre-autonomic neurons identified in 
each mouse were also positive for TdTomato, indicating that a substantial proportion of 
these pre-autonomic neurons express CRH. 








% of pre-autonomic 
neurons identified 
which are CRH+ 
Paraventricular 
hypothalamus 
30 ±3 9 ±2 30 ±3 
Lateral 
hypothalamus 
32 ±12 17 ±11 32 ±12 
Zona incerta 8 ±2 1 ±0 12.5 
n=4 mice, 1:4 series 
The data from all 4 animals was collated to generate a map of CRH positive cells 
projecting to the NTS, as shown in Figure 3.17.  
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Figure 3.16 A subset of CRH neurons project to the NTS/DMX as evidenced by 
retrograde labelling 
Co-labelling of neurons for CRH (red, Tdtomato), and retrogradely transported GFP from 
NTS/DMX.  White arrows indicate cell bodies with both Tdtomato and GFP  
Green: Retrogradely labelled 
cell bodies with terminals in 
NTS/DMN- Alexa 488 enhanced
GFP
Red: CRH neurons expressing 
Tdtomato
Blue: DAPI
Figure 3.15 A subset of CRH neurons project to the NTS/DMN as evidenced by retrograde 
labelling
Co-labelling of neurons for CRH (red, Tdtomato), and retrogradely transported GFP from 
NTS/DMN.  White arrows indicate cell bodies with both Tdtomato and GFP
3V
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Figure 3.17 Map of PVN neurons retrogradely transduced from the NTS 
Unilateral NTS injection in one representative mouse (Mouse C) 
Black arrow; pre-autonomic neuron 
Red arrow; pre-autonomic neuron co-expressing CRH  
Bregma -0.70 Bregma -0.82
Bregma -0.94 Bregma -1.06
Bregma -1.22 Bregma -1.34
Figure 3.16 Map of retrogradely transduced neurons following NTS injection from one 
representative mouse (Mouse C)
Black arrow; one pre-autonomic neuron
Red arrow; one pre-autonomic neuron co-expre sing 
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This is the first demonstration of a CRH PVN pre-autonomic pathway in the mouse.  This 
PVN-brainstem tract has previously been identified in mice, but neuronal subtypes were 
not investigated (Biag et al., 2012).  These data also provide more details regarding the 
targets of these neurons when compared to previous studies in the rat (Sawchenko, 
1987b, Simmons and Swanson, 2009).  In rats, evidence had been presented that some 
PVN neurons are CRH expressing but do not belong to the neuroendocrine population 
(projecting to the pituitary gland), and these were hypothesised to have autonomic 
projections (Swanson et al., 1983, Simmons and Swanson, 2009, Sawchenko, 1987b).  Up 
until this thesis, the sole area of the brainstem that had been clearly demonstrated to 
receive CRH PVN terminals was the NTS/DMX.  Investigations regarding which other 
areas of the brainstem such neurons would project to have not previously been carried 
out, although reports of multi-synaptic connections to via brainstem outflow tracts to 
downstream autonomic targets had been published (Jansen et al., 1995, Stanley et al., 
2010).  There were no other reports regarding CRH expression in pre-autonomic neurons 
of the PVN in mice at the time that this study was carried out.  However, a subsequent 
very similar experiment has been carried out as part of the Allen Mouse Brain Atlas 
connectivity project, experiment 266840498 (Oh et al., 2014, Atlas, 2011).  In this 
experiment, an AAV encoding floxed EGFP was injected into the PVN of a CRH-ires-Cre 
mouse of an alternative strain, developed by Lowell and colleagues (Kong et al., 2012).  
Data in the study is presented visually and also as a total projection volume for each 
area of the brain.  It is not clear whether terminal projecting fibres were differentiated 
from fibres of passage or puncta.  The results are broadly comparable to those 
presented here, with particular enrichment of terminals in the NTS, DMX, reticular 
nuclei, and raphe magnus in the medulla, the parabrachial nucleus in the pons and the 
PAG in the midbrain.  Within the hypothalamus itself, increased local terminals are 
reported in the periventricular nucleus, ARC, DMN, medial preoptic area, sub 
paraventricular zone, anterior hypothalamic nucleus, LH, posterior hypothalamic 
nucleus, parasubthalamic nucleus, perifornical nucleus, retrochiasmatic nucleus, tuberal 
nucleus and ZI, as well as the ME.  The VMN does not appear to receive as many fibres in 
this study.  The study also reports a significant projection to the thalamus, but on 
examining the images, much of this appears to be due to transduction of cells dorsal to 
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the PVN in the path of the injection.  Projections to forebrain structures are also 
described, but because they are presented as total volume rather than density of 
projection, they appear more substantial in numerical values than when viewing the 
fibres, as the total area of the forebrain is much larger.  Indeed, only the BNST and 
central amygdala appear to have increased density of fibres when the sections are 
inspected visually. 
The existence of a CRH expressing population of autonomic projecting neurons is of 
particular interest in the context of the counterregulatory response to hypoglycaemia, 
as the autonomic component of this response is more rapidly activated than the HPA 
axis, and is key to maintaining effective counter-regulation and hypoglycaemia 
awareness, as discussed in sections 1.4 and 1.6 of the introduction.  This therefore 
strengthens the case for a role for CRH PVN neurons in this scenario. 
3.5.1 Local projections 
Projections within the hypothalamus are dominated by the major projection to the 
median eminence, a finding in alignment with previous descriptions of non-subtype 
specific projections within the hypothalamus (Geerling et al., 2010).  Interestingly, it is 
also clear that there are extensive CRH dendritic networks within the PVN itself.  It was 
not clear from the experiments reported here whether these fibres originated from 
neuroendocrine or pre-autonomic cells.  However, this effect has previously been 
reported in the mouse for pre-autonomic, non-subtype specific PVN neurons, with 
dendritic networks essentially extending to form a shell around the whole 
neuroendocrine PVN (Biag et al., 2012).  Liposits et al. (1985) used electron microscopy 
and immunohistochemistry to examine local CRH circuits in the PVN.  They report 
extensive connections between CRH neuronal axons and CRH as well as non CRH 
containing neuronal soma and dendrites of the PVN.  These connections may represent 
a means by which neurons can feedback directly via local networks and has been 
suggested to provide a means of ultrashort negative feedback (Liposits et al., 1985, 
Herman et al., 2003).  
Fibres are seen within the bounds of the VMN (and to a lesset extent the DMN), but 
these are sparse in comparison to the main tracts.  Interestingly, the VMN is known to 
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contain CRH/urocortin receptors, and CRH/urocortin have been reported as modulating 
glucose sensing in this nucleus (McCrimmon et al., 2006, McCrimmon RJ, 2005).  Few or 
no fibres were seen within the arcuate nucleus.  In general, this fits with the hypothesis 
that whilst the PVN receives extensive inputs from other areas of the hypothalamus, its 
own outflow is not predominantly to these same areas. 
3.5.2 Tracts to brainstem 
CRH neuronal fibres travel in two major tracts towards the brainstem, again closely 
matching descriptions of generalised PVN projections from anterograde studies (Saper 
et al., 1976, Luiten et al., 1985).  There appears to be a degree of lateralisation in these 
fibre tracts in their early course, and at the level of the PAG, but beyond the midbrain 
the innervations of centres in the brainstem appeared to be bilateral.  It is likely that a 
bilateral injection to the PVN would result in a larger number of visible fibres. 
Previous evidence from the literature suggests that the ventral tract is the main source 
of innervation for the hindbrain and spinal cord, and that the dorsal tract does not 
continue significantly beyond the midbrain as a separate entity; the remaining fibres 
from the dorsal tract travel laterally to join the ventral tract (Luiten et al., 1985). 
3.5.3 Targets in the mid brain 
Both the PAG and VTA received projections from the CRH PVN neurons, in addition to 
fibres passing through these regions.  The ventrolateral PAG, where most terminals were 
observed, is a centre with known projections to the raphe magnus and RVLM, and is 
thought to be of importance in coordinating the behavioural, autonomic and 
antinociceptive responses to stressful stimuli (Behbehani, 1995).  The VTA contains 
multiple dopaminergic neurons and is a key area for motivation, reward or aversion.  It 
has many connections to the forebrain, unlike most of the projections of the CRH PVN 
neurons.  VTA activity measured by BOLD fMRI signal in humans has been shown to be 
altered by hyper-insulinaemia, which tends to depress VTA activation and reduce the 
palatability scores of foods.  This effect is lost in insulin resistant individuals (Tiedemann 
et al., 2017).  A further study using fMRI in healthy human subjects showed VTA 
activation during mild hypoglycaemia in obese individuals (Page et al., 2011).  This 
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suggests that the VTA may be implicated in food seeking behaviour during 
hypoglycaemia.   
3.5.4 Autonomic targets in the pons and medulla 
A wide range of autonomic targets were identified throughout the brainstem.  The NTS 
received by far the densest innervation in these studies.  This is of interest as this is a 
key autonomic relay area, and has previously been identified as playing a role in the 
counter-regulatory response to hypoglycaemia (Lamy et al., 2014, Marty et al., 2005, 
Ritter et al., 2000).  In addition, the NTS has previously been shown to directly and 
indirectly respond to hypoglycaemia (Adachi et al., 1984, Balfour et al., 2006). 
Other areas of particular interest include the RVLM, which has recently been implicated 
in stress induced hypoglycaemia (Zhao et al., 2017), with a necessary input from the 
PVN.  It is tempting to speculate that the pathway identified here could contribute the 
response described, in the context of hypoglycaemia, with activation of CRH PVN 
neurons in response to hypoglycaemia contributing to activation of catecholaminergic 
RVLM neurons, which in turn can clearly act to increase glucose levels via descending 
projections to the spinal cord. 
The lateral parabrachial nucleus also received a significant input from the CRH PVN 
neurons.  Again, this is a nucleus that has been shown to be important for counter-
regulation to hypoglycaemia, and indeed can also sense changes in glucose (Flak et al., 
2014, Garfield et al., 2014).  Interestingly, the effect of the PBN to effect counter-
regulation was upstream to the ventromedial hypothalamus in this study, rather than 
via activation of the sympathetic nervous system.  Given the known projections from 
VMN to PVN, it is possible that these anatomical connections could represent a closed 
feedback loop important in the counter-regulatory response. 
In general, the areas with fibres closely followed those previously identified in non-
subtype specific tracing experiments in the rat (Geerling et al., 2010, Luiten et al., 1985).  
There were some significant differences, however.  Of particular note, the NAmb does 
not appear to receive a significant input from CRH neurons of the PVN.  The compact 
part of the NAmb has primarily been identified as important for swallowing and 
Chapter 3 CRH neurons in the paraventricular hypothalamus project widely to 
autonomic areas of the brainstem 
125 
 
laryngeal control.  The external formation of the NAmb is important for parasympathetic 
cholinergic outflow to the heart, and has previously been demonstrated to have 
innervation from vasopressin and oxytocinergic neurons of the PVN modulating this 
outflow (Buijs, 1978).  Given that CRH neurons appear to have a greater role in 
sympathetic outflow, it is perhaps less surprising that they do not appear to have a 
major projection to the compact NAmb. 
The locus coeruleus also exhibited a paucity of terminals from the PVN CRH neurons.  
This fits with previous reports that much of the CRH input to the LC comes from the 
central amygdala (McCall et al., 2015).  Geerling and colleagues also described minimal 
projections from non-specific PVN neurons to the LC, and similarly to here, saw more 
terminals in the pre-LC (Geerling et al., 2010). 
Interestingly, the sympathetic preganglionic neurons of the thoracic spinal cord also 
clearly received CRH PVN innervation.  This is a new finding and represents a further 
direct means by which these neurons could modulate the known counter-regulatory 
response to hypoglycaemia.  The sections in which the SPN/CRH terminals were 
observed were from the mid thoracic regions, which are known to supply the abdominal 
viscera via the coeliac and superior mesenteric ganglia, which includes innervation to 
the pancreas and adrenal glands, areas which are clearly relevant to the 
counterregulatory response to hypoglycaemia.  A previous tracing experiment had 
demonstrated a connection between the CRH PVN neurons and the cervical spinal cord 
in rats, but this was a retrograde study, and so did not examine specific spinal cord 
targets, and aimed to label all fibres of passage passing through the cervical spinal cord 
(Sawchenko, 1987a). 
3.5.5 Retrograde tracing 
The second experiment carried out here explored the location of CRH neurons within 
the PVN with projections specifically to the NTS/DMX.  As would have been predicted 
from earlier work, these neurons were located primarily in the caudal part of the PVN 
and extending into the zona incerta and lateral hypothalamus- this area has been 
described as a continuation of the caudal PVN in the mouse (Biag et al., 2012).  Whilst 
the rat is thought to have around 2000 CRH PVN neurons, work by Biag et al. (2012) 
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suggest the mouse has a smaller population; ~1650 (n=3).  Wamsteeker et al. (2013) 
used fluorogold to identify the neuroendocrine population and suggested that ~86% of 
CRH neurons in their model were neuroendocrine (so a maximum of 14.1% could be pre-
autonomic), whilst previous work in rats suggested that a figure of 5-10% might be pre-
autonomic (Sawchenko, 1987b).  Extrapolating from these figures, we might estimate 
that a maximum of 82-230 neurons might be pre-autonomic (5-14% of 1646 neurons).  
We here counted a mean of 9 CRH PVN neurons to be pre-autonomic with projections to 
the NTS/DMN, in a 1:4 series.  The total number including zona incerta and lateral 
hypothalamus CRH neurons was 27.  If these figures are multiplied up and an 
Abercrombie correction applied, the value achieved for the PVN CRH neurons is 30, a 
rather smaller number than extrapolated here.  For the ZI plus LH plus PVN, the value is 
90, which falls within the estimated number mentioned above.  This work was based on 
a unilateral injection at one level of NTS/DMX.  We might expect somewhat larger 
numbers of neurons to be labelled with a bilateral injection, or indeed with injection at 
multiple levels of the NTS.  In addition, further neurons might project only to other 
nuclei within the brainstem. 
3.5.6 Summary 
This chapter expands and develops previous work examining the projections of CRH PVN 
neurons to autonomic areas of the brainstem.  In particular, the mapping of detailed 
CRH PVN outflow to the brainstem and spinal cord in the mouse is novel and useful.  In 
the context of hypoglycaemia and HAAF, the sympathetic outflow of the brainstem is of 
particular interest.  Key brainstem areas involved in sympathetic outflow include the 
RVLM, caudal ventrolateral medulla and the NTS, with inputs from higher centres 
including circumventricular organs and the paraventricular nucleus.  The data presented 
here confirm that CRH PVN neurons project to all three of the major centres in the 
medulla oblongata, as well as further down to the sympathetic preganglionic neurons of 
the spinal cord.  This provides clear neuroanatomical routes by which these neurons 
might modulate the response to hypoglycaemia. 
The question of what signalling molecules might be released by these pre-autonomic 
CRH neurons has been addressed in previous work.  It is known that pre-autonomic PVN 
neurons express a wide range of peptides including CRH and glutamate, but not GABA.  
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CRH PVN neurons in rats have been previously shown to express glutamate transporters 
(VGLUT2) using immunofluorescence and single cell RT-PCR (Dabrowska et al., 2013).  
Similar work has not been performed in the mouse.  CRH receptors are expressed in 
certain brainstem areas, including the NTS, PAG, VTA, LC and raphe nuclei (Henckens et 
al., 2016), but are not expressed in all of the areas that CRH neurons of the PVN appear 
to project to, and therefore it seems likely that additional signalling molecules, for 
example glutamate, are also likely to be employed. 
With regard to the retrograde tracing study presented here, it is clear from work in 
other areas of neuroscience that even a small population of neurons can have a 
significant effect on physiology, if they are placed at a pivotal point in a circuit.  A recent 
example would be the identification of a small population (~30 neurons) of parvocellular 
oxytocin neurons in the PVN which, when activated, can cause significant functional 
analgesia in a model of inflammatory pain (Eliava et al., 2016).  The population identified 
here certainly appear to be ideally suited anatomically to collate information about 
whole body homeostasis and effect/modulate responses throughout the autonomic 
system.
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Chapter 4 Evidence for glucose sensitivity in PVN CRH 
neurons 
4.1 Introduction 
This chapter sets out the background to what is known about glucose sensing within the 
CNS, and in particular the hypothalamus.  The proposed mechanisms underlying glucose 
sensing in the CNS will be discussed in Chapter 5 and are not covered here.  New 
evidence for glucose sensitivity in CRH PVN cells is then presented, using both 
electrophysiological recordings and calcium imaging in vitro. 
4.1.1 Glucose sensing by specific neurons within the central nervous system. 
Glucose sensing neurons within the central nervous system were first described by 
Oomura and colleagues (1969, 1964) and Anand and colleagues (1964).  In these studies, 
extracellular recordings in vivo were made from the ventromedial nucleus of the 
hypothalamus in anaesthetised cats and dogs, and responses to intravenous infusion of 
glucose and/or insulin were recorded.  Glucose sensing neurons exhibit distinct 
responses to increases in glucose levels; glucose-excited neurons increase their firing 
rate, while glucose inhibited neurons are silenced.  This effect is independent of changes 
in osmolarity.  Hypoglycaemia can cause more generalised reductions in neuronal 
activity due to reductions in energy supply, but the response of the glucose sensing 
populations was distinct in that reversible increases and decreases in activity were seen 
in direct response to changes in glucose levels (Mobbs et al., 2001).  Other neurons 
within the CNS show responses to changes in glucose due to alterations in synaptic 
inputs, but true glucose sensing is direct/intrinsic i.e. persists in the presence of synaptic 
blockade (Fioramonti et al., 2017). 
4.1.2 Defining electrophysiological responses to glucose 
A wide variety of electrophysiological methods have been used to identify and 
categorise neurons as GI, GE or non-responsive.  Depolarisation and hyperpolarisation as 
measured in current clamp are commonly used measures of response, often in 
combination with changes in action potential frequency (Fioramonti et al., 2007, 
Fioramonti et al., 2004, Garfield et al., 2014, Gonzalez et al., 2008).  Changes in 
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membrane resistance in response to current steps, indicative of ion channels opening or 
closing, are also commonly used (Burdakov et al., 2005a, Fioramonti et al., 2007, 
Gonzalez et al., 2008).  In addition, the tendency of a given cell to fire in response to a 
current step has also been used as evidence of increased or decreased excitability 
(Burdakov et al., 2005a).  Relatively few papers list absolute thresholds above or below 
which a cell is defined to be a responder, most commonly the group of cells deemed to 
be GE or GI are presented as having a statistically significant change in, for example 
resting potential.  Comparable data is sometimes available for non-responsive neurons 
but not in all cases.  This can present problems in interpreting the statistical significance 
of the effects seen due to selection bias.  For example, if the only data presented is from 
10% of cells, which show a depolarisation in response to a glucose step, whilst the other 
90% are not discussed, then the question arises as to why that threshold was set, and 
how the other cells responded.  If they all, in fact, depolarised to a much lesser extent, 
that would be very different from if they behaved in a heterogeneous fashion, or did not 
change their activity at all.  Care should therefore be taken in interpreting results. 
4.1.3 Physiological glucose levels within the central nervous system 
Initial descriptions of glucose sensing neurons within the CNS used steps in glucose 
to/from 10mM, in vivo as intravenous infusions (Oomura et al., 1964, Oomura et al., 
1969, Anand et al., 1964).  With the development of acute slicing and recording 
techniques, an arbitrary choice of glucose level to use in the slices was made.  Therefore 
early in vitro recordings also used steps from 10mM glucose (Ashford et al., 1990a, 
Ashford et al., 1990b).  This would be a relatively high plasma glucose level in the fed 
state, and it is known that the CNS is not as a whole exposed to plasma levels of many 
substances due to the presence of the blood brain barrier.  The major transporter for 
glucose across the blood brain barrier is GLUT-1, a high affinity glucose transporter, 
which is essential to maintain CNS glucose levels (Mueckler and Thorens, 2013, Simpson 
et al., 1994).  Indeed, cerebrospinal fluid contains much lower levels of glucose than 
plasma- generally around 30% of the blood level.  This raises the question as to whether 
the cells being identified in the initial in vitro studies were in fact ever likely to be 
exposed in vivo to the glucose levels being used. 
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Subsequent studies have demonstrated that interstitial CNS glucose levels are indeed 
much lower.  Silver and Erecinska (1994a), performed early work in the anaesthetised 
rat, and this has been followed up by microdialysis experiments in awake animals (Dunn-
Meynell et al., 2009, de Vries et al., 2003, McNay and Gold, 2001).  Table 4.1 summarises 
some of these findings.  Overall, the summary of this work is that in the fed state, a rat is 
likely to have a CNS glucose level of 2-2.5mM, and that this level will fall to 0.2-0.5mM 
after induction of hypoglycaemia.  The maximum level recorded during pathological 
hyperglycaemia might be as high as 4.5mM.  Therefore, one might consider these to be 
more physiological levels to apply in vitro. 
Table 4.1 Studies comparing CNS glucose levels to blood levels in rats 
 
There are a few areas of the CNS, the circumventricular organs, where the blood-brain 
barrier is deficient, and here cells could be exposed to higher (plasma) levels of glucose 
via fenestrated capillary networks.  Examples include the arcuate nucleus of the 
hypothalamus and the area postrema in the brainstem, as well as the subfornical organ.  
The PVN is not considered to be a circumventricular organ, although it does receive 
projections from these areas.  Interestingly, it has been shown that within the 
hypothalamus, neurons which respond to higher levels of glucose (above 2.5mM) are 
only found in the arcuate nucleus, a circumventricular organ, whilst GI and GE neurons 
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in other areas of the hypothalamus respond to changes below 2.5mM (Fioramonti et al., 
2004). 
4.1.4 Cell subtypes of interest in glucose sensing 
The hypothalamus is a key CNS area sensing and integrating information on glycaemic 
state, with specialized glucose-sensing neurons in distinct regions, including the arcuate 
and ventromedial nuclei (Kang et al., 2006, Kang et al., 2004), dorsomedial nucleus 
(Otgon-Uul et al., 2016), paraventricular hypothalamus (Melnick et al., 2011) and lateral 
hypothalamic area (Marston et al., 2011).  Anteriorly, the preoptic area has also been 
reported to contain GnRH neurons which are glucose excited (Beall et al., 2012a, Roland 
and Moenter, 2011).  Plasticity has been reported in neuronal responses to glucose with 
changing environment, e.g. lowered glucose thresholds with recurrent hypoglycaemia in 
VMN (Song and Routh, 2006).  Changes have also been reported related to age and 
exposure to high fat diet (van den Top et al., 2017).  In addition, van den Top et al. 
describe glucose sensing neurons which behave in an adaptive fashion, altering their 
responses to glucose depending on the context of the whole animal’s energy state. 
Other areas of the brain have also been identified as playing a role in glucose sensing.  In 
particular, the brainstem has been identified as a further important area.  Areas in the 
brainstem which have been implicated as having intrinsic glucose sensing include the 
nucleus of the solitary tract ((Balfour et al., 2006, Mimee and Ferguson, 2015); Mimee 
and Ferguson did not examine intrinsic glucose sensing), dorsal motor nucleus of the 
vagus (Balfour et al., 2006), and area postrema (Funahashi and Adachi, 1993).  The 
lateral parabrachial nucleus has recently been the focus of interest.  A group of 
cholecystokinin expressing neurons, a proportion of which also express the leptin 
receptor, within the lateral parabrachial nucleus have been shown to be intrinsically 
glucose inhibited and to be involved in the counterregulatory response to 
hypoglycaemia (Flak et al., 2014, Garfield et al., 2014).  
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Table 4.2 Hypothalamic glucose sensing areas and neuronal subtypes (after Fioramonti 
et al. (2017)) 
Area GE GI 
Arcuate POMC (Parton et al., 2007) 
unclear if direct glucose sensing 
Unknown additional subtypes 
(Fioramonti et al., 2007) 
NPY (Muroya et al., 1999, 
Fioramonti et al., 2007, Murphy 
et al., 2009b) 
GHRH (Stanley et al., 2013) 
unclear if direct glucose sensing 
VMN SF1(Toda et al., 2016) 
Unknown additional subtypes 
(Fioramonti et al., 2004, Wang 
et al., 2004) 
SF1 (Toda et al., 2016) 
Unknown additional subtypes 
(Wang et al., 2004, Fioramonti 
et al., 2004) 
DMN GABA (Otgon-Uul et al., 2016) GABA (Otgon-Uul et al., 2016) 
LH MCH (Burdakov et al., 2005a) Orexin (Burdakov et al., 2005a) 
NPY (Marston et al., 2011) 
GABA (Karnani et al., 2013)  
PVN Unknown subtypes (Melnick et 
al., 2011) 
Unknown subtypes (Melnick et 
al., 2011) 
PO GnRH (Roland and Moenter, 
2011, Beall et al., 2012a) 
None found 
PO- preoptic area, POMC- pro-opiomelanocortin, NPY- neuropeptide Y, GHRH- growth 
hormone releasing hormone, SF1-steroidogenic factor-1 , MCH-melanin concentrating 
hormone, GnRH- gonadotrophin releasing hormone 
4.1.5 Evidence for glucose sensing in the PVN 
The PVN is believed to have a role to play in glucose homeostasis and in particular the 
response to hypoglycaemia, as discussed in the introduction, section 1.8.3.  There is a 
small body of existing evidence for glucose sensing in the PVN.  One electrophysiological 
paper using acute slices has been published in rats, which suggests that some putative 
pre-autonomic neurons (defined by their response to a depolarising current step, see 
also section 4.2.5 below) may be glucose excited (~24% of neurons), some may be 
glucose inhibited (~26%), and that these responses persist in the presence of TTX 
(Melnick et al., 2011).  Putative neurosecretory neurons were not shown to be glucose 
responsive.   
Prior to this, a publication performing extracellular recordings in anaesthetised rats 
reported that 12/92 cells in the PVN behaved in a GI fashion in one experiment, and a 
further 4/40 in a second experiment (Shiraishi et al., 2000).  No GE neurons were 
reported in this study. A more recent paper using extracellular recordings in 
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anaesthetised rats demonstrated both GE (27) and GI (20) cells in the PVN, in response 
to microinjections of 5mM glucose (Guan et al., 2017).  No statement is made as to how 
many non-responsive neurons were observed in the PVN in this paper.  The authors 
report that ‘changes in neuronal firing frequencies were considered to be responses if 
they were statistically significant (p < 0.05) and exceeded 20%’.  GE neurons increased 
their firing rate from 3.34 ± 0.65 Hz to 6.12 ± 0.94 Hz, no data is provided for the 
magnitude of response of GI neurons.  In addition, it does not appear that any control 
was made for the osmotic effect of microinjecting 5mM glucose in this study. 
As previously discussed, the PVN contains a wide range of differing neuronal subtypes, 
and little or no work has been done to examine subtype specific responses.  One review 
paper (Fioramonti et al., 2017), suggests that there is evidence that some PVN GE 
neurons are nesfatin-1 expressing cells (Sedbazar et al., 2014).  However, on closer 
examination of the original paper, mention is made in the text of calcium rises in the 
presence of 5mM glucose in dissociated neurons in culture, but not what the previous 
glucose level was or whether there was any change.   No other evidence is presented 
regarding the glucose sensitivity of these cells, and the paper focuses on their responses 
to NPY and alpha-MSH in the presence of 5mM glucose. 
4.1.6 The electrophysiological properties of CRH neurons of the PVN 
Most work has focused on the differences between broad subtypes within the PVN, in 
particular seeking to identify electrophysiological differences between parvocellular, 
magnocellular and pre-autonomic neurons (Tasker and Dudek, 1991, Luther et al., 
2002).  As is the case for other techniques, it is also true here that most studies have 
been performed in slices from rats, and there is relatively little mouse data available.  It 
is clear that there are differences between the broad subtypes of neurons present in the 
rat PVN.  Putative neurosecretory neurons, which project to the anterior pituitary gland, 
exhibit brisk firing in response to a depolarising current injection, whilst pre-autonomic 
neurons are seen to fire in bursts.  In addition, the bursting activity seen in pre-
autonomic neurons is often superimposed on a slow depolarisation, mediated by T-type 
calcium currents (Luther et al., 2002, Melnick et al., 2007). 
Chapter 4 Evidence for glucose sensitivity in PVN CRH neurons 
135 
 
Wamsteeker and colleagues (2013), published a paper which briefly describes the 
electrophysiological properties of CRH neurons in mice, as identified using the 
fluorescent reporter gene TdTomato.  This is the same CRH-ires-Cre strain of mice, 
developed by Huang and colleagues (Taniguchi et al., 2011) used for electrophysiology 
reported in this thesis and therefore direct comparisons will be made with their results.  
Wamsteeker et al. patched neurons (n=23) in the mid PVN, and reported these as a 
single group of neurons, with properties similar to the rat putative neurosecretory cells.  
No low threshold spiking activity indicative of putative pre-autonomic neurons was 
observed in this mid PVN population, such as was described in rat putative pre-
autonomic neurons.  Wamsteeker et al. report relatively high input resistance (933MW) 
and a near linear current-voltage relationship over the range -20pA to +20pA from a 
holding potential of -80mV.  It is not clear whether the resting potential of these cells is  
-80mV or whether they were held at this level.  The current: action potential frequency 
relationship is also near linear with injections of current up to +60pA from a holding 
potential of -80mV.  This paper also presents evidence for inputs onto these neurons 
which are NMDA, AMPA and GABAA mediated, using a combination of pharmacological 
antagonists and assessment of reversal potentials to identify the nature of the 
conductances mediating the synaptic events. 
4.1.7 Other techniques used to identify glucose sensing neurons in the CNS 
Although electrophysiology remains the gold standard for the identification of glucose 
sensing neurons in the CNS, a range of other techniques have been employed.  The use 
of extracellular recordings in in vivo has already been described (Guan et al., 2017, 
Shiraishi et al., 2000, Oomura et al., 1964, Oomura et al., 1969, Anand et al., 1964).  
Voltage sensitive fluorescent signals have also been used to investigate glucose sensing 
(Vazirani et al., 2013, Murphy et al., 2009b, Murphy et al., 2009a, Canabal et al., 2007a, 
Canabal et al., 2007b), largely in dissociated adult hypothalamic neurons in culture.  A 
similar approach in dissociated cells using fura-2 calcium imaging has also been 
employed (Kang et al., 2004, O'Malley et al., 2006, Dunn-Meynell et al., 2002).  These 
techniques have not been employed in acute slices or in vivo in the glucose sensing field 
up to this point, perhaps largely due to technical considerations such as the challenge of 
loading neurons evenly with dye, and time constraints on experiments following loading.  
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There are clear limitations to primary cell culture of neurons, in particular, the normal 
connectivity of these neurons is disrupted, and they will also lack the broader supportive 
network of astrocytes, glia and other non-neuronal cells.  It is also challenging to identify 
which type of neuron is present in the culture, in particular in a very heterogeneous 
brain area such as the hypothalamus where many neuronal subtypes are found in close 
proximity.   
4.1.8 Beyond electrophysiology- GECIs and potential for neuronal subtype 
specific calcium imaging 
The recent advent of GCaMP6f and similar calcium sensitive fluorescent indicators 
(GECIs) (Grienberger and Konnerth, 2012), which can expressed in specific cell subtypes, 
has the potential to offer further avenues of investigation of glucose sensing.  This 
technique has not thus far been used in glucose sensing work, but has been used in the 
related field of feeding signals in vivo in the arcuate hypothalamus, examining responses 
of AgRP neurons to feeding compared to sham feed (Betley et al., 2015).  The potential 
for expressing GECIs in specific cell subtypes, and indeed imaging in vivo makes this an 
appealing technique for further development. 
Successful calcium imaging requires two main technologies acting in synergy, firstly the 
ability to signal calcium levels, which has largely relied on development of fluorescent 
calcium dependent molecules, and secondly the ability to image the fluorescence with 
appropriate spatial and temporal accuracy.  This section will firstly consider the 
signalling molecules before briefly covering recent advances in imaging techniques. 
4.1.8.1 History of calcium indicators 
The initial development of calcium indicators involved the development of small 
molecules or proteins combining some form of binding of calcium with the ability to 
fluoresce at a specific wavelength.  Aqueorins (bioluminescent photoproteins), and 
arsenazo III, a synthetic compound which altered its light absorption when bound to 
calcium, were among the earliest calcium sensors.  However, the major problem with 
these indicators lay in getting them into cells.  The development of the next generation 
of calcium sensors by Tsien and colleagues (Tsien, 1980) significantly advanced the field.  
These compounds combined calcium chelators such as EGTA or BAPTA with a 
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fluorescent chromophore.  Fura-2 was the most widely adopted of these molecules and 
has been very widely used in a range of cell types, both neuronal and non-neuronal 
(Grynkiewicz et al., 1985).  Fura-2 was particularly useful as it fluoresces at  340 and 
380nm, and alters the ratio on binding calcium.  Ratiometric comparison of the 2 
wavelengths allows more accurate calcium measurements (Neher, 1995).  Further small 
molecule calcium sensors were developed, with improved signal to noise properties and 
photostability, including Oregon Green BAPTA and fluo-4 (Paredes et al., 2008). 
The disadvantages of all the small molecule calcium sensors lay in their lack of cell 
subtype specificity.  They could also be problematic in terms of the need to load cells 
with dye, which could lead to variability in loading, increased background signal from 
dye not loaded into cells and dye failing to remain in cells for more than 2-3 hours.  They 
were thus unsuitable for chronic imaging. 
The advent of genetically encoded calcium indicators (GECIs), again by Tsien and 
colleagues (Miyawaki et al., 1997) resolved many of these problems.  These indicators 
use a calmodulin binding protein fused with a fluorescent protein (initially GFP) to create 
a molecule which alters its fluorescence on binding calcium.  Initially these indicators 
were less appealing due to poor signal: noise ratios and slow kinetics, limiting the time 
course over which they could detect events.  However, newer GECIs have largely 
surmounted these early problems, such that specific subtype cells of interest can now 
be transduced to express a calcium indicator and imaged readily. 
Two major groups are currently in widespread use.  The first, the FRET group (e.g. yellow 
cameleon (Nagai et al., 2004), use a conformational change on binding calcium to bring 
two flourophores close enough together that Forster resonance energy transfer can 
occur, with reduction in the fluorescence signal of one (the donor) and increase in the 
second (acceptor).  This results in a ratiometric change in fluorescence.  The second 
group, of which the GCaMP family are excellent examples, are single fluorophore 
molecules, again undergoing conformational changes on binding calcium to a calmodulin 
element, in this case acting to increase overall fluorescence.  The GCaMP molecules 
initially had less favourable signal to noise ratios and kinetics, but newer generations 
have resolved both problems, for example comparing GCaMP3 and the GCaMP6 family, 
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the signal to noise ratio is 6-11 fold improved for GCaMP6 family members, and the rise 
time for GCaMP6f is ~80ms compared to ~137ms for GCaMP3 (Chen et al., 2013, Ye et 
al., 2017).  Figure 4.1 illustrates calcium sensing in a GCaMP molecule. 
It is important to remember that all calcium sensors are only able to provide an 
indication of free calcium levels within a cell, and also that they are effectively acting as 
an additional calcium buffer within cells.  Those with low affinity calcium binding, such 
as GCaMP2 will have less of a buffering effect than the high affinity molecules such as 
Fura-2 and Oregon Green BAPTA-1, but they will all have some effect.  In addition, the 
higher the concentration of the indicator in the cell, the greater the buffering effect.  
This factor is not always readily under the control of the investigator, particularly when 
expressing a GECI using a viral vector or genetically modified mouse line (Grienberger 
and Konnerth, 2012). 
GCaMP6f, the GECI used in this thesis, is a highly useful, fast responding GECI, with rapid 
on and off kinetics (tau 74ms on, 400ms off), which has a linear signal response over 
small numbers of action potentials (1 action potential~120% increase in signal, 8 action 
potentials~870%) (Chen et al., 2013).  Additionally, GCaMP6f has been reported to allow 
identification of neurons without the addition of a co-expressed fluorescent molecule, at 
low levels of calcium (typical resting calcium ~0.1µM in cytoplasm).  The dynamic range 
of fluorescence for this GECI in vitro is wider than its predecessors.  Overall, these 
properties result in a signal which is dim but still visible in quiescent cells, good temporal 
resolution and a bright signal in response to activity dependent increases in calcium.  




Figure 4.1 Schematic to illustrate calcium sensitive fluorescence in GCaMP family of 
genetically encoded calcium indicators 
Upon binding calcium (4 binding sites), GCaMP undergoes a conformational change 
which results in greatly increased GFP fluorescence.  
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4.1.8.2 2-photon imaging in vitro and in vivo 
The development of 2-photon imaging techniques has greatly expanded the potential 
uses of GECIs, particularly in vivo (for a detailed minireview, see (Svoboda and Yasuda, 
2006).  The principles underlying 2-photon imaging as compared to confocal imaging are 
summarised in Figure 4.2.  Essentially, the key advantage of the technique over 
conventional widefield microscopy lies in the ability to image at deeper levels within 
tissues.  The tissue penetration of near red and infrared wavelengths used in 2-photon 
microscopy is greater and causes less tissue damage.  Traditional confocal imaging is 
able to image at depth, but causes much greater damage and bleaching effects, both in 
the plane of imaging and above and below, compared to 2-photon.  Particular 
advantages are gained for in vivo studies, but even in slices, the ability to image a z-
plane below the surface is of great value, as it enables imaging of a plane of healthy 
neurons, whilst neurons on the surface of a slice often exhibit very bright signals, due to 
cell damage in the slicing process.  




Figure 4.2 Schematic to illustrate principles of 2-photon compared to confocal 
microscopy 
Ai Confocal microscopy- a single high energy photon excites a fluorescent protein which 
emits fluorescence on returning to ground state. 
ii Excitation can occur wherever a high energy photon is found, including all photons 
which are scattered. 
iii A pinhole is needed to collect emitted fluorescence from a focused area which means 
that only aligned photon emissions contributed to signal- scattered emitted photons 
contribute to noise. 
Bi 2-photon microscopy; 2 low energy photons (infrared or near infrared) act 
cooperatively to excite a fluorescent molecule, which then emits a single high energy 
photon on returning to its ground state.  The excitation by 2 photons is a non-linear 
process, and is therefore confined to a very small focal area. 
ii Single scattered photons cause no excitation, reducing noise from out of focus tissue. 
iii In addition, because excitation only occurs in a focused area, all emitted light 
contributes to signal, whether or not it is scattered; there is no need for a pinhole for 
emission fluorescence.  




• CRH PVN neurons show altered activity with reductions in extracellular glucose 
o seen with steps from high and physiological baseline glucose  
 
4.3 Aims 
• Investigate electrophysiological properties of CRH neurons in vitro 
• Characterise their responses to a fall in perfused glucose from 10mM 
• Develop a calcium imaging approach and analysis pipeline using CRH x GCaMP6f 
mice  




4.4.1 Initial electrophysiological characterisation of CRH neurons in the PVN 
4.4.1.1 Baseline electrophysiological characteristics of CRH PVN neurons 
In the whole cell current clamp configuration, baseline current voltage relationships 
(n=13) and action potential firing frequencies were recorded (n=22).  Initial data were 
obtained in 10mM glucose, to enable comparison of properties with those previously 
reported for this neuronal population (Wamsteeker Cusulin et al., 2013).  Some of the 
CRH neuronal properties reported here appear comparable to those reported previously 
(shown in Table 4.3 and Figure 4.3) and additional features were also observed.  This 
was a spontaneously active neuronal population, with a brisk baseline firing frequency 
of 6.9±0.7Hz from a resting potential of -52±0.9mV (Table 4.4).  Many cells were 
tonically active, whilst 10.2% (6/59) showed bursting patterns of activity (Figure 4.4).  In 
addition, these neurons showed synaptic drive from elsewhere in the slice with multiple 
EPSPs and IPSPs visible when hyperpolarised below the action potential threshold 
(Figure 4.4C).  Wamsteeker et al. did not comment on the intrinsic firing rate or resting 
potential of their neuronal population.  Input resistance was significantly lower than that 
described by Wamsteeker et al. (751±50.1 MW here, 933±19.8 MW for Wamsteeker, 
unpaired t-test p=0.0024).  This could be due to a number of reasons.  Wamsteeker et al. 
in general used younger animals (4-6 weeks) and recorded at a lower temperature (30-
32°C).  They also patched solely in the mid PVN, whilst the results here are from the 
entire length of the PVN.  In addition, it is not entirely clear what potential Wamsteeker 
et al. held their cells at to measure input resistance.  
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Table 4.3 Comparison of CRH neuronal properties here with Wamsteeker Cusulin et al. 
(2013) 
Reported property Wamsteeker Simpson 
Input resistance 933±19.8 MW 751+/-50.1 MW 
Current- membrane 
potential relationship  
Near linear over range -20 
to + 20pA from holding 
potential of -80mV 
Held to -70mV.  Similar 
over relationship over -20 
to +20pA range, above this 
linearity lost as cell nears 
action potential threshold 
Current- action potential 
frequency relationship 
Near linear over range +10 
to +60pA from -80mV 
Held to -70mV, steeper 
increase in AP frequency 
seen 
EPSCs Present- combination of 
NMDA and AMPA 
Present 
IPSCs Present, GABAA Present 
Intrinsic properties Not reported See Table 4.4 
  




Figure 4.3 Baseline electrophysiological properties of CRH-Cre x TdTomato expressing 
neurons in 10mM glucose 
A Example images of fluorescent neurons seen under 5X (left) and 40X objectives.  40X 
fluorescence image (red) superimposed onto image from infrared camera (greyscale), 
with pipette visible touching cell membrane 
B Example whole cell recording showing voltage response to current steps from -40 to 
+30pA with cell held at -70mV between steps 
C Current voltage relationship from cells patched in 10mM glucose (n=13) 




























Figure 4.4 Further illustrations of CRH-Cre x TdTomato cell properties 
Example whole cell current clamp traces from cells in 10mM glucose, with differing 
action potential firing profiles 
A Tonically active cell, inset blown up part of trace to show action potential profile 
B Cell exhibiting bursting pattern of activity 
C Illustration of excitatory and inhibitory post synaptic currents in voltage clamp, cell 
held at -65mV  
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4.4.1.2 Comparing baseline characteristics in 10mM or 2.5mM glucose  
The same data was also obtained from cells with 2.5mM glucose as their baseline 
solution (n=10), which more closely represents likely physiological levels in the brain 
tissue.  The results of the comparison between the intrinsic properties of CRH neurons 
with baseline glucose of 10mM and 2.5mM is shown in Table 4.4.  The only parameters 
where statistically significant differences were observed were action potential (AP) 
amplitude and after-hyperpolarisation (AHP) amplitude. 
In order to examine whether the difference in AHP amplitude had an effect on other cell 
properties, the current-firing frequency relationship was plotted for cells patched in 
10mM glucose compared to those in 2.5mM glucose.  Cells in 2.5mM glucose were in 
fact less likely to fire action potentials in response to any given current injection, 
compared to those in 10mM glucose (data not shown).  This is the opposite effect to 
what might have been predicted based on the larger AHP amplitude in 10mM glucose, 
and suggests that the larger AHP seen in 10mM glucose, whilst statistically significant, 
may not result in a relevant biological effect. 
Table 4.4 Cell properties in 2.5mmol glucose (n=10) compared to 10mmol glucose (n=20) 
 2.5mMglucose 10mMglucose P value 
Resting Potential 
(mV) 
-53±2.2 -52±0.9 0.66 
Threshold (mV) -43±2.1 -39±1.0 0.08 
AP Amplitude (mV) 31.81±3.5 39.90±2.1 0.04 
AP duration (ms) 2.73±0.3 3.02±0.2 0.46 
AHP amplitude 
(ms) 
-15.39±0.8 -20.08±1.2 0.02 
AHP duration (ms) 52.5±8.9 61.65±7.1 0.45 
AP frequency (Hz) 7.07±1.3 6.9±0.7 0.93 
Input resistance 
(MΩ) 
704.4±39.1 751.6±50.1 0.55 
Time constant (ms) 18.3±1.6 21.6±1.4 0.16 
Capacitance (pF) 26.0±1.7 30.7±2.7 0.27 
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4.4.3 Initial electrophysiological evidence for glucose sensitivity in PVN CRH 
neurons 
4.4.3.1  Defining cell responses and spatial locations 
A priori, neurons were arbitrarily classified on the basis of their potential responses to 
glucose.  Neurons increasing their firing frequency by >30% on transitioning to a low 
glucose solution were defined as glucose inhibited (GI).  Neurons that decreased their 
firing frequency by >30% when stepped to low glucose were labelled glucose excited 
(GE).  The remaining neurons were classified as non-responsive to glucose (NR). 
It was possible to identify the approximate location of cells recorded within the PVN.  In 
general, each mouse brain gave rise to 2 or occasionally 3 slices containing PVN cells.  
Slices were marked on one edge to indicate left and right, allowing orientation in the 
bath that preserved the rostro-caudal orientation of each slice, and kept in rostro-caudal 
order.  It was therefore possible to distinguish rostro-caudal levels between slices.  In 
addition, it was possible to state whether cells were located ventrally or dorsally within 
the PVN. 
4.4.3.2 Effect of a step from baseline 10mM to a hypoglycaemic perfusate 
The majority of cells (59/68) were observed to fire spontaneous action potentials, as 
described in Table 4.4. (mean resting potential -52±0.9mV, mean AP frequency 6.9±0.7, 
n=20).  An outlier subset of cells (9/68) were also identified; these did not fire action 
potentials at rest and were significantly more hyperpolarised (-85±5.36mV).  This 
smaller subset of ‘silent’ cells will be discussed in more detail in section 4.4.3.4. 
23 neurons from the main, spontaneously active group were maintained throughout the 
entire protocol to provide interpretable data including a low glucose step and washout.  
Of these, 35% fitted the criteria for being glucose excited neurons, and 8% were glucose 
inhibited.  The remainder (57%) were not responsive to glucose (Figure 4.5).  The 
thresholds described in section 4.4.3.1 appear to appropriately delineate three distinct 
populations with regard to their change in AP frequency in response to glucose (Figure 
4.5B).  The GE responses were large (5.6±1.5Hz in 10mM glucose falling to 1.1±0.66Hz in 
2.5mM glucose, n= 8) and reversible in 7/8 recordings.  In 4/8 cells the GE response was 
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repeatable as shown in Figure 4.5C.  GI responses were also reversible in 2/2 cells, with a 
change in AP frequency of 1.7-5.0 rising to 6.2-7.4Hz (range).  




Figure 4.5 Initial electrophysiological evidence for glucose sensitivity in CRH neurons in 
the PVN 
A Classification of 23 neurons according to a response to a step from 10mM to 2.5mM 
glucose 
B Graph to show cut off levels for categorisation of neurons. Lines at +30% and -30% 
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4.4.3.3 Difficulties with stability of recordings in slices obtained in 2.5mM glucose 
The initial experimental plan was to go on to investigate the responses of cells following 
slicing in 2.5mM glucose, with a step to 0.5mM.  This would more closely replicate 
physiological levels of recorded in brain tissue (Silver and Erecinska, 1994b).  However, 
cutting in 2.5mM glucose produced slices in which it was challenging to establish stable 
recordings.  Gigaohm seals were more difficult to achieve and cells did not often remain 
stable in the whole cell configuration. It did not prove possible to obtain stable 
recordings for long durations in most of the neurons patched.  From the few cells 
recorded in 2.5mM glucose with steps to 0.5mM glucose, 2 GE and 4 NR neurons were 
observed, with recordings appearing comparable to those seen in 10mM glucose (Figure 
4.6).  GI neurons were not observed in this group, which is unsurprising given the small 
sample size. 
The rest of the electrophysiological data obtained and presented here uses slices cut 
and maintained in 10mM glucose, with steps to 2.5mM glucose, which (whilst not 
physiological) is in line with the levels used in previous studies and did allow data 
collection with a much higher degree of consistency.  




Figure 4.6 Glucose excited cells seen in 2.5mM and 10mM glucose 
A Spontaneously active CRH neuron strongly and reversibly inhibited in response to a 
change of solutions from 2.5mM to 0.5mM glucose. 
B Example of a comparable response to a change of solutions from 10mM to 2.5mM 
glucose.   
Top panel indicates action potential frequency, lower panel displays whole cell current 
clamp trace.  Bar indicating application of low glucose solution commences from time 
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4.4.3.4 A subgroup of ‘silent’ neurons was observed which did not fire action potentials 
at rest and depolarised in response to a low glucose step 
An outlier subset of PVN CRH neurons with distinctive cell properties was also identified 
in 10mM glucose (9/68, 13%).  These cells were silent at rest and were significantly more 
hyperpolarised (-85 ± 5.4mV, n=7).  In addition, they had lower input resistances, and a 
slightly higher capacitance, which would be consistent with the idea that they were 
larger neurons (Figure 4.7).  This subgroup was largely found in more caudal slices of the 
PVN and tended to be located ventrally within the PVN.  4 cells were challenged with a 
low glucose step to 2.5mM glucose.  All became more depolarised (change in membrane 
potential +13.4 ± 2.74 mV) and one cell began firing spontaneously suggesting that these 
are glucose inhibited neurons (Figure 4.8).  None of these neurons were exposed to TTX.  




Figure 4.7 A second population of silent neurons with differing properties from the 
main spontaneously active subgroup 
Ai) Current voltage relationships for 'silent' neurons, which do not fire action potentials 
at rest and are a small minority ii) example of voltage response of a neuron to 150pA 
current injection showing that these cells can still fire healthy action potentials 
B Comparison of cell properties of silent neurons with previously described spontaneous 
subgroup (n=20 spontaneous, n=7 silent, ***=p<0.001, **=p<0.01, *=p<0.05, unpaired 
t-test)  




































































Figur  5.7 A second population of neuro s with differing properti s
Ai Current voltage relatio ships for 'Silent' neur ns, which do not fire action potentials at rest 
and are a small minority ii) example of voltage reponse of a neuron to 150pA current injection
showing that these cells can still fire healthy action potentials
B Comparison of cell properties of silent neurons with previously described spontaneous 









Figure 4.8 Responses of ‘silent’ neurons to a low glucose step 
A Significant depolarisation seen in all cells where a step from 10mM to 2.5mM glucose 
solution was applied (n=4, p<0.05, paired t-test) 
B Example cell which depolarises and increases firing frequency in low glucose (n=1; 
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4.4.4 Electrophysiological investigation of the anatomically distinct neuronal 
population projecting to NTS/DMX 
One possibility was that the silent neurons might represent a pre-autonomic population.  
In an attempt to investigate this further, 8 CRH x Td mice, aged 6-12 weeks received 
brainstem injections to the NTS/DMX of the CAV-CMV-eGFP virus with the aim of 
retrogradely transducing the pre-autonomic PVN CRH neurons.  Their brains were 
subsequently sliced for electrophysiology (after 2-4 weeks).  As expected, retrogradely 
transduced eGFP positive neurons were observed, predominantly localised in the 
posterior part of the PVN, but there were relatively few of these in each slice, and even 
fewer which were also showing red fluorescence indicating CRH.  Increasing the 
incubation time following injection did not increase the number of cells observed.  
Despite repeated attempts it was not possible to make stable recordings from any of 
these cells, and so no further conclusions could be drawn. 
4.4.5 The effect of TTX on glucose responses 
It is not possible to tell from the data presented thus far whether the neurons 
responding to glucose were directly sensing a change in glucose levels, or were 
responding to inputs from neurons in other areas within the slice- for example, VMN 
neurons which are known to be glucose sensitive (and would be expected to be 
contained in a coronal slice through the PVN).  The effect of the same glucose step in the 
presence of TTX (to prevent action potential propagation and hence remove synaptic 
inputs) was therefore investigated.  TTX was effective in blocking spontaneous action 
potentials in the majority of cells to which is was applied (12/17, 70%) (Figure 4.9A).  5 
cells exhibited wide based spiking activity at a lower frequency- an appearance 
consistent with a calcium spikes (Figure 4.9 C).  TTX had no effect on the resting 
potential Figure 4.9B).  The protocol used to investigate the effect of TTX involved an 
initial control low glucose step, washout and subsequent application of TTX.  Following 
this a second low glucose step in the presence of TTX was applied.  Interestingly, 
regardless of the response of the same cells in the absence of TTX, 8/10 neurons 
depolarized when stepped to low glucose in the presence of TTX (Figure 4.10).  Of these 
8, 7 had a step to low glucose prior to perfusion with TTX.  5 were NR, 1GE and 1GI in 
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the absence of TTX.  The final 2 neurons, which hyperpolarised in the presence of TTX, 
were both NR prior to application of TTX.  




Figure 4.9 Effect of TTX on CRH PVN neurons in current clamp 
A Example trace showing cessation of action potentials after TTX application 
B TTX has no significant effect on the resting potential of this group of neurons.  Graph 
shows mean and SEM as well as individual neuronal responses (n=10, p=0.64, paired t-
test) 
C A few cells exhibited persistent firing prior to and in the presence of TTX.  Slower time 
course and smaller amplitude in TTX is suggestive of voltage gated calcium channels  
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Figure 4.10 The majority of CRH neurons depolarise in response to a step from 10mM 
to 2.5mM glucose in the presence of TTX 
Ai) A step to 2.5mM glucose in the presence of TTX resulting in a significant 
depolarisation.  Graph shows mean and SEM as well as individual neuronal responses 
(n=10, p=0.012, paired t-test) 
Bi) example trace of neuron which depolarised 
Bii) individual changes in resting potential for all depolarising neurons, washout effect 
also shown (-54.5±2mV in 10mM glucose, -46.4±2mV in 2.5mM glucose, p=0.0003, 
paired t-test) 
Ci)Example trace of neuron which hyperpolarised. Inset, zoomed in section to show mini 
excitatory post synaptic potentials.  Gaps in trace at times of current injections 
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4.4.6 A calcium imaging strategy to characterise glucose sensing properties of 
PVN CRH neurons 
The electrophysiological data presented thus far suggests a proportion of CRH neurons 
are glucose sensitive.  However, it was challenging and time consuming to collect the 
data; in part this reflects the fact that only a small subset of the neurons are glucose 
responsive (35% GE and 8% GI).  To potentially obtain a higher throughput of data, 
investigate responses with steps from 2.5 to 0.5mM glucose, and in addition collect 
more spatial information about where within the PVN responsive cells might be found, a 
second set of experiments were carried out utilising calcium imaging in slices, using CRH 
x GCaMP6f mice. 
As mentioned in the introduction, GCaMP6f is visible but not highly fluorescent in 
neurons with low levels of calcium (most neurons will have resting levels of 50-100nm 
(Berridge et al., 2000)).  It is therefore difficult to identify non-responsive neurons, which 
could artificially amplify the numbers of responsive cells. A strategy to identify non-
responsive neurons was employed- after performing low glucose steps and washouts, 
the slices were subsequently perfused with a high potassium solution to depolarize and 
increase calcium in all GCaMP6f containing neurons.  This depolarisation typically 
revealed a much larger number of neurons and this data was used to inform ROI 
selection during analysis offline. 
4.4.6.1 Specificity of GCaMP6f expression in the CRH x GCaMP6f mouse strain 
A CRH x GCaMP6f homozygous mouse was bred successfully, as shown in Figure 4.11A.  
Unfortunately, it became apparent on imaging that expression of GCaMP6f in the CRH x 
GCaMP6f homozygous strain was off target, with high levels of expression throughout 
the forebrain (Figure 4.11B and C).  Indeed, expression of GCaMP6f was so widespread 
that these off-target animals could be identified using a fluorescent light source and 
goggles, (excitation 440-460nm, emission 500nm longpass (Nightsea Dual Fluorescent 
Protein Flashlight, MA, USA)) when viewing the freshly dissected brain, as shown in 
figure 4.11B.  This strategy was, therefore, abandoned and heterozygous CRH x 
GCaMP6f animals were used for all subsequent calcium imaging.  These animals clearly 
expressed GCaMP6f in a circumscribed manner, which recapitulated that observed in 
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CRH x TdTomato mice.  Expression of GCaMPf in heterozygous CRH x GCaMP6f mice in 
the PVN is demonstrated in Figure 4.11D.  




Figure 4.11 Inconsistent expression of GCaMP6f in mice bred from parents with both 
GCaMP6f and CRH-ires-Cre present in each parent 
A Example of genotyping of GCaMP6f.  WT band 297bp, mutant band 450bp 
B Macroscopic demonstration of off target expression.  The left-hand brain in each 
image expressed GCaMP6f under the control of the CRH promotor.  The right-hand brain 
is from an off-target mouse and can be seen to fluoresce by the naked eye using 
Nightsea Lightsource and goggles (right hand image) 
C Example images from calcium imaging (60X objective) in the periventricular region 
after application of high potassium to depolarise cells and increase their calcium signal.  
A much larger number of cells are visible in the image from the off-target mouse on the 
right. 
D On target expression of GCaMP6f in the PVN in a mouse bred from a CRH-ires-Cre 
homozygous female and a GCaMP6f heterozygous male after application of high 
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4.4.6.2 Establishing recording and thresholding protocols 
Small numbers of bright cells were readily visible in the PVN using epifluorescent 
microscopy, and this facilitated identification of relevant areas i.e. the PVN for 2-photon 
imaging.  Some of these cells were likely to be undergoing necrosis, and fewer were 
observed deeper in the slice (consistent with the surface cells being more damaged by 
slicing).  2-photon imaging was therefore performed in a z-plane deeper than the 
surface of the slice to avoid the majority of these cells.  A wide range of levels of 
baseline fluorescence were observed across cells.  Therefore, each recording was 
normalised to its own baseline (lowest 5% of values) to allow reliable identification of 
relevant signals and thresholding (for more details of the data processing pipeline, see 
methods section 2.8).  A baseline period of 200-400 seconds was recorded for each slice 
prior to any change in the perfusate.  In order to assign neurons to GI and GE categories, 
a threshold of >3 standard deviations from the mean of the final 100 seconds of the 
baseline was chosen.  For more details on thresholding, again see methods chapter 2 
section 2.8. 
On perfusion with low glucose for ~400s, a subset of cells responded with an increase 
(GI) or decrease (GE) in fluorescence which was taken as corresponding to an increase or 
decrease in intracellular calcium ((Grienberger and Konnerth, 2012) Figure 4.12 A,B).  
The majority of neurons had calcium signals which did not change until potassium was 
applied to depolarise all cells (NR).  Examples are shown in Figure 4.12 C.  A further 
subset were ‘spontaneously active’ (SA) with marked fluctuations in their fluorescence 
(calcium levels) but not responsive to changes in glucose (Figure 4.12 D). 
The size of response was calculated differently for GI and GE neurons, as the profile of 
the calcium signal change was very different for the 2 groups.  For more details please 
refer to the methods section 2.8.  For GE neurons, a rolling mean of 40 seconds (20 
images) was obtained for each time point from the raw data.  The peak value during the 
baseline prior to changing the perfusate was calculated, and the trough value of the 
response to the low glucose solution was also obtained.  The data was then normalised 
to the baseline by calculating (response-baseline)/baseline.  For GI neurons, many 
responses were spiking in nature rather than slow rises in calcium level.  This made a 
similar approach, or indeed calculation of area under the curve of limited value, as 
Chapter 4 Evidence for glucose sensitivity in PVN CRH neurons 
163 
 
values were small, and differences were not numerically significant between groups 
evens for cells that markedly changed their behaviour.  Instead, the time spent with 
calcium levels greater than 3 standard deviations above the mean was calculated for 
each baseline and experimental period, and is expressed out of a maximum time of 450 
seconds (the time spent in low glucose). 
Images were acquired at 0.5Hz for the majority of the calcium experiments presented 
here.  A single slice was imaged at a higher frequency (5Hz).  Examples GI traces from 
this experiment are shown in Figure 4.14D.  The gaps in the recording were necessary to 
maintain a manageable file size.  It can be seen that response is still easily identified.  
However, the increased frequency of imaging did not reveal any further detail with 
regard to calcium transients, suggesting that 0.5Hz is a reasonable frequency for data 
acquisition for these experiments. 
To enable comparison with previous electrophysiological data, 4 slices were cut and 
maintained in 10mmol glucose with steps to 2.5mM glucose.  30 GI and 9 GE cells were 
observed.  Overall the response to the first application of 2.5mM glucose was greater 
than that to the second with regard to the number of neurons observed to respond 
(Figure 4.13 A).  There was no statistically significant change in the size of the second 
response when compared to the first for either GI or GE neurons (Figure 4.13 B).  Both 
spiking and slow rising responses were observed amongst GI cells (for examples see 
figure 4.12 A).  59.3% of GI cells had spiking responses, 40.7% exhibited slow calcium 
rises  
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Figure 4.12 Example traces for the 4 possible categories of CRH x GCaMP6f neuron 
observed using calcium imaging 
A Glucose inhibited (GI), showing increased calcium after exposure to 0.5mM glucose 
B Glucose excited (GE), showing decreased calcium after exposure to 0.5mM glucose 
C Non-responsive (NR); changes in glucose had no effect 
D Spontaneously active (SA); changes in calcium levels not associated with glucose 
changes 
All data from CRH neurons in a single slice of paraventricular hypothalamus, cut and 
maintained in 2.5mM glucose.  Steps down to 0.5mM glucose are indicated by the 
shaded areas of the graphs.  A high potassium solution was applied at the final dotted 
line K 
Inset images of GI and GE cells are averages of 10 images around time points 112s 
(baseline), 788s (0.5mM glucose), 1238s (washout) and 2464s (potassium response).  
White scale bars are 10microns  
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Figure 4.13 Calcium responses of CRH PVN neurons following steps from 10mM glucose 
to 2.5mM glucose 
A Categorisation of neurons following a first and second step to 2.5mM glucose.  Fewer 
cells respond to a second application of low glucose (Chi square value 8.942, p=0.0341) 
B There is no change in the size of the response of GI (i) or GE (ii) cells to a second 
application of low glucose compared to the first (GI-Friedman test with Dunn’s multiple 
comparisons, GE paired t-test) 
C Example calcium traces for i) a GI cell and ii) a group of 4 GE cells (all from a single 
slice). Perfusion with low (2.5mM) glucose is indicated by shading in grey. Application of 
a high potassium solution occurs at the final vertical line (K) 
Data from 4 slices, 2mice, 70±23.3 cells per slice.  Data presented as median and IQR for 
GI, mean and SEM for GE  
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4.4.6.3 Comparison of recordings made in 10mM and 2.5mM glucose 
Having established an imaging and processing protocol, slices were next cut in 2.5mM 
glucose and recorded following a step to 0.5mM glucose.  Imaging was straightforward 
and there was no appreciable deterioration in cell health compared to slices obtained in 
10mM glucose (as assessed by number of fluorescent cells per slice, stability of 
fluorescence and number of very bright (presumed necrotic) cells seen).  Again, both 
spiking calcium responses and slower rises were observed in the GI population, with 
similar proportions to those seen in the 10mM slices (39.1% spiking, 60.1% slow rise).  A 
similar pattern of responses to a first and second application of low glucose was seen to 
that observed for slices in 10mM glucose with fewer cells responding to a second 
application of low glucose (Figure 4.14A).  However, in these conditions the size of both 
GI and GE responses were smaller after the second application of low glucose compared 
to the first (Figure 4.14B).  Slicing and recording in 2.5mM glucose increased the 
numbers of GI and GE cells seen compared to 10mM (Chi-square 46.52, p<0.0001, Figure 
4.15B).  There was no significant change in the size of the first GI or GE response 
observed comparing cells in 10mM glucose with cells in 2.5mM (Figure 4.15C). 
In this larger dataset, the question of whether cells could be pre-identified as, for 
example, GE, on the basis of their initial levels of fluorescence was raised.  The 
hypothesis was that GE cells would have a higher baseline fluorescence (raw) compared 
to GI and NR cells in the same slice, due to their higher activity levels in baseline glucose 
(leading to elevated intracellular calcium).  This was broadly correct, as shown in Figure 
4.16 and suggests that GE cells do generally have an increased baseline firing rate 
compared to GI or NR cells.  However, it did not hold true for every cell or indeed every 
slice, as is apparent from Figure 4.16C.  This approach was not useful practically in pre-
identifying GE cells, as some cells with very high baseline levels of fluorescence were in 
fact undergoing cell death, and it was not possible to differentiate these from possible 
GE cells at baseline. 
Having established slicing in 2.5mM glucose with healthy appearing slices and 
performed an initial comparison with 10mM glucose slices, all subsequent data 
presented here uses 2.5mM glucose as a baseline level with steps to 0.5mM glucose to 
further investigate glucose sensing in CRH neurons. 
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4.4.6.4 Location of responsive cells within the PVN 
It was possible to record precisely where each responsive cell was within each imaged 
slice, and also to estimate the rostro-caudal location of each slice with reference to the 
mouse brain atlas.  These data are presented for the 2.5mM glucose slices in Figure 
4.17.  It appears that GE cells are primarily located more rostrally, whilst GI cells are 
found throughout the rostro-caudal extent of the PVN.  GI neurons also appear to be 
more generally found at the edges of the CRH population, whilst GE neurons are located 
more centrally.  
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Figure 4.14 Calcium responses of CRH PVN neurons following steps from 2.5mM 
glucose to 0.5mM glucose 
A Categorisation of neurons following a first and second step to 0.5mM glucose. Fewer 
cells respond to a second application of low glucose (Chi square value 8.942, p=0.0341) 
B The size of the response of both GI (i) and GE (ii) cells is smaller following a second 
application of low glucose (Wilcoxon matched pairs signed rank test for GE, Friedman 
test with Dunn’s multiple comparisons for GI, ****p<0.0001) 
C Example calcium traces for i) a GI cell and ii) a group of 51 GE cells (all from a single 
slice), mean (black) and SEM (green) of the recordings shown. Perfusion with low 
(2.5mmol) glucose is indicated by shading in grey. Application of a high potassium 
solution occurs at the final vertical line (K) 
D Example cell recorded at 5Hz rather than 0.5Hz.  Gaps in recording due to file size 
limitations. 
Data obtained from 3 mice, 5 slices, 106.4 ±28.7cells/slice.  Data presented as median 
and IQR  




Figure 4.15 Comparison of CRH PVN cell responses to a low glucose step for cells cut 
and maintained in 2.5mM glucose compared to 10mM glucose 
A Protocol for each group outlining glucose concentrations used 
B Pie charts illustrating the distribution of cell responses for each population.  There is 
an increase in GE cells and a decrease in SA cells in the 2.5mM glucose group (Chi 
square=46.52, p<0.0001) 
Ci) There is no change in the size of the GI response seen between the 2 groups ii)There 
is no change in the size of the GE response seen between the 2 groups (Mann Whitney U 
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Figure 4.16 Baseline fluorescence in the raw data is indicative but not reliably 
predictive of response to low glucose 
Examples of the mean raw fluorescence of the baseline (first 90seconds).  Data is shown 
for individual slices as there is interslice variation between the maximum and minimum 
fluorescence levels. 
A In the majority of slices, GE neurons, on average, have significantly higher baseline 
fluorescence than GI or NR.  Spontaneously active cells are not distinguishable from GE 
cells on the basis of their baseline fluorescence (Kruskal Wallis test with Dunn’s multiple 
comparisons, all comparisons not shown on the graph are ns) 
B Some slices have very few GE neurons 
C A slice in which the mean baseline fluorescence appeared similar for GI and GE 
neurons (Kruskal Wallis test with Dunn’s multiple comparisons)  
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Figure 4.17 Spatial distribution of GI and GE cells after a step from 2.5mM to 0.5mM 
glucose 
Images are arranged rostral to caudal, GI neurons are red, GE green. Approximate 
bregma values are indicated on the left. 
Data obtained from 8 mice, 1-3 slices per mouse.  
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4.4.6.5 Potential double labelling strategy- to use TdTomato to pre-identify CRH 
neurons for calcium imaging using GCaMP6 
As a strategy to improve the ability to initially identify all CRH neurons, triple transgenic 
mice expressing both GCaMP6 and TdTomato under the control of CRH-Cre were bred.  
However, calcium imaging experiments carried out using these animals did not show any 
responses to glucose.  The filter sets on the 2-photon microscope do not fully segregate 
the green and red signals (see Figure 4.18).  This is particularly relevant given that the 
TdTomato signal is very bright, and the GCaMP6f fluorescence is dim, especially in 
quiescent cells.  Even a small amount of bleed through of TdTomato into the GFP 
channel leads to problems with signal: noise in the data (given that the GCaMPf signal at 
basal levels of calcium was relatively small).  The need to image 2 channels for each Z-
plane or stack also led to a reduction in the temporal resolution of the images.  This 
approach was therefore not pursued. 
 
Figure 4.18 Emission spectra for TdTomato and GFP (GCaMP6F) are not fully 
segregated using the filters on the 2-photon microscope 
Graph superimposing emission spectra and filter sets (derived from Chroma spectra 
viewer).  There is overlapping of the emission spectra in both the green and red filters. 
%T is percentage of light transmitted at that wavelength   
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4.5 Discussion  
These data present the first evidence for glucose sensing in specific subsets of CRH 
neurons within the PVN.  GI and GE responsive neurons were identified responding to a 
reduction in extracellular glucose, using both whole cell patch clamp electrophysiology 
and calcium imaging techniques.  This discussion will examine in more detail the effects 
observed using each technique, whilst considering these findings in the wider context of 
glucose sensing within the hypothalamus. 
4.5.1 Electrophysiological properties of CRH neurons 
Initial data obtained in 10mM glucose demonstrated some comparable cell properties to 
those previously reported for this neuronal population (Wamsteeker Cusulin et al., 
2013).  It is notable that the slicing methods used in this paper were somewhat different 
to that used here, with 25mM glucose present in the slicing aCSF used by Wamsteeker 
Cusulin et al., compared to 10mM here.  However, the external and internal solutions 
used during patch clamping were otherwise comparable, and the data collected here 
made reference to this study protocols and data presented by the Wamsteeker group to 
facilitate comparisons.  The previously reported input resistance (933±19.8 MΩ) is 
higher than that reported here (752+/-50.1MΩ), and the IV relationship appears similar 
(near linear relationship from -20 to +20pA).  The cells recorded from here fire at a 
higher frequency following the same current injection, which may be partially explained 
by the differing holding potentials (-80mV for Wamsteeker et al. (2013), -70mV here).  
Of interest, when cells are held at negative resting potentials, frequent EPSPs and some 
IPSPs can be observed, suggesting that these neurons receive significant inputs from 
elsewhere in the slice.  This aligns with the report by Wamsteeker et al. of GABAA, 
NMDA and AMPA synaptic inputs onto CRH neurons. 
The data presented here expands on that already published, in particular providing 
information about the intrinsic firing frequencies and resting potentials of CRH neurons.  
It is interesting to note that cells sliced and maintained in 10mM glucose appeared to 
have very similar cell properties to those sliced and maintained in 2.5mM glucose.  The 
observation of a second subset of neurons with markedly differing cell properties is a 
new finding, not previously reported.  Given that Wamsteeker et al. patched primarily in 
Chapter 4 Evidence for glucose sensitivity in PVN CRH neurons 
178 
 
the mid PVN, it is unsurprising that they did not observe these cells, which were found in 
the posterior PVN. 
Previous reports of cell properties in rat PVN neurons have noted a difference in the 
morphology of the action potential profile in response to current injection in pre-
autonomic cells compared to neurosecretory cells.  In particular, the presence of a low 
threshold spike (LTS) in pre-autonomic cells has been considered as a significant 
identifying marker of these neurons.  This property is thought to be due to T-type 
calcium channels in pre-autonomic rat neurons.  It is not known whether mouse pre-
autonomic and neurosecretory neurons can be similarly differentiated.  As previously 
discussed, the mouse PVN differs significantly in anatomical structure compared to the 
rat.  Spike morphologies suggestive of LTS were not observed in any of the cells patched 
here and there was no evidence of rebound spiking after hyperpolarising pulses 
(another marker of T-type conductances).  However, on application of TTX, some cells 
(5/17, 30%) did maintain wide based spiking, suggestive of voltage gated calcium 
channels, likely L, N or R-type.  More investigation of this phenomenon would be 
required to draw any firm conclusions in the mouse. 
4.5.2 Glucose sensitivity- evidence for intrinsic glucose sensing from 
electrophysiological recordings 
Both GI and GE neurons were observed in response to a step to a lower glucose 
perfusate.  The subsets of responsive neurons were relatively small, with 35% of 
neurons GE and 8% GI in the main electrophysiology dataset, with steps from 10 to 
2.5mM glucose.  A further group of silent neurons were all GI (4/4 neurons depolarised 
after a step from 10 to 2.5mM glucose).  Although it proved difficult to achieve stable 
recordings in lower levels of glucose, those recording which were made appeared similar 
in their responses to a step from 2.5 to 0.5mM glucose.  These data can be compared 
with the evidence published by Melnick et al. (2011), regarding glucose sensing in the 
PVN.  That paper initially examined responses to steps in glucose from 10mM to 2.5mM 
as described here.  However, they saw no effect at these levels.  They did observe GI 
(24%) and GE (26%) cells when glucose was stepped from 10 to 0.2mM, but this was 
only seen in cells which had properties suggestive of pre-autonomic neurons, as outlined 
in section 4.5.1 above. 
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In the data presented here, relatively long periods of perfusion in low glucose were 
required before a response was observed.  Figure 5.3 provides examples of GE 
responses.  It can be seen that perfusion for around 5 minutes in 2.5mM glucose occurs, 
before a fall in action potential frequency is evident (5.3B).  Several possible 
explanations exist for this delay.  Firstly, there will be a delay from the time that the 
perfusion is switched due to delay in exchanging the medium in the chamber.  The 
perfusion system ran at 2-3ml/minute in both electrophysiology and calcium imaging 
experiments.  The chamber used in electrophysiological recordings is relatively large, 
especially compared to that used for calcium imaging (~1ml for electrophysiology, 
~0.5ml for calcium imaging), and so it could be expected that this delay will be longer 
under these conditions.  In addition, the mechanism by which cells sense changes in 
glucose may add to a delay to response.  If glucose is required to enter cells and be 
metabolised to effect a response, this will lead to a delay.  Finally, if signalling were from 
other cells in the slice, rather than intrinsic signalling, this might also contribute to a 
delayed effect. 
Interestingly, a second step to 2.5mM glucose results in a more rapid response.  A 
shorter delay to response is also seen with a step from 2.5 to 0.5mM glucose 
(Figure5.3A).  This seems likely to be due to a more rapid fall to a low glucose level 
within the slice, reaching the cell’s threshold for activation faster.  An alternative cause 
of this effect would be that the cell has already been metabolically activated by the first 
stimulus and so is more sensitive to a second stimulus.  However, the counter argument 
to this is that not every cell responds a second time. 
4.5.2.1 Effect of TTX on glucose responses in patch clamp recordings 
In patch clamp recordings, TTX had a clear effect in removing action potential spiking, 
but no significant effect on the resting potential of cells.  As previously mentioned, a few 
cells were observed to continue to spike, presumably due to calcium channels, but these 
were not stepped to low glucose and are not included in subsequent analysis.  It was 
notable that the majority of neurons responded to a step to low glucose in the presence 
of TTX by depolarising.  This may suggest that the majority of CRH neurons are 
intrinsically glucose inhibited.  This was of particular interest as GI neurons were not 
frequently seen in the absence of TTX.  This could imply that these neurons are being 
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synaptically inhibited by neurons elsewhere in the slice, and are therefore only revealed 
when these inputs are removed. 
4.5.3 Glucose sensitivity- evidence from calcium imaging 
Both GI and GE responses were observed in CRH neurons in PVN slices using GCaMP6f 
calcium imaging, both in slices cut in 10mM and 2.5mM glucose.  This technique has not 
previously been used in the investigation of glucose sensing (in vitro or in vivo).  Some 
but not all neurons were able to respond reversibly and repeatably to perfusion with 
low glucose.  GI neurons were present in roughly equal numbers to GE in many slices 
(9% of cells GE and 9% GI after slicing in 2.5mM glucose), and overall more GI and fewer 
GE cells were observed than was the case during electrophysiological experiments, 
where 8% of cells were GI and 35% GE.  It is possible that this could be due to 
differences in the ease of patching different CRH neurons, preselecting for GE and NR 
cells.  Another explanation could be related to the relatively high firing rate seen in 
many neurons in whole cell patch clamp.  When looking for evidence of excitation, it 
may be easier to detect this when a cell is firing slowly or is silent than with a baseline 
AP frequency of 6-7Hz.   
The data presented here using calcium imaging is novel in its use of a genetically coded 
calcium indicator, GCaMP6f, in hypothalamic cell subtypes to identify changes in calcium 
in response to a low glucose stimulus.  Initial validation using the same conditions as in 
the electrophysiological experiments shows that it is indeed possible to detect 
responses to low glucose using this mode of calcium imaging in slices.  As previously 
noted, both GI and GE responses could be detected.  The resting calcium levels of a CRH 
neuron are unknown.  The high action potential frequencies recorded in many CRH PVN 
neurons during patch clamp recordings suggest that some cells might be expected to 
have relatively high resting calcium levels. 
GI responses as observed in calcium experiments are readily understood- the cell 
becomes more active, resulting in calcium influx and possibly release from intracellular 
stores, leading to increased binding of GCaMP6f and increased fluorescence.  The 
changes observed in GE neurons require a little more thought.  If these cells are already 
active at baseline, possibly with relatively high calcium levels, one needs to consider 
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what changes in fluorescence would result from a reduction in activity.  Essentially, with 
falling calcium levels, the binding of GCaMP6f will be reduced and fluorescence will fall.  
However, the kinetics of this effect must be considered.  The tau off for GCaMP6f is 
400ms, as compared to a tau on of 74ms (Chen et al., 2013).  Therefore, the delay 
before a reduction in calcium will result in a fall in fluorescence will be considerably 
longer than for the onset of activation.  This should not be a major issue for the data 
collected here, as the imaging frequency is 0.5Hz, so 5 half-lives of GCAMP6f decay can 
pass between acquiring one image and the next.  This point has been considered in 
some work by Otis and colleagues, covered in the extended data of their publication, 
where the effect of inducing and then pausing action potentials was examined, 
recording the decay in fluorescence during a pause in action potentials compared to a 
hyperpolarisation without action potentials (Otis et al., 2017).  They showed that a fall in 
action potential firing is needed to generate a reduction in fluorescence, and that 
pauses in firing of 3 seconds can be tracked as a fall in fluorescence, with the magnitude 
of the fall in fluorescence being linearly related to the action potential frequency prior to 
the pause.  Sternson and colleagues also present data when cells become less active in 
response to feeding, using GCaMP6f in awake mice, and again, observe similar falls in 
calcium sensitive fluorescence after exposure to a stimulus (Betley et al., 2015).  This 
study imaged cells in vivo, and so no comparison could be made to AP frequency.  As 
described in section 4.4.6.3, GE neurons were found to tend to have higher raw baseline 
fluorescence when compared to GI and NR cells. This lends support to the hypothesis 
that these cells have higher activity levels in 2.5mM glucose when compared to GI and 
NR cells. 
In addition, it is of interest to consider what happens to the fluorescence in a tonically 
firing cell.  GCaMP6f is widely used to identify events due to small numbers of action 
potentials in cells with low frequency spiking patterns and the focus is on extrapolating 
fluorescence signals to infer events due to 1 or a small cluster of action potentials.  
However, in the data presented here, at least some of the cells are likely to be firing at 
very much higher rates, and in this case the fluorescence signal should read out at a 
steady state for a given firing frequency, with changes in fluorescence due to changes in 
AP frequency occurring over a slower time-course. 
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4.5.4 Do calcium levels represent neuronal activity? 
The measurement of calcium levels as a valid indication of neuronal activity is widely 
accepted (Grienberger and Konnerth, 2012).  Calcium signalling has been demonstrated 
as a trigger for a very wide range of neuronal events, including exocytosis at pre-
synaptic terminals, generation of action potentials post synaptically, nuclear calcium 
rises related to transcription and apoptosis.  In particular, calcium is an appealing 
molecule for imaging because the change in calcium levels in response to activation is 
very large, and the time course is relatively slow in comparison to changes in cell 
membrane potentials.  In addition, because changes in calcium levels occur within the 
cytoplasm, or a sub-compartment of the cell, they are more readily imaged than small 
changes in membrane potential, only affecting the cell membrane.  There are some 
caveats which should be considered when employing calcium imaging as a technique to 
investigate neuronal activity.  The most important is that an assumption is being made 
that levels of fluorescence within the cell reflect calcium levels, and that these in turn 
represent the level of activity of the cell, which is more directly measured in 
electrophysiological recordings.  GECIs have been extensively investigated and validated 
in multiple modalities, and have been shown to robustly reflect neuronal activity across 
species from drosophila to primates, in vitro and in vivo, and in soma, dendrites and 
subcellular compartments (Grienberger and Konnerth, 2012, Badura et al., 2014, 
Grynkiewicz et al., 1985).  Much of the current debate in the field revolves around which 
is the best choice of GECI for the desired experiment, rather than whether to use a GECI. 
4.5.5 Advantages and disadvantages of calcium imaging compared to patch 
clamping 
Calcium imaging was initially frequently used in conjunction with patch clamp 
electrophysiology in the literature, as the micropipette offered a means of introducing 
the calcium indicator into the cell.  The advent of, firstly, acetoxymethyl (AM) esters of 
small molecule calcium indicators,  and subsequently GECIs, which can be delivered via 
viral vectors or expressed in genetically modified mouse lines, allows the imaging of 
multiple cells in a single experiment.  This offers several attractive advantages over 
electrophysiology for the investigation of glucose sensing.  The ability to collect data 
from multiple cells in one experiment and to gain more information about the spatial 
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distribution of responsive cells are important considerations.  Additionally, calcium 
imaging is potentially less invasive to the cells involved than whole cell patch clamp.  No 
dialysis of the cytoplasm occurs and there is no physical disruption to the cells.  Finally, 
this method can allow multiple imaging sessions when carried out in vivo. 
It is more complex to directly influence the activity of the cells being imaged, although 
combination with an optogenetic technique could achieve this.  A great deal of 
information can be obtained from voltage or current steps in a patch clamped neuron, 
which is not available from calcium imaging.  In addition, there is always a trade-off 
between spatial and temporal resolution, which can be viewed as an advantage or 
disadvantage, depending on the question being asked.  In order to image a larger 
number of cells, the temporal resolution for each cell must fall. 
4.5.6 Optimisation of calcium imaging  
The experiments presented here did not aim to simply recapitulate the results seen in 
the electrophysiological section (i.e. of action potential discharge).  Rather, the intent 
was to capture slower calcium events.  Given that the timescale of responses to low 
glucose seen in electrophysiological studies occurred over 100-200s, it seemed that 
0.5Hz would be an adequate temporal resolution.  One experiment was performed here 
at 5Hz, and this did not reveal further information than those performed at 0.5Hz.  
Therefore, this appears to be a suitable time course. 
Several experiments were performed to establish which objectives were most suitable 
for imaging in slices.  A 60X (Nikon)and a 40X (Olympus) objective were both tried, with 
imaging through a z-stack of 15-24 planes.  However, this greatly increased the time 
interval between acquisition of sequential images, from 2.1s for a single z-plane to 11-
20s for a stack.  In addition, this setup was more sensitive to drift, especially in the z-
plane, and 4-dimensional registration is much more challenging to achieve.  Overall, 
temporal and spatial resolution was improved by using a 16X objective and a single z-
plane of around 1-2µm. 
Two major problems with the breeding of CRH x GCaMP6f mice were experienced 
during optimisation of calcium imaging in this thesis.  Firstly, the breeding of double 
Chapter 4 Evidence for glucose sensitivity in PVN CRH neurons 
184 
 
homozygous CRH x GCaMP6f mice resulted in widespread expression of GCaMP6f, which 
was no longer linked to CRH expression.  It is known that having a Cre recombinase and 
a reporter gene present in the germline can lead to spontaneous recombination events 
during gametogenesis (Morrison and Munzberg, 2012, Schmidt-Supprian and Rajewsky, 
2007, Weng et al., 2008), and it seems likely that this is what occurred here.  The 
commonest cause of this is recombination of the floxed reporter gene in germline cells, 
due to transient expression of Cre recombinase during development.  Subsequent to 
this, all offspring will have reporter gene expressed in a non-specific fashion.  The 
germline recombination event can occur in males only, females only, or both, and is 
dependent on the gene under which Cre recombinase is expressed.  The most 
straightforward way to avoid this is to avoid breeding with animals which have Cre 
recombinase and the floxed reporter both present, and this was the solution adopted 
here. 
The second problem which arose was in the development of a mouse line co-expressing 
GCaMP6f and TdTomato in offspring, as a means of identifying all of the GCaMP6f 
neurons by expressing a second, non-calcium dependent fluorescent protein.  A more 
complex breeding strategy was planned to express GCaMP6f (calcium sensitive reporter 
protein) AND TdTomato (standard reporter protein) under the control of the CRH-ires-
Cre line.  This involved the breeding of a CRH-Cre x GCaMP6f mouse, to cross with a 
homozygous TdTomato animal to gain all three genes in the offspring.  The TdTomato 
and GCaMP6f genes were not introduced into a single breeding animal, as they are both 
inserted at the same locus (ROSASor 2.6) and there is therefore a high chance of 
recombination which could lead to deletion or silencing of one or both reporter genes. 
As described in section 4.4.6.5, this approach, whilst intuitively attractive, did not prove 
successful, as responsive cells were not found using GCaMP6f imaging.  Problems with 
overlap of TdTomato and GCaMP6f signal have already been described in the results 
section, and essentially the signal to noise was much less favourable in the presence of 
TdTomato.  In addition, there was a loss of temporal resolution due to the need to 
image 2 channels.  It was also apparent that some neurons expressed only one 
fluorescent protein at a level which could be seen on imaging, rather than both, which 
further reduces the value of having a double fluorescent signal.  It is unclear why this 
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should occur.  Both GCaMP6f and TdTomato are present at the same locus (ROSASor 
2.6), although they are on separate chromosomes as the mice are bred as 
heterozygotes.  However, there could be an issue with chromosome inactivation, or a 
recombination event in some neurons.  It is also possible that both genes are being 
expressed, but with one at a much higher level than the other.  This approach was 
therefore abandoned. 
4.5.7 Spatial location of GI neurons is suggestive of a pre-autonomic population 
The small subset of ‘silent’ neurons observed during whole cell patch clamp experiments 
were of interest in a number of ways.  Clearly, the fact that the majority depolarised in 
response to a low glucose step, (i.e. GI) was of interest.  It was notable that these cells 
appear to have lower input resistances and may be larger (based on their capacitance).  
Their location in more posterior areas of the PVN was suggestive that these cells could 
be pre-autonomic.  Melnick and colleagues report low firing frequencies more similar to 
these neurons, in the range 0.2-0.5Hz, in their pre-autonomic cell population (Melnick et 
al., 2011).  However, no low threshold spike activity (characteristic of pre-autonomic 
neurons in the rat, see also section 4.5.1) was observed in the neurons patched here. 
Calcium imaging data could be translated into more precise information on where cells 
were located within the PVN as well as their responses.  Of interest, GI neurons 
predominated in more caudal sections, and scattered in the periphery of the PVN, whilst 
GE neurons tended to be found more rostrally and centrally.  This information is of 
interest as it can give clues as to the underlying mechanisms and connectivity of 
subgroups of neurons.  For example, the GE neurons of the VMN are largely found in the 
ventrolateral part, which is thought to be a key mediator of metabolic regulation and 
body weight (King, 2006).  The mouse PVN is a much less stereotyped nucleus than the 
rat, and so it is more difficult to infer possible functions from anatomy (Biag et al., 2012).  
However, the posterior location of many GI neurons is suggestive that at least some of 
these may be part of the brainstem projecting pre-autonomic population. 
Attempts to record in whole cell patch clamp from an anatomically defined pre-
autonomic population using retrograde tracing from the NTS were unsuccessful.  This 
was partially due to the scarcity of retrogradely transduced neurons visible in the fresh 
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slice.  In addition, it was challenging to identify ‘truly’ green eGFP+ neurons as the 
brighter red (TdTomato+) cells were also visible in the green channel, although it was 
possible to distinguish these by their colour.  It is extremely difficult to circumvent this 
problem for direct microscopy even using alternative filters, as TdTomato fluorescence 
remains bright in comparison to eGFP even at the extremes of its excitation and 
emission spectra, and if a filter is chosen to exclude it, eGFP fluorescence is also 
significantly reduced.   
One method which could overcome these problems would be to use a Cre dependent 
vector in a retrograde virus, injected into brainstem areas of a CRH-Cre mouse without 
TdTomato.  In this case, all visible fluorescent neurons identified in the PVN would be 
both CRH positive and brainstem projecting, without the need for co-localisation.  A 
potentially higher transduction yield might also result from the opposite strategy, 
injecting a Cre recombinase vector in a retrograde virus into the brainstem of a reporter 
mouse. Either of these methods could be a useful alternative strategy for the future. 
4.5.8 Consideration of physiological glucose levels 
4.5.8.1 Electrophysiology 
Although few cells were recorded here in 2.5mM glucose, with steps to 0.5mM, the fact 
that their properties and responses appear broadly similar to those in 10mM glucose 
suggests that at least some of the observed responses in CRH neurons can still operate 
at physiological levels.  It seems highly unlikely that CRH neurons in the PVN would ever 
be exposed to levels of glucose of 10mM. However, it is interesting to note that the 
majority of responses observed in the initial datasets, with synaptic inputs intact, were 
GE, and that these responses were seen at much lower frequency, if at all, in the 
presence of TTX which would abolish synaptic inputs.  This is significant given that cells 
responding to high and low levels of glucose have been reported in other parts of the 
hypothalamus, in particular the VMN.  Both high glucose excited (HGE) and high glucose 
inhibited (HGI) neurons, responding to steps from 10 to 0.5mM glucose, have been 
described in the VMN, where BBB is thought to be deficient and experience extracellular 
levels of glucose that are close to blood levels of glucose (Fioramonti et al., 2004).  It is 
therefore possible that HGE or HGI neurons could synapse onto the PVN CRH neurons 
recorded here to cause some of the responses seen. 




Calcium imaging provided a high throughput and effective means of collecting data from 
slices cut in 2.5mM glucose.  This was valuable as steps from 2.5mM glucose to 0.5mM 
are much more likely to represent the glucose levels experienced by PVN cells in vivo.  
Glucose responses were clearly present under these conditions, and indeed there was 
an increase in the numbers of GE neurons observed compared to slices cut in 10mM 
glucose with steps to 2.5mM.  This is an important finding as it suggests that moving 
glucose concentrations into the normal physiological range allows more cells to respond, 
likely to be due to examining effects in a situation where the sensing processes are not 
saturated. 
4.5.9 Summary 
Overall, the data presented here provides initial evidence of a glucose sensitive 
population of CRH PVN neurons, with a GI population which persists in the presence of 
TTX.  This suggests that at least some GI neurons in this population are intrinsically 
sensing glucose.  Further investigation of this population will be presented in the next 
chapter.
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Chapter 5 A subset of CRH PVN neurons intrinsically sense a 
fall in glucose, and this is dependent on glucose 
metabolism. 
5.1 Introduction 
This chapter continues from the previous work to characterise the glucose sensitive CRH 
cells within the PVN.  The focus is on intrinsic versus synaptically-mediated glucose 
sensing, and on the mechanisms of glucose sensing.  The introduction summarises what 
is currently known about mechanisms of glucose sensing in the central nervous system, 
and also discusses what inputs the PVN receives from other glucose sensing regions.  
Glucose sensing by non-neuronal cells will also be considered. 
5.1.1 Mechanisms of glucose sensing in the CNS- glucose excited cells 
The cardinal peripheral glucose sensor is the pancreatic beta cell, which utilises an ATP-
sensitive potassium channel to respond to changes in blood glucose.  Glucose enters the 
beta cell via low affinity GLUT-2 transporters and is metabolised by glucokinase, 
generating ATP.  ATP in turn binds to KATP channels, causing them to close.  This reduces 
potassium conductance across the cell membrane, depolarising the cell, and leading to 
generation of action potentials, calcium influx and insulin release (Ashcroft and 
Rorsman, 2004).  This elegant system links the extracellular glucose level to the degree 
of depolarisation of the cell, and thus to insulin release.  Early thinking on glucose 
sensing within the CNS drew parallels with peripheral nervous system and this has been 
reviewed extensively in the context of glucose sensing in the CNS (Burdakov et al., 
2005b, Routh, 2002). 
Glucokinase, GLUT2 and the subunits of the KATP channel (Kir6.2 and SUR1) are all widely 
expressed in glucose sensing areas of the CNS (Kang et al., 2004, Lynch et al., 2000, 
Stanley et al., 2013).  In particular, there is evidence that GE VMN neurons use 
glucokinase (Dunn-Meynell et al., 2002, Kang et al., 2006) and KATP channels (Ashford et 
al., 1990a, Song et al., 2001, Kang et al., 2006) to respond to changes in glucose.  
Glucose sensing neurons of the dorsal vagal complex have also been shown to utilise 
glucokinase (Balfour et al., 2006).  However, this is unlikely to be the only mechanism of 
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glucose sensing in the CNS.  Not all GE cells express glucokinase, GLUT-2 and KATP 
channels, and they can also be found in cells which are not glucose sensing (Kang et al., 
2004, Lynch et al., 2000).  In addition, measurement of ATP levels in glucose sensing cells 
in the hypothalamus, whilst elevating glucose, failed to show any change in ATP 
(Ainscow et al., 2002).  Studies exploiting KATP channel mutations have also been 
informative.  In the Kir6.2 global knockout mouse, there is indeed loss of VMN glucose 
excitation (Miki 2001).  However, the same mouse had preserved GE neurons in the ARC 
(Fioramonti et al., 2004).  Investigations using a GM mouse with a mutation in the KATP 
channel that renders it insensitive to ATP have shown that POMC neurons have an 
altered glucose sensitivity (Parton et al., 2007).  However, in both the Kir6.2 knockout 
and the mutated KATP channel mouse lines the baseline firing and excitability of the cells 
was significantly different from that seen in native neurons, and it is very difficult to 
unpick how much of the observed effects were due to this alteration rather than to a 
direct effect on glucose sensing. 
Alternative potential contributors towards intrinsic glucose sensing in glucose excited 
neurons are summarised in table 5.1.  In addition, it is important to note that more than 
one mechanism could be operating in any one cell.  It is also likely that the whole milieu 
in which any glucose sensing cell exists will also be important (for example, many 
glucose sensing cells also express receptors for insulin, leptin and other molecules which 
inform overall metabolic state)(Canabal et al., 2007b, Cotero and Routh, 2009, Flak et 
al., 2014, Roland and Moenter, 2011, Santiago et al., 2016). 
With regard to the PVN, Melnick et al. (2011), report that glibenclamide or tolbutamide 
(KATP channel blockers) had no effect on GE currents evoked by a step to low glucose.  In 
addition, the KATP activators diazoxide (SUR1) and chromakialin (SUR2) did not evoke 
any significant change in membrane potential or conductance.  Immunohistochemistry 
for SUR1 (a component of the KATP channel) in the PVN did not convincingly demonstrate 
fluorescence at primary antibody concentrations which did result in bright fluorescence 
in the VMN and ARC, areas known to express SUR1.  Melnick et al. suggest that either a 
potassium leak channel or a chloride conductance is involved in GE cell glucose sensing 
in the PVN.  Alternative candidates for PVN GE responses might include the sweet taste 
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receptors, which have been shown to be expressed in both PVN and ARC (Ren et al., 
2009). 
Table 5.1 Potential mechanisms contributing to glucose sensing in the hypothalamus 
Potential mechanism Neurochemical phenotype  References 
AMPK POMC 
GnRH 
(Claret et al., 2007) 
(Beall et al., 2012b, Roland 
and Moenter, 2011) 
Sodium glucose co- 
transporters 




(Kang et al., 2004) 
 
(O'Malley et al., 2006) 
Non-specific cation 
channel 
(Could include TRP, SGLTs) 
Pre autonomic PVN 
GnRH 
ARC 
(Melnick et al., 2011) 
(Roland and Moenter, 
2011) 
(Fioramonti et al., 2004) 
Sweet taste receptors Expressed in PVN and ARC (Ren et al., 2009) 
Reactive oxygen species ARC.  Possibly POMC (Pauliina Markkula et al., 
2016, Leloup et al., 2006) 
AMPK- 5' adenosine monophosphate-activated kinase, TRP-transient receptor potential 
channel , SGLT- sodium glucose co-transporters, GnRH- gonadotrophin releasing 
hormone 
5.1.2 Mechanisms of glucose sensing in the CNS- Glucose inhibited cells 
Less is understood about the mechanisms which may operate in GI cells.  Vanessa Routh 
and colleagues have extensively investigated mechanisms by which VMN GI neurons 
may respond to glucose and suggest a model in which glucose metabolism leads to 
decreased AMPK activity, NO generation, increased cGMP levels, and opening of a 
chloride channel (possibly a member of the CFTR family), leading to hyperpolarisation of 
the cell (Canabal et al., 2007b, Dunn-Meynell et al., 2002, Kang et al., 2006, Kang et al., 
2004, Murphy et al., 2009a) summarised in (Zhou et al., 2018).  CFTR channels have also 
been implicated in the glucose inhibited ARC neurons (Fioramonti et al., 2007).  AMPK 
could also operate via other means to alter cell excitability via phosphorylation of 
additional membrane and cytosolic proteins (Song et al., 2001) and is also know to alter 
gene transcription via CREB co-activation by CRTC2 (Lerner et al., 2009).  With regard to 
the PVN, AMPK is expressed in PVN neurons and hypoglycaemia has been shown to 
result in activation of AMPK in the PVN and the VMN, but not in other parts of the 
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hypothalamus (Han et al., 2005).  However, mechanisms of glucose sensing in GI 
neurons of the PVN have not been previously investigated. 
Denis Burdakov and colleagues (Gonzalez et al., 2009) have investigated the 
mechanisms by which orexin neurons in the lateral hypothalamus are inhibited by 
glucose, and suggest a very different mechanism for these cells, independent of 
metabolism.  A series of experiments demonstrated that some non-metabolisable 
sugars such as 2-deoxyglucose could elicit the same response as glucose in these cells 
(Gonzalez et al., 2008), and that inhibition of glucokinase had no effect.  In addition, 
glucose or an analogue needed to be applied to the external cell membrane to cause a 
response.  The channel responsible for hyperpolarisation of these cells appears to be a 
potassium ‘leak-like’ channel.  However, the sensor linking the change in glucose to the 
potassium channel is thus far unknown. 
Other putative mechanisms for GI neurons include reduction in activity of Na-K-ATPase 
at the cell membrane leading to depolarisation (Oomura et al., 1974, Silver and 
Erecinska, 1994b), and the concept of voltage induced inactivation of sodium channels 
as a result of KATP channels closing and causing prolonged depolarisation (Burdakov and 
Lesage, 2010, Gromada et al., 2004).  Generation of reactive oxygen species has also 
been identified as a potential mediator of glucose sensing in the central nervous system, 
(Pauliina Markkula et al., 2016). 
5.1.3 Mechanisms of glucose sensing in the CNS- Non-neuronal cells 
Neurons are not the only cells in the CNS which are capable of responding to changes in 
their environment.  It is clear that glial cells in general are much more active in signalling 
locally than originally thought (Araque et al., 2001).  Indeed, re-expressing GLUT-2 in 
astrocytes restored glucagon responses to hypoglycaemia in global GLUT-2 knock out 
mice (Marty et al., 2005).  Neither TTX nor fast synaptic blockade will have any effect to 
block signalling from glial cells, astrocytes or tanycytes.  Astrocytes store glucose as 
glycogen, and release lactate into the surrounding interstitium.  A recent bioarchiv 
preprint reported increases in AMPK activation and lactate release in response to 
hypoglycaemia in primary human astrocyte cultures and an astrocytoma cell line 
(Weightman Potter et al., 2018).  Lactate can be taken up via monocarboxylase 
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transporters on neuronal cell membranes and converted to pyruvate, generating ATP 
(Kang et al., 2004, Magistretti et al., 1999).  These transporters are present at relatively 
high levels within the hypothalamus, and may provide an additional means of signalling 
metabolic state, which could operate in GI and GE neurons (Ainscow et al., 2002, Pierre 
et al., 2000).  This mechanism could provide an alternative means of inactivating KATP 
channels and depolarising GE neurons, independent of glucokinase and GLUT 
transporters. 
Tanycytes lining the third ventricle have also been shown to be able to respond to 
glucose application in vitro (Frayling et al., 2011).  These cells extend processes into the 
surrounding neuronal tissue and could therefore signal to neurons in their locality.  Both 
lactate and ATP have been suggested as potential signalling molecules from tanycytes to 
neurons (Frayling et al., 2011, Elizondo-Vega et al., 2015). 
5.1.4 Investigating whether cell metabolism is involved in glucose sensing 
The commonest method by which this question is address is by examining the effect of a 
non-metabolisable sugar in place of glucose.  2-deoxyglucose (2-DG) is a glucose 
analogue which is transported by most glucose transporters, and is metabolised by 
hexokinase to form 2DG-6-phosphate, which cannot then leave the cell or be further 
metabolised.  This results in inhibition of hexokinase and glucoisomerase, depleting ATP 
(Wick et al., 1957).  It is commonly used intracerebroventricularly, to mimic localised 
hypoglycaemia in vivo (Marty et al., 2005, Sanders and Ritter, 2000) and has also been 
used in vitro in patch clamp experiments to examine the role of metabolism in glucose 
sensing cells (Lamy et al., 2014, Gonzalez et al., 2008).  Gonzalez et al. were able to show 
that GI orexin neurons in the LH responded to increases in 2-DG in the same way as they 
did glucose, suggesting a metabolism independent mechanism was operating in these 
neurons.  Lamy et al. examined GI neurons in the NTS (expressing GLUT-2), and suggest 
that glucose metabolism was required in these cells, as perfusion with 2-DG in the 
presence of 5mM glucose caused similar responses to a step to 0.5mM glucose. 
5.1.5 Synaptic inputs to the PVN from glucose sensing areas 
This topic has already been covered in some detail in the general introduction (Chapter 
1 section 1.8.2).  The focus here will be on which nuclei with known intrinsic glucose 
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sensing properties could provide inputs to CRH neurons of the PVN during in vitro slice 
experiments. 
The hypothalamus is a key glucose sensing area and there are a number of candidate 
areas surrounding the PVN which could be contributing to the responses to glucose 
reported in chapter 4.  In particular this is relevant to the GE responses, which were 
largely abolished by TTX in electrophysiological recordings and so are likely to be 
synaptically-mediated.  If a coronal section, around 300microns thick through the PVN is 
considered, then the VMN, ARC, DMN and LH are all potentially included in the slice, and 
all are recognised to contain glucose sensing neurons (Burdakov et al., 2005b, Otgon-Uul 
et al., 2016, Fioramonti et al., 2004).  In addition, all these areas are known to send 
processes to synapse onto neurons of the PVN (Larsen et al., 1994).  Figure 5.1 provides 
a summary.  The preoptic area is the other hypothalamic area which has been identified 
as containing glucose sensing neurons and having connections to the PVN, but this 
seems an unlikely candidate as it is situated very anteriorly in the hypothalamus, and so 
would not be in the slice. 
 
Figure 5.1 Potential nuclei containing glucose sensing populations in a coronal slice 
which could synaptically influence CRH PVN neurons in response to a low glucose step   
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• LH: As described in section 4.1.4, orexin neurons of the LH are glucose inhibited.  
It is also known that orexin expressing neurons send processes into the PVN 
(Sakurai et al., 1998) and that these projections can affect a range of PVN 
functions including autonomic regulation, food intake and metabolism, 
(Edwards et al., 1999) and PVN neuron excitability (orexin neurons appear to be 
excitatory in the PVN) (Samson et al., 2002, Ferguson et al., 2008).  Additional 
glucose sensing populations within the LH are the NPY subgroup (Marston et al., 
2011), and MCH neurons (GE, (Burdakov et al., 2005a)).  The effects of NPY and 
MCH neuronal inputs on the PVN are not known. 
• ARC: POMC and AgRP neurons are well recognised PVN projecting populations, 
and these pathways are of key importance in modulation of feeding behaviour 
via the MC4R, with melanocortin activating this receptor and AgRP inhibiting it.  
Glucose sensing has been demonstrated in ARC neurons, although some 
controversy exists as to whether the POMC neurons are glucose sensing, or 
responding to other neurons.  Ibrahim et al. (2003) reported that 80% of POMC 
neurons in slices from mice were GE, but did not investigate whether this was an 
intrinsic effect or via synaptic inputs.  Increased glucose levels have been shown 
to cause increased α-melanocyte-stimulating hormone release in hypothalamic 
slices in vitro, but again the effect may be indirect (Parton et al., 2007).  Reports 
by Wang et al. (2004) in rats and Fioramonti et al. (2007) using mice have not 
found any evidence for direct glucose sensing by POMC neurons of the ARC.  It is 
likely based on these findings that POMC neurons are indirectly glucose 
responsive (Fioramonti et al., 2017). 
AgRP/NPY neurons have been shown to directly sense glucose, with 40% found 
to be GI (Fioramonti et al., 2007).  GI AgRP neurons are sensitised by fasting 
(Murphy et al., 2009b).  This population is less likely to be able to act on PVN 
CRH neurons to give a GE response, unless an interneuron is involved. 
GE neurons are certainly present in the ARC, and would be good candidates to 
act on CRH PVN GE neurons, but the cell subtypes remain unknown (Fioramonti 
et al., 2007). 
• VMN: This is a key glucose sensing area which has been extensively investigated 
(Routh, 2003).  Again, projections to the PVN have been demonstrated (Larsen 
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et al., 1994).  This region has been of particular interest with regard to 
responses to hypoglycaemia, and is known to contain intrinsic glucose inhibited 
and glucose excited neurons.  Modulation of the thresholds of GI neurons 
following recurrent hypoglycaemia has been described for this region (Routh, 
2003, Song and Routh, 2006). 
• DMN: GABAergic neurons of the DMN have been described as exhibiting both GI 
and GE responses (Otgon-Uul et al., 2016).  Again, this nucleus is known to 
connect to the PVN as described in the same paper. 
 
5.2 Hypotheses 
• PVN CRH neurons are intrinsically glucose sensing 
• Glucose sensing is dependent on glucose metabolism in CRH neurons of the PVN 
 
5.3 Aims 
• Use tetrodotoxin to block action potentials and test whether glucose sensitivity 
is intrinsic to CRH neurons 
• Investigate effect of pharmacological synaptic blockade on glucose responses in 
CRH PVN neurons 




5.4.1 Is glucose responsivity intrinsic to CRH PVN neurons or a function of 
synaptic drives from elsewhere in the coronal slice? 
5.4.1.1 Effect of TTX on glucose responses during calcium imaging 
Having seen a significant change in glucose responsiveness to a primarily GI population 
when using TTX in electrophysiological experiments, it was logical to proceed to perform 
the same experiment using calcium imaging, to examine whether this phenomenon 
could also be seen using calcium levels as an indicator of cell activity.  After application 
of 0.5mM glucose in the presence of TTX, GI neurons were readily observed, and were 
possibly more numerous than in the control group, suggesting that these cells do not 
require sodium dependent action potential firing to generate a calcium response to low 
glucose, and that these responses are unlikely to be synaptically-mediated (Figure 5.2 
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A,B).  However, in contrast the number of GE neurons was significantly decreased 
(Figure 5.2 A).  The size of the GI and GE responses were not affected by TTX (Figure 5.2 
D).  The morphology of the GI responses was altered, with 76.9% of responses now 
appearing slow rising (39.1% in control population), and 23.1% spiking (60.1% in control 
populations) (p<0.0001, Fishers exact test compared to GI cells from 2.5mM glucose 
control population). 
TTX in itself resulted in a small but significant reduction in calcium levels when measured 
across the whole population (Figure 5.2 Ci), as would be expected for an agent which 
blocks sodium dependent action potentials (so reducing influx across the membrane) 
and also synaptic transmission.  This effect was also observed in the small population of 
GE cells which were still identifiable in the presence of TTX (Figure 5.2 Cii).  TTX had no 
effect on calcium levels in the larger population of GI neurons, which is what would be 
expected if this cell population were not firing action potentials in the presence of 
2.5mM glucose (Figure 5.2 Ciii).  TTX was observed to slow the onset of effect of a high 
potassium solution (360.0±31.0s from start of perfusion with high potassium to start of 
response, compared to 95.0±10.7s in control cells), again as would be expected on 
blocking sodium dependent action potentials (Figure 5.2 B). 
The location of GI and GE cells in the presence of TTX was similar to that seen in control 
slices.  However, more GE cells were found caudally in the presence of TTX.  The GI cells 
appeared to be spread more generally through the CRH neurons of the PVN, rather than 
primarily in the periphery of the CRH population (Figure 5.3).  This could be due to 
removal of inhibitory inputs in the presence of TTX revealing a more widespread GI 
population.  
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Figure 5.2 Effect of TTX on CRH PVN neurons 
A Comparison of responses to 0.5mM glucose step in the presence of TTX and control.  
Significant reduction in number of GE cells seen (Chi-square 115.6, p<0.0001) 
B Examples of 3 GI cells in the presence of TTX.  TTX applied at first vertical line, shaded 
area represents perfusion with 0.5mM glucose, high potassium applied at final vertical 
line (K) 
C Effect of TTX alone on calcium levels prior to a step to 0.5mmol glucose.  i) all cells, 
****p<0.0001, n=1101 ii) GE cells only, **p=0.0015, n=22cells, iii) GI cells only, no 
significant change in calcium levels, n=198cells.  Wilcoxon matched pairs signed rank. 
D Effect of TTX on the size of responses to step to 0.5mM glucose compared to control.  
i) GE effect size is significantly increased, p=0.0015, Mann-Whitney U ii) GI effect size, no 
significant difference, Mann Whitney U. 
TTX data obtained from 4 mice, 11 slices, 111.2 ±16.0 cells/slice.  Data presented as 
median and IQR  
Chapter 5 A subset of CRH PVN neurons intrinsically sense a fall in glucose, and this is 




Figure 5.3 Spatial distribution of GI and GE cells after a step from 2.5mM to 0.5mM 
glucose in the presence of TTX 
Images are arranged rostral to caudal, GI neurons are red, GE green.  Approximate 
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5.4.1.2 Effect of excitatory synaptic blockade on glucose responses 
Having established that TTX ablates and/or reduces GE responses, but not GI, the effect 
of blocking excitatory fast glutamatergic synaptic inputs was investigated using a cocktail 
of 50µM D-AP5 (NMDA antagonist) and 10µM CNQX (AMPA/kainate receptor 
antagonist).  For this series of experiments, the glucose responsiveness as assessed with 
GCaMP6f imaging of each slice was first assessed in the absence of synaptic blockade, 
and subsequently after application of D-AP5/CNQX.  Data is therefore presented as 
repeated measures comparing each neuron’s response within the same slice, and group 
responses are also compared to the effects seen after the second application of 
0.5mmol glucose in control slices (as the second response was significantly different to 
the first).  The effect of D-AP5/CNQX in itself on basal GCaMP6f fluorescence was subtle 
in most cells.  The median effect for the entire cell population was no change in calcium 
sensitive fluorescence following application of D-AP5/CNQX, and this was also the case 
for the GI subgroup (Figure 5.4 A and Bi).  The GE subgroup showed a significant 
reduction in fluorescence, which would fit with the concept that these cells are receiving 
significant synaptic inputs, which are causing them to fire spontaneously (Figure 5.4 Bii). 
As for TTX, the overall effect of D-AP5/CNQX was to abolish the responses of GE 
neurons, whilst leaving the GI response largely intact (Figure 5.5).  The size of the GI 
response appears to be slightly smaller after application of D-AP5/CNQX, when 
compared within the same cell (Figure 5.5 Ci).  However, this effect had also been 
observed after a second application of 0.5mM glucose in control cells (Figure 4.14).  If 
the GI response in D-AP5/CNQX is compared to the second application of glucose in GI 
cells in control slices, then there is no significant difference in response size (Figure 5.5 
Cii).  This indicates that there is no overall effect of D-AP5/CNQX on GI neurons, either 
with regard to the number of responsive cells or the size of response- suggesting that 
this response is not dependent on fast excitatory glutamatergic synaptic transmission. 
The GI cells observed in the presence of D-AP5/CNQX were scattered throughout the 
rostro-caudal extent of the PVN, in a similar fashion to that seen for the TTX experiment 
(Figure 5.6).  
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Figure 5.4 Effect of D-AP5/CNQX on calcium levels 
A Overall effect of D-AP5/CNQX on calcium levels for all cells.  There is no significant 
change in mean calcium levels (Wilcoxon paired signed rank, n=720) 
B D-AP5/CNQX has no effect on mean calcium levels for the GI subgroups of cells 
(Wilcoxon paired signed rank, ns, n=60).  There is a significant decrease in mean calcium 
levels for the GE subgroup of cells (Wilcoxon paired signed rank, p<0.0001, n=50) 
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Figure 5.5 Effect of excitatory synaptic blockade on responses to low glucose in CRH 
PVN cells 
A Cell population responses to a step to low glucose in presence of D-AP5/CNQX 
compared to control population.  GE responses no longer present in D-AP5/CNQX (Chi 
square 96.16, p<0.0001) 
B Population of GE neurons identified prior to application of D-AP5/CNQX no longer 
show any calcium response to low glucose in presence of D-AP5/CNQX, (Wilcoxon paired 
signed rank, p<0.0001, n=50) 
Ci) GI responses are reduced in size but not ablated in presence of D-AP5/CNQX.  ii) the 
size of GI response is not significantly different to the size of response seen after second 
application of low glucose in control cells.  (Kruskal Wallis test with Dunn’s multiple 
comparisons) 
D Example calcium traces showing GI cells responding to low glucose before and after 
synaptic blockade.  D-AP5/CNQX applied at 3rd vertical line, shaded grey areas represent 
application of low glucose, high potassium solution applied at final vertical line K. 
Data for D-AP5/CNQX from 3 mice, 4 slices, 166.3±25.5 cells/slice.  Data shown as 
median and IQR  
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Figure 5.6 Spatial distribution of GI and GE cells after a step from 2.5mmol to 0.5mmol 
glucose in the presence of synaptic blockade 
Images are arranged rostral to caudal, GI neurons are red, GE green.  Approximate 
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5.4.1.3 Effect of excitatory and inhibitory synaptic blockade (EISB) 
A further set of slices were exposed to a cocktail of CNQX, D-AP5 and in addition 100µM 
picrotoxin (GABAA antagonist) to block inhibitory inputs in addition to excitatory inputs 
(Figure 5.7).  Again, this was a 2-exposure protocol, with low glucose applied before and 
after EISB.  GI responses were preserved in the presence of D-AP5, CNQX and picrotoxin.  
The slices exhibited a smaller population of GI and GE neurons prior to application of 
EISB compared to the control slices (Chi square 96.24, p<0.0001, Figure 5.7A).  In 
particular only 5 cells in total were identified as GE, and essentially this means that the 
effect on GE responses cannot be commented on using this dataset.  There was a 
reduction in the size of the GI response after EISB compared to the response seen in the 
same slice prior to EISB (Figure 5.7Ci).  There was no change in the size of GI responses 
in the presence of EISB compared to a second application of 0.5mM glucose in control 
slices (Figure 5.7C ii). 
The effect of EISB itself was to cause an average decrease in calcium levels across all 
cells (0.58(0.36-0.93) to 0.43(0.27-0.98), median and IQR, Wilcoxon signed rank 
p<0.0001, n=444), which was also observed in the GI subgroup (Figure 5.7B).  The spatial 
distribution of responsive cells in this experiment was similar to that for D-AP5/CNQX 
and to TTX, although far fewer cells were observed to respond (data not shown).  
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Figure 5.7 Effect of inhibitory and excitatory synaptic blockade (EISB) on responses to 
0.5mmol glucose in CRH PVN cells 
Ai) GI cells are present both before and after application of EISB (Chi square 1.227, ns).  
The numbers of GE cells are very small in this data set (5 in total) 
Aii) Example cell responding to 0.5mM glucose in absence and presence of EISB. 
B EISB application reduces median calcium sensitive fluorescence i) on all cells, ii) on GI 
subgroup (Wilcoxon signed rank, ****p<0.0001, ***p=0.0006) 
C There is a reduction in the size of the GI response in the presence of EISB when 
comparing responses within the same slice (i).  There is no significant change in the size 
of response compared a second application of 0.5mM glucose in control slices (ii)  
(Kruskall Wallis test with Dunn’s multiple comparisons) 
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5.4.2 Glucose sensitivity and glucose metabolism 
The protocols used so far have been designed to examine the effect of a step from a 
baseline level of glucose representative of levels in a fed animal to a level which would 
be expected during significant hypoglycaemia.  If sensing this change in glucose does not 
depend on metabolism, then replacing 2.5mM glucose with a combination of 2mM 2-DG 
and 0.5mM glucose will not have any effect on glucose responsive cells (so long as 2-DG 
is a substrate for the transporter or sensor which usually carries/detects glucose).  If, 
however, sensing requires metabolism, then this combination will if anything show an 
enhanced effect because of the ATP depleting effect of 2DG.  In this experimental 
protocol, 2-DG and 0.5mM glucose were applied twice with washout being performed in 
between, similar to the initial protocol where steps from 2.5mM glucose to 0.5mM were 
performed twice. 
GI and GE responses were maintained in the presence of 2-DG (Figure 5.8), there was 
even some expansion of the number of GI cells.  Interestingly, the size of both the GI and 
GE responses was reduced on first application of 0.5mM glucose plus 2-DG when 
compared to control slices with 0.5mM glucose alone.  However, the second response 
was larger compared to the first where 2-DG was present in the case of the GE cells.  
This might suggest an accumulation of the effect of 2-DG over time.  This experiment 
suggests that both the GE and GI responses depend on metabolism. 
There was no change in the spatial locations of responsive cells with 2DG compared to 
control or TTX groups (data not shown).  
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Figure 5.8 Application of 2-DG expands number of GI cells observed in CRH PVN cells 
A Proportion of GI, GE, NR and SA cells observed in presence of 2mM 2DG with 0.5mM 
glucose compared to control slices.  Chi square=63.82, p<0.0001 
B Example GI cell responding in presence of 2-DG throughout.  Shaded areas- 0.5mM 
glucose, final dotted line- application of high potassium 
C Size of the GI response (i) and GE response (ii) both reduced compared to control 
responses. GI * p=0.0241, GE *** p=0.0007, Mann Whitney test 
D Size of the second response to application of 2-DG significantly larger than size of first 
response in GE but not GI cells.  i) GI cells ns Friedman test with Dunn’s multiple 
comparisons.  ii) GE cells, ** p=0.0026, Wilcoxon matched pairs signed rank 
Data obtained from 2 mice, 4 slices, 54.25 ± 13.7cells/slice.  All data displayed as median 
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5.5 Discussion  
5.5.1 Intrinsic glucose sensing by a subgroup of PVN CRH neurons; evidence 
from TTX experiments 
The defining aspect of a glucose sensing neuron is that it should be intrinsically able to 
respond to changes in glucose.  Clearly, synaptic inputs can result in cells appearing to 
be glucose sensing, where they are in fact responding to glucose sensing via synaptic 
input from the primary GI or GE neuron.  The hypothalamus is richly supplied with 
glucose sensing populations (LH, VMN, ARC, DMN, PVN, PO), and many of these could 
maintain synaptic inputs to the PVN in 300micron thick slice as discussed in section 
5.1.5.  It was therefore important to examine the effect of glucose on CRH neurons in 
the absence of such inputs.  TTX was chosen as the simplest method to reduce/remove 
all synaptic inputs, by blocking voltage gated sodium channels necessary for the 
transmission of action potentials required to trigger synaptic release. 
The calcium imaging data collected in the presence of TTX supports and enhances the 
findings from patch clamping.  These data were collected at lower glucose levels than in 
patch clamping.  Here, GI responses were preserved in the presence of TTX compared to 
control cells, and very few GE cells were observed in TTX.  This would fit with the 
hypothesis that a proportion of CRH PVN cells have intrinsic GI responses (~20% based 
on the TTX data).  This could represent a means by which the intrinsic excitability of the 
neurons in question could be modulated by the glucose status of the local environment. 
The reduction in numbers of GE neurons compared to control slices implies that the 
majority (if not all) of these neurons are synaptically activated, and not directly sensing 
glucose. 
5.5.2 Intrinsic glucose sensing by a subgroup of PVN CRH neurons; Evidence 
from synaptic blockade experiments 
In all cases involving synaptic blockade, GI responses are maintained.  This confirms a 
novel population of intrinsically glucose sensing GI CRH PVN neurons, which has not 
previously been identified.  Given the known roles of CRH at the top of the ACTH-cortisol 
axis, and in addition the newly identified autonomic projections from CRH PVN neurons, 
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these cells are well positioned to be involved in the counter-regulatory response to 
hypoglycaemia. 
One further possibility should not be discounted.  Although TTX and synaptic blockade 
remove neuronal inputs from these cells, it is still possible that non-neuronal cell 
signalling could be responsible for the effects seen.  A local glucose sensing astrocyte 
population could release glucose or lactate onto the CRH PVN GI cells, for example 
(Leloup et al., 2016).  However, this is true of almost all of the previous studies of 
intrinsic glucose sensing neurons within the CNS, as few experiments are carried out in 
conditions which would block non-neuronal inputs.  It is also unlikely to alter the overall 
implications of this finding significantly.  If GI CRH PVN cells are in fact the first order 
downstream neuron of the ‘true’ glucose sensing cells, they remain important and 
specific effector cells in the response to hypoglycaemia, and would still be attractive for 
further investigation and indeed as potential future therapeutic targets. 
The finding that the GE responses to glucose amongst CRH PVN neurons are abolished 
by TTX and excitatory synaptic blockade indicates that these cells are not in fact 
intrinsically glucose sensing but are responding to synaptic inputs from other glucose 
sensing cells within the slice.  As described in section 5.1, there are a wide range of 
possible candidate populations which could fulfil this role.  Depending on whether any 
synaptic connection is direct, or involves an interneuron and on whether the primary 
sensing neuron is itself excitatory or inhibitory, either GE or GI cells from elsewhere in 
the slice could be involved as outlined in section 5.1.5. 
5.5.3 Metabolism is necessary for both GE and GI responses 
The 2-DG experiment suggests that metabolism is necessary for both GE and GI 
responses within the CRH PVN neurons.  A non-metabolism dependent cell population 
would have shown no effect with the switch from 2.5mM glucose to a combination of 
2mM 2DG and 0.5mM glucose.  The fact that the second response to application of 2-DG 
was larger than the first is also supportive of this interpretation of the data as 2-DG is 
likely to accumulate in cells and cause increasing metabolic effects with time. 
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Further confirmatory work would be helpful to explore these findings.  Repeating the 
experiment in the presence of TTX or synaptic blockade would remove the possibility of 
inputs from elsewhere in the slice confusing the issue, and allow a focus on the GI CRH 
PVN neurons.  A step from 0.5mM glucose to 0.5mM glucose plus 2-DG would be 
expected to show lack of inhibition by glucose in GI cells.  Logical experiments beyond 
this would be to examine the effect of pharmacological blockade/activation of 
glucokinase or AMPK and then downstream candidate molecules previously identified as 
important in glucose sensing cells. 
GE responses are also preserved in CRH PVN neurons in the presence of 2-DG.  This 
suggests that metabolism is necessary for the glucose sensing population acting on GE 
CRH PVN cells.  LH GI neurons sense glucose independent of metabolism, which would 
make a LH input much less likely.  Essentially, every other GI and GE population in the 
hypothalamus remains a potential candidate.  Further investigation might be possible 
using alternative slicing strategies to anatomically remove individual hypothalamic 
nuclei from the slice and examine the effect of this on CRH PVN responses.  
Alternatively, pharmacological investigation based on known mechanisms of glucose 
sensing in other glucose sensing populations could provide clues as to identity of the 
upstream glucose sensing population. 
5.5.4 Effect of TTX or synaptic blockers on PVN CRH neuronal calcium levels. 
The effect of TTX prior to a low glucose step on calcium levels in these experiments was 
interesting.  The effect on individual cells was very variable, with some cells showing 
large falls in fluorescence whilst many others showed little or no change or indeed slight 
rises.  The effect seen might be expected to depend on the balance of excitatory and 
inhibitory inputs onto each individual cell.  In the overall cell population, there was a 
small fall in fluorescence after application of TTX.  This would fit with the concept that 
many of these cells receive overall excitatory inputs, and that blocking these would 
result in a fall in calcium levels.  The GE neurons showed responses similar to the overall 
group. This would also fit with the idea that these neurons are spontaneously active, and 
are reducing their activity in the presence of TTX.  However, the GI neurons did not as a 
group exhibit a significant fall in fluorescence.  This might suggest that these cells 
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receive a differing set of inputs to the population as a whole, or that their basal firing 
rates are lower (or indeed that these neurons are quiescent in 2.5mM glucose). 
The effect of excitatory blockade alone was not significant in the whole cell population, 
or in the GI subgroup.  D-AP5/CNQX did result in a median decrease in fluorescence in 
the GE subgroup, suggestive of blockade of excitatory synaptic inputs to these neurons.  
This would fit with the effect seen with TTX, adding to the evidence that these neurons 
are tonically active, and driven by excitatory inputs.  PVN cells receive extensive 
excitatory inputs from elsewhere in the hypothalamus, and the primary inhibitory inputs 
are from a surrounding ‘shell’ of GABA releasing axons, often from cells within the PVN 
itself including CRH neurons (Ramot et al., 2017, Roland and Sawchenko, 1993).  It is 
important to note that some of the excitatory inputs are in fact thought to synapse onto 
the inhibitory shell rather than directly onto PVN neurons (Herman et al., 2003).  This 
might explain why in the majority of cells no direct effect was seen on application of 
excitatory blockade- the removal of direct inputs and those acting via the inhibitory shell 
could balance one another out to no overall effect. 
Combined excitatory and inhibitory blockade caused a decrease in fluorescence in the 
whole neuronal population in a similar fashion to TTX.  This would be consistent, as 
combined excitatory/inhibitory blockade or TTX should result in removal of rapid action 
potential dependent synaptic inputs in a similar manner.  However, additional 
modulation of synaptic inputs may be being blocked by TTX compared to combined 
excitatory/inhibitory blockade.  Examples would include the effects of CRH itself on local 
receptors, MC4 receptor effects, vasopressin and oxytocin receptors. 
5.5.5 Summary 
This chapter presents the evidence for a novel population of GI neurons which express 
CRH and are situated in the PVN.  Experiments using 2-DG suggest that metabolism of 
glucose is important for glucose sensing in this new population.  In addition, a further 
subgroup of CRH PVN GE neurons are indirectly modulated by synaptic inputs from 
elsewhere in the hypothalamus, with potential primary glucose sensing candidates 
including neurons in the LH, VMN, DMN or ARC, or indeed the newly identified CRH GI 
PVN neurons.  




Chapter 6 CRH-Cre neurons have a role to play in the 
response to recurrent hypoglycaemia 
6.1 Introduction 
This chapter describes models of insulin induced hypoglycaemia (IIH) and HAAF in 
humans, rats and mice, with their advantages and disadvantages.  Data from mouse 
models of both single and recurrent episodes of hypoglycaemia are presented.  The CRH 
x Td mouse is used in the single hypoglycaemia model to demonstrate neuronal 
activation as evidenced by cfos expression in the hypothalamus.  Finally, CRH x GCaMP6f 
mice are exposed to recurrent hypoglycaemia and data are presented showing the 
responses of the subsequent acute slices to low glucose using calcium imaging. 
6.1.1 Models of hypoglycaemia and autonomic failure in human and animal 
models 
The development of HAAF was described in the introductory chapter.  As established 
there, the mechanisms underlying this phenomenon remain poorly understood.  In 
order to gain a better understanding, reliable models of HAAF are needed, both in 
humans and in animals (Tkacs and Thompson, 2006). 
6.1.1.1 Human models of HAAF 
HAAF has been produced under controlled conditions in both diabetic subjects and 
healthy volunteers.  In most cases, following an overnight fast, a hyper-insulinaemic 
glucose clamp technique is used, with insulin and glucose being infused into an 
indwelling cannula in one arm.  Glucose infusion is used in addition to insulin to allow 
much tighter control of glucose levels and ensure that the subject does not become 
excessively hypoglycaemic.  Repeated sampling of blood is performed from a cannula in 
the other arm.  By warming the sample hand/arm, ‘arterialised’ venous blood can be 
sampled, as warmth opens up additional capillary beds, bypassing metabolically active 
tissue.  A range of durations and depths of hypoglycaemia have been induced using this 
technique.  Information on the hormonal response provoked by a given level of 
hypoglycaemia can be obtained from blood sample assays.  In addition, questionnaires 
can be used to gain an understanding of the subject’s experience of neurogenic and 




neuroglycopenic symptoms of hypoglycaemia (Senthilkumaran et al., 2016).  Some 
studies report that after a single hypoglycaemic episode a degree of HAAF can develop 
(Heller and Cryer, 1991), whilst others suggest 2 or 3 prior episodes are required (Davis 
et al., 1996, Moheet et al., 2014).  Healthy volunteers have been reliably shown to 
exhibit all the canonical features of HAAF (Senthilkumaran et al., 2016), even though 
they would not experience this degree of hypoglycaemia outside the test arena. 
Diabetic subjects are in some ways a more appropriate subject group for investigation as 
they are the patients suffering the adverse sequelae.  A range of protocols with differing 
frequencies and depth of hypoglycaemia have been described (Dagogo-Jack et al., 1993, 
Rattarasarn et al., 1994, Lingenfelser et al., 1993).  However, it is challenging to control 
for degree of prior glycaemic control, and especially to recruit a group who do not 
already have any degree of HAAF.  For this reason, in many cases healthy volunteers 
have been preferred. 
The major limitation of human studies is that it is not possible to study neuronal activity 
or the underlying mechanisms with the same level of resolution, and possible 
interventions are limited.  Imaging has provided some insights, but to gain a greater 
understanding of underlying mechanisms, models, particularly in rodents, have been 
developed.  In addition, this provides the potential for use of genetic modification, 
analysis of gene expression, activation/inactivation of brain areas/systems and indeed 
the production of more severe degrees of hypoglycaemia than would be deemed 
acceptable in a human subject (Senthilkumaran et al., 2016). 
6.1.1.2 Rat models of HAAF 
A number of rat models of HAAF have been reported in the literature.  The route of 
administration of insulin varies, with some groups using subcutaneous insulin (Sanders 
et al., 2006, Orban et al., 2015) and others i.p insulin (Flanagan et al., 2003, McCrimmon 
et al., 2005) to induce hypoglycaemia.  There has been a move towards chronic 
cannulation of the internal jugular for insulin (and sometimes additional glucose) 
infusion, with blood samples being withdrawn either from an arterial cannula (Herzog et 
al., 2008, Al-Noori et al., 2008, Evans et al., 2001), or by repeated tail tip (de Vries et al., 
2004).  Chronic cannulation allows a similar degree of control of hypoglycaemia to that 




achieved in human subjects.  It also reduces stress due to restraint and pain from 
injection.  However, a degree of technical skill is required to prepare the animals.  
Repeated sampling is generally not a significant issue.  An adult rat’s blood volume is 
approximately 25mL (64mL/kg, 400g rat), and 15% total blood volume is suggested as a 
maximum to withdraw over a 28 day period if the animal is to recover, which is 
equivalent to 3.84mL (nc3rs, 2018b).  Terminal samples are unrestricted.  In some cases, 
replacement of blood samples with donor rat blood has been used to allow larger 
samples to be taken (Evans et al., 2003). 
Effects similar to those seen in humans have been reported in rat models of recurrent 
hypoglycaemia.  Between one (Kang et al., 2008, Tkacs et al., 2005) and four (Orban et 
al., 2014, Herzog et al., 2008) prior hypoglycaemic episodes have been reported to be 
required to produce a hormonal profile consistent with HAAF.  Of note, some studies do 
not see a fall in epinephrine levels in recurrent hypoglycaemia animals compared to 
single hypoglycaemia (Figlewicz et al., 2002, Paranjape and Briski, 2005).  However, as 
we will discuss in more detail below, it is difficult to unpick the effect of restraint and 
intervention stress from the stress evoked by the study conditions and this may be a 
confounding factor. 
Clearly, it is advantageous to be able to sample tissue for either imaging, recording or 
analysis of gene expression following induction of HAAF and this is the major advantage 
of a rat model.  However, because of the lack of verbal report it is not possible to gain 
information regarding neurogenic or neuroglycopenic symptoms as in the human.  In 
addition, very few rat models with genetic modifications are available.  Potentially 
interesting transgenic rats might include the CHAT-CRE, TH-Cre and TPH2-CreERT2 
strains, which express Cre recombinase under the control of cholinergic, 
adrenergic/noradrenergic (Witten et al., 2011) and serotonergic (Weber et al., 2011) 
cells respectively.  A CRH-Cre transgenic rat has been developed, using a BAC (Pomrenze 
et al., 2015).  However, although expression of Cre recombinase was observed in the 
amygdala and parts of the BNST, no expression was found in the paraventricular 
hypothalamus in this strain, so this would not be of use to investigate CRH PVN neurons.  
In the future, it seems likely that a larger number of relevant models will become 




available, using the newer gene editing toolkits, for example CRISPR (Li et al., 2013), 
TALEN (Tesson et al., 2011) and zinc finger nucleases (Geurts et al., 2009). 
6.1.1.3 Mouse models of HAAF 
The very wide range of transgenic and knock in mouse models available make 
developing a mouse model of HAAF very attractive.  However, there are a number of 
important considerations which have made this a challenging prospect. 
Firstly, technically obtaining blood samples which provide useful information from an 
animal which has a circulating volume of around 1.5mL  (58.5mL/kg, 25g mouse) is 
challenging.  Clearly the number and volume of samples must be limited, with the limit 
for an animal which is to recover being 15% of total blood volume over 28 days (0.21mL) 
(nc3rs, 2018a).  Even with a terminal procedure, the maximum blood sample that could 
be obtained is the total blood volume or less.  This reduces the amount of information 
that can be gathered, particularly with regard to hormonal levels which tend to require 
larger blood volumes.  For example, the glucagon RIA used here requires 100µL of 
plasma or serum for a single time point, which is equivalent to approximately 180µL of 
blood. 
Secondly, mice as a prey animal species are extremely easy to stress, simply by handling 
or indeed any change in their housing and environmental conditions.  This is especially 
problematic for measuring epinephrine and norepinephrine levels.  Anaesthesia can be 
used but induces a different range of stressors, and has been shown to alter the 
response to hypoglycaemia (Ayala et al., 2010).  This, as well as the fact that only a small 
number of samples can be taken from any one animal, may explain why no publication 
has yet been able to show blunting of the epinephrine response to hypoglycaemia in a 
mouse model (Senthilkumaran et al., 2016). 
There is also the question of how to induce hypoglycaemia.  A single i.p injection of 
insulin is probably the most commonly used method for a single hypoglycaemic episode, 
and is widely used to perform an insulin tolerance test in mice (Dearden and Balthasar, 
2014, Ayala et al., 2010).  A dose of 2-2.5units/kg of a fast-acting insulin such as Actrapid 
or Humulin S is commonly used (Poplawski et al., 2011, Dearden and Balthasar, 2014).  




However, it is more challenging to reliably induce hypoglycaemia repeatedly as required 
to induce HAAF. Poplawski and colleagues used i.p insulin at 2.5units/kg to induce HAAF, 
with tail tip blood glucose (2011).  Potentially chronic cannulation is more attractive, as 
it allows use of an insulin (± glucose) infusion to induce controlled hypoglycaemia, and 
this was used by Jacobson et al. (2006b, 2006a).  However, cannulation in the mouse is 
technically challenging.  In addition, infusion of i.v fluids into a very small circulating 
volume without significant dilution effects is required.  The limitations already 
mentioned for blood sampling are also an important consideration, even with a tightly 
controlled infusion. Glucose control may be less tight as there are limits to the frequency 
at which measurements can be safely taken. 
Neither an i.p nor an i.v approach induced a fall in epinephrine levels back towards 
baseline levels in publications in mice to date, but both techniques did show falls in 
cortisol and glucagon, as would be expected in HAAF.  A review by Senthilkumaran et al. 
therefore concludes that until a loss of the epinephrine elevation is seen in a mouse 
model, it cannot be reasonably concluded that a mouse model of HAAF exists 
(Senthilkumaran et al., 2016).  However, it is very difficult to unpick the effect of 
hypoglycaemia and other stressors on mouse epinephrine levels.  It is clear that it is 
possible to reliably induce recurrent hypoglycaemic episodes in mice, using either i.p or 
i.v insulin, and that using these methods an attenuation of both the glucagon and 
cortisol response to hypoglycaemia can be produced which would be consistent with the 
development of HAAF. 
6.1.2 cfos as a marker of neuronal activation 
CFos is an immediate early gene which has been widely used as a marker of neuronal 
activation in a wide range of studies, both in vitro and in vivo (Kovacs, 1998, Hoffman et 
al., 1993).  It was first described in 1984 (Greenberg and Ziff, 1984), and it encodes a 
55kDa protein, with a short half-life of around 2hours.  cfos interacts with cjun and other 
members of the jun family to form the AP-1 transcription factor. CFos mRNA is 
measurable within minutes of an acute stimulus, and peaks at 30-60mins.  cfos protein 
levels peak 1-3hours after the onset of a stimulus.  Activation of CFos transcription is 
mediated by both a CRE (cAMP response element) and SRE (serum response element) 
sited in the promotor region of the CFos gene.  This allows a range of different forms of 




activation of a neuron to initiate CFos transcription, including rises in PKA, CAM kinase 
IV, PKC and other MAP kinases (Kovacs, 1998). 
cfos acts as a transcription factor in concert with other members of the immediate early 
gene family including cjun.  It is known to target AP-1 promotor regions, and was initially 
identified as a proto-oncogene in the periphery, causing transcription of genes involved 
in initiating cell division amongst other roles.  The downstream targets of cfos in the 
brain, where very little mitosis occurs, are less well understood, although cfos is known 
to activate transcription of genes including cytokines, growth factors, stress signals and 
oncogenes (Alberini, 2009).  The primary value of cfos in the brain has been as a marker 
of neuronal activation, allowing functional mapping of anatomical areas within the brain 
which are activated by an acute stimulus.  An important caveat in the use of cfos for this 
purpose is that cfos will only identify cells that become activated by a stimulus.  Cells 
which are inhibited cannot be identified.  There is also a threshold that must be reached 
to induce cfos, and additional cells may be activated subthreshold and so not identified. 
In addition, cfos is not a specific marker, and it is possible that unidentified events could 
induce cfos in the same time frame as the experimental stimulus.  Therefore, careful 
choice of control groups is required. 
Several previous studies in rats have reported increased cfos labelling in a range of 
hypothalamic areas following a single episode of hypoglycaemia, including in the PVN 
(Ao et al., 2005, Al-Noori et al., 2008, Evans et al., 2001, Niimi et al., 1995).  Interestingly, 
the VMN, which is believed to be a key area in the response to hypoglycaemia 
(McCrimmon, 2009), does not exhibit an elevation in cfos under the same conditions 
(Niimi et al., 1995).  Some studies have gone on to show a reduction in cfos expression in 
the PVN, and also the DMN and arcuate nucleus, following recurrent hypoglycaemia 
when compared to a single hypoglycaemic episode (Al-Noori et al., 2008, Evans et al., 
2001).  Several equivalent studies have been performed in mice, and show similar 
patterns of cfos after insulin induced hypoglycaemia in the PVN (Tamaki et al., 1995, 
Diggs-Andrews et al., 2010). 
There have been few attempts to define neuronal subtypes which show elevated cfos 
and other early genes in response to hypoglycaemia within hypothalamic areas.  Al-




Noori et al. (2008) examined the expression of fosB in CRH, TRH, vasopressin and 
oxytocin neurons in the PVN after recurrent hypoglycaemia.  fosB is a slower onset 
transcription factor, which is activated after recurrent hypoglycaemia to a greater extent 
than after single hypoglycaemia. They showed that around 30% of the fosB expressing 
cells were CRH positive.  This may be an underestimate of the CRH positive proportion, 
as the animals were not colchicine treated.  None of the other 3 neuronal subtypes 
examined (TRH, vasopressin and oxytocin) co-localised with fosB.  Equivalent work has 
not been performed for cfos and neuronal subtypes in mice or rats. 
Importantly, cfos expression can be produced in the PVN in response to a wide range of 
other acute stimuli, including restraint, osmotic stress, fear, pain and immobilisation 
(Kovacs, 1998).  It is therefore important to design experiments to minimise confounds 
and improve the signal to noise of the cfos expression to allow effects of the 
intervention to be detected.  Stress must be minimised as far as possible, and control 
groups must be designed to reproduce those effects which cannot be minimised, and 
which are not part of the intended stimulus. 
6.2 Hypotheses 
• CRH neurons are activated by a single episode of hypoglycaemia as indicated by 
cfos expression 
• The counterregulatory response is blunted in a mouse model of recurrent 
hypoglycaemia 
• Recurrent hypoglycaemia reduces the numbers of glucose responsive CRH PVN 
neurons 
6.3 Aims 
• Develop a mouse model of IIH 
• Seek evidence of neuronal activation (using cfos) following single hypoglycaemia 
• Develop a mouse model of recurrent hypoglycaemia and HAAF 
• Assess whether glucagon and corticosterone levels fall after recurrent 
hypoglycaemia compared to single hypoglycaemia 




• Examine effect of recurrent hypoglycaemia on glucose sensing in CRH PVN 
neurons in vitro using calcium imaging 
6.4 Results 
6.4.1 Developing a mouse model of insulin induced hypoglycaemia 
A insulin dose finding pilot experiment was carried out in male CRH x TdTomato mice as 
shown in table 6.1.  A dose of 2units/kg i.p Humulin S was sufficient in to induce 
hypoglycaemia in 50% of mice (5/10) (blood glucose <4mM).  2.5units/kg induced more 
consistent hypoglycaemia (4/4, 100%).  2.5units/kg was therefore used for induction of 
hypoglycaemia. 
Table 6.1 Insulin dose finding in CRH x TdTomato male mice 
Dose (units/kg) 1.5  2  2.5  
Blood glucose at 
30minutes mM 
(Mean ± SEM) 
6.5± 0.8 
n=4 
4.5 ± 0.6 
n=10 
3.3 ± 0.2 
n=4 
 
This dose of insulin was then used in a protocol to induce single hypoglycaemia (SH), as 
summarised in figure 6.1.  A control group (CT) of mice were handled in exactly the same 
manner as the hypoglycaemia group, but received i.p saline rather than insulin.  The 
resulting blood glucose measurements are summarised in figure 6.2, with a significant 
fall in blood glucose levels in the SH at 30 minutes compared to CT.  All SH animals had 
glucose levels below the defined threshold for hypoglycaemia (4mM) at 30 minutes.  





Figure 6.1 Single hypoglycaemia protocol  




Tail tip and baseline blood glucose
IP insulin (or saline control) 2.5U/kg (=5μl/g)
Wait 30minutes
Check blood glucose (from tail tip)
Wait 2hours
Terminal anaesthesia and 
check blood glucose
Perfuse/fix with formalin
Collect brain for cfos
6-12 weeks.  Male. C57Bl6 strain
For cfos, CRHXTdTomato





Figure 6.2 Glucose levels for single hypoglycaemia protocol mice 
Blood glucose levels measured from tail tip blood samples for mice subsequently used 
for cfos immunohistochemistry. n=4 per group 
A Blood glucose 0.5 hours after a single IP injection of insulin (SH group) or saline (CT 
group) p=0.0019, unpaired t-test 
B Blood glucose at time 0, 0.5 and 2.5 hours after IP insulin (SH group, i) or saline (CT 



























































6.4.2 Activation of PVN CRH neurons in a mouse model of IIH 
Mouse brains were processed for cfos IHC to look for evidence of PVN-CRH neuronal 
activation in response to hypoglycaemia, after undergoing the protocol described in 
section 6.4.1.  cfos expression in the PVN is markedly increased after a single episode of 
IIH, when compared to a saline injected control (Fig 6.3A, n=4 for each group).  Co-
localisation of cfos and Tdtomato showed that 84% of CRH neurons are activated in 
response to IIH compared to 30% in the control group (Figure 6.3B, Figure 6.4B).  
Interestingly, there appeared to be a correlation between blood sugar level at 30 
minutes post injection and cfos cell count as shown in figure 6.4A.  Co-localisation in the 
posterior part of the PVN was also examined, as this area is thought to be the site of 
projections to autonomic areas (Biag et al., 2012), but in these sections no difference 
between levels of expression of cfos was observed, either in the PVH in total or in CRH 
neurons (Figure 6.3C). 
As a control experiment, a second series of slices from the same animals was double 
labelled for oxytocin and cfos using IHC (Figure 6.5).  There was no increase in cfos 
expression in oxytocin expressing neurons in the PVN when comparing SH and CT groups 
(5 ± 2.5 cells, n=3 for SH vs 0 ± 0, n=4 for CT, unpaired t-test ns, Figure 6.6).  There was a 
significant increase in cfos expression for all cells in the PVN (124 ± 14, n=3 for SH vs 18 ± 
5.6, n=4 for CT, unpaired t-test p=0.01).  There was no difference in the numbers of 
oxytocin neurons between the 2 groups (19 ± 3, n=3 for SH vs 24 ± 5.6, n=4 for CT, 
unpaired t-test ns).  





Figure 6.3 CRH neuronal activation by hypoglycaemia: cfos expression after a single 
episode of insulin induced hypoglycaemia 
A i) Representative images after immunohistochemistry for cfos in mid PVN ii) cells 
counts, one slice per animal, n=4 for each group.  Mean SEM and data spread shown 
B i) Confocal images of hemi PVN and associated high power images (single z plane) to 
show co-localisation of CRH (TdTomato positive) and cfos positive neurons ii) manual 
cells counts, one slice per animal, n=4 for each group *=p<0.05 
C i) cfos cell counts in a single posterior PVN slice for each animal, ii) co-localisation of 















































































































Figure 6.4 Additional cfos information 
A Correlation between blood glucose measurement 0.5 hours after i.p injection of 
insulin or saline and cfos positive cell counts.  Line of best fit and 95% confidence 
intervals plotted, R square= 0.776 
B Diagram to show effect of SH vs CT on induction of a cfos population which is largely 
co-localised with CRH.  Red box=CRH neurons, green=cfos, numbers are mean ± SEM of 






























Figure 6.5 Images to show oxytocin staining from a SH mouse from the same cohort as 
the cfos CRH colocalisation 
A Image of hemi PVN, blue is Alexa 405 secondary antibody (oxytocin), green is Alexa 
488 secondary antibody (cfos) 
B Zoomed in to show colocalisation of oxytocin and cfos in 1/4 oxytocin neurons in the 
field of view (white arrows)  





Figure 6.6 Cfos, oxytocin and CRH cell counts in PVN following single episode of 
hypoglycaemia compared to control saline injection 
A Cfos cell counts are significantly increased in SH mice compared to CT (p=0.01) 
B No significant difference in CRH or oxytocin cell counts 
C Significant increase in cfos positive CRH neurons in SH group compared to CT 








































































6.4.3 Development of a recurrent IIH model to investigate HAAF in mice. 
Having successfully induced single hypoglycaemia, a model of recurrent IIH (RH) was 
developed as outlined in Figure 6.7.  A rapid acting insulin was used (Lispro), with the 
aim of achieving more rapid onset of hypoglycaemia compared to Humulin S.  A 20% 
lower insulin dose was used for this protocol than the SH protocol above reflecting 
concern that the mice would need to be able to recover from 4 sequential episodes of 
hypoglycaemia.  Hypoglycaemia of <2mM was relatively uncommon (observed in 17.5% 
of 40 hypoglycaemic episodes) and was successfully treated with i.p glucose (20% 
solution).  No animals in the experimental groups were observed to experience seizures 
or became comatose. 
Initial samples were collected from a cohort of mice to assess for evidence of HAAF.  24 
male mice aged 12-20 weeks were used, all on a CRH-ires-Cre C57Bl6 background.  
Glucose levels recorded for the cohort showed that hypoglycaemia was achieved 
following 75% of insulin injections (summarised in Figure 6.8A).  Glucagon and cortisol 
levels were assessed using radioimmunoassay (Figure 6.8B). 
Elevation of both glucagon and corticostreone was seen after single hypoglycaemia 
when compared to control mice.  There was a trend towards elevation in glucagon 
above control levels in the RH group, however, this did not reach statistical significance.  
It was notable that the SH group showed very variable glucagon levels, and that higher 
glucagon levels were observed in mice with lesser severity of hypoglycaemia in the SH 
group, which is counterintuitive (Figure 6.9C).  However, the lines of best fit for the RH 
and SH groups of mice were not significantly non-zero in either direction.  Elevation of 
corticosterone levels in the RH group was observed, compared to control, with no 
significant difference from the SH group. 
  





Figure 6.7 Recurrent hypoglycaemia protocol 
A Scheme of work over 3 days 
B Table to show i.p injections received by recurrent hypoglycaemia (RH), single 
hypoglycaemia (SH) and control (CT) mice respectively  
C57Bl6 strain, CRHXAi95D
Male (for RIA) Female (for calcium imaging)
6-12 weeks
Day 1 House individually
Fast for 2 hours 
(from 8am for am episode, from 1pm for pm episode)
Tail tip for baseline blood glucose
IP insulin 2U/kg (or saline 4μl/g)
Wait 30 minutes
Tail tip for blood glucose
Refeed
Recover for minimum of 2 hours 
(10:45-12:45 for am episode, overnight for pm episode)
If <2mmol, IP 20%
glucose 3μl/g
Day 2 As day 1 Teminal anaesthesia 
and collect blood for 
RIA
Day 3 Terminal anaesthesia and remove brain 




Insulin Insulin Insulin Insulin
InsulinSaline Saline Saline
Saline Saline Saline Saline
B
A
am pm am pm
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Figure 6.8 Glucose, glucagon and corticosterone levels after RH protocol 
A Glucose levels for cohort of mice subsequently used for glucagon and corticosterone 
RIAs.  Glucose levels for individual mice shown, followed by a summary graph (in green 
box) showing the mean and SEM for RH, SH and CT groups 
Bi) Glucagon levels in CT, SH and RH treated mice n=7-8 per group. p=0.0066, one way 
ANOVA with Sidak’s multiple comparisons test.  **CT vs SH. No significant difference 
between CT and RH or RH and SH groups. 
Bii) Corticosterone levels in same groups, n=7-8 per group. p=0.0016, one way ANOVA 
with Sidak’s multiple comparisons test.  ** CT vs SH and CT vs RH. No significant 
difference between SH and RH 
  





Figure 6.9 Relationship between glucose and glucagon levels following RH protocol. 
A Glucose and glucagon levels just prior to perfusion for all animals used in the RH 
protocol for RIA- SH, RH and CT n=23 
B Glucose and glucagon levels in RH group, with line of best fit and 95% confidence 
intervals.  R square= 0.1840, ns 
C Glucose and glucagon levels in SH with line of best fit and 95% confidence intervals.  R 
square=0.3732, ns  



















































6.4.4 Effect of recurrent hypoglycaemia on subsequent glucose sensing in CRH 
PVN neurons 
A further 6 CRH x GCamp6f female mice aged 6-9 weeks were subjected to the same 
recurrent hypoglycaemia protocol, with 3 animals injected with insulin and 3 matched 
controls receiving saline injections in place of insulin.  The insulin injected group of 
animals achieved very consistent hypoglycaemia over four episodes, and their glucose 
levels are summarised in table 6.2. 
Table 6.2 Glucose levels in mice exposed to recurrent hypoglycaemia (RH) or saline (CT) 
prior to slicing for calcium imaging 








RH1 2.4 1.5 2.1 1.3 
RH2 2.3 1.9 3.5 2.1 
RH3 3.6 1.6 2.5 3.3 
CT1 7.4 8.5 9.6 7.8 
CT2 6.9 5.8 5.8 6.5 
CT3 7.7 6.9 6.1 6.3 
 
On the third day, the animals were culled, and acute brain slices cut as detailed in the 
methods section 2.7.1.  Slices were imaged with two repeated steps from 2.5mM 
glucose to 0.5mM glucose using the same protocol as developed in chapter 4 (section 
4.4.6.3).  The results were not as predicted.  There was in fact a substantial expansion of 
the number of both GI and GE neurons in the RH group compared to control (for GI 11% 
RH, 4.5% CT, and for GE, 6.8% RH, 3.7% CT, Chi square 17.08, p=0.0007), as shown in 
Figure 6.10A.  It was also notable that the numbers of responsive cells in the CT group 
were smaller than observed in comparable experiments without antecedent i.p 
injections (4.5% of cells GI, 3.7% of cells GE in the CT group here, 9.5% GI and 9.9% GE in 
the 2.5mM glucose baseline group).  There was no difference in the size of the GI or GE 
responses between the 2 groups on the first application of glucose (Figure 6.10B, Mann-
Whitney test, ns).  





Figure 6.10 Effect of recurrent hypoglycaemia on glucose sensing as observed using 
calcium imaging 
A There is a significant increase in the numbers of GI and GE cells identified in the RH 
group compared to control (Chi square 17.08, p=0.0007) 
B There is no significant difference in the size of the GI response between the 2 groups 
(Mann Whitney test) 
C There is no significant difference in the size of the GE response between the 2 groups 
(Mann Whitney test)  
Data obtained from 3 mice in each group.  RH 6 slices, 90.8 ± 23.4cells/slice, Control 5 
























































6.5.1 A mouse model of insulin induced hypoglycaemia 
Single hypoglycaemic episodes were successfully induced in mice, using i.p insulin 
injections at 2.5units/kg.  This is a relatively simple model, and has been used 
extensively in the published literature to assess insulin tolerance (Dearden and 
Balthasar, 2014, Ayala et al., 2010).  The SH cohorts reliably responded to a single i.p 
insulin injection by lowering their glucose to <4mmol/L after 30 minutes, and remaining 
stable without significant sequelae over the next 2 hours prior to perfusion.  This 
appears to be a good model for a single hypoglycaemic episode. 
6.5.2 A mouse model of recurrent hypoglycaemia 
Developing a recurrent hypoglycaemia protocol proved more challenging.  In particular, 
occasionally a mouse fails to become hypoglycaemic following an insulin injection, 
possibly due to injection into bowel or bladder, rather than intraperitoneal.  The failure 
of mice to become hypoglycaemic can be seen in the data for the RH group of mice used 
to assess glucagon and corticosterone levels, where several mice experienced 3 or even 
just 2 out of an intended 4 hypoglycaemic episodes.  In addition, the RH mice need 
monitoring to identify any which become excessively hypoglycaemic.  Injection of i.p 
glucose (20%) in mice with blood glucose measured as <2mM was used to ensure full 
recovery from the episode, allowing continuation of the RH protocol.  This was required 
in 17.5% of hypoglycaemic episodes.  It was however difficult to manage 2 episodes of 
hypoglycaemia per day for large numbers of animals.  Where animals are to be used for 
in vitro work following the protocol, and only 2-3 are required at any one time, this is 
straightforward.  However, for samples for RIA (or IHC), where 4-6 animals in each group 
are needed, a limit of 6 animals for each iteration of the protocol was employed, with 
repeats over subsequent days/weeks.  This introduced the potential for increased 
variation between batches of animals. 
It is possible that this model could be improved by extending the intervals between 
hypoglycaemic episodes to once every 24 hours.  This has been described previously in 
one mouse model of recurrent hypoglycaemia (Poplawski et al., 2011).  The initial 
protocol used here was based on a rat protocol (Al-Noori et al., 2008).  A number of 




other rat models successfully use once daily insulin injections to induce HAAF (Herzog et 
al., 2008, Orban et al., 2014).  This could also make it more practical to give animals a 
slightly higher dose of 2.5units/kg insulin and still allow them sufficient recovery time.  
This could be explored in future work.  Part of the appeal of a 2 day protocol was the 
option to readily extend the protocol on day 3 for example to in vitro electrophysiology 
or calcium imaging, but this is only of value if the model is successful in reliably inducing 
recurrent episodes of hypoglycaemia.  It is also possible that more reliable and 
repeatable hypoglycaemic episodes could be achieved using chronic cannulation and a 
hyperinsulinaemic clamp, which would result in more controlled hypoglycaemia and 
remove variability due to the site of injection of insulin compared to i.p injection.  This 
has been reported by one group in mice (Jacobson et al., 2006a, Jacobson et al., 2006b) 
and requires  a significant investment in technical expertise, as well as a possible 
increase in the stress experienced by the animals. 
6.5.3 Difficulties with finding evidence for hypoglycaemia induced autonomic 
failure in a RH model in mice 
HAAF has been demonstrated in both humans and rodents, as evidenced by failure to 
elevate counterregulatory hormones including glucagon, cortisol/corticosterone, 
epinephrine, norepinephrine and growth hormone (Senthilkumaran et al., 2016).  This is 
discussed in some detail in the introduction to this chapter, section 6.1.1.  It is important 
to note that not all models of HAAF recapitulate the full profile of counterregulatory 
hormone failure.  For example, i.v insulin administration by Figlewicz et al. (2002) did 
not result in significant attenuation of epinephrine rises following recurrent 
hypoglycaemia in their rat model.  A similar effect was seen in the paper by Paranjape et 
al. (2005) using s.c insulin in rats. 
The model used here showed a clear increase in both corticosterone and glucagon 
following a single episode of hypoglycaemia.  There was no significant difference 
between control and RH glucagon levels, suggestive of a trend towards return of 
glucagon levels to baseline, but equally there was no significance difference between RH 
and SH levels, so the evidence for a failure of glucagon counterregulation is equivocal.  
There was no evidence of any form of HAAF as evidenced by corticosterone levels 
following recurrent hypoglycaemia, with corticosterone levels in SH and RH mice both 




being significantly increased from baseline and no significant difference between the SH 
and RH groups. 
There are several reasons why this may have occurred.  Firstly, there are limits to the 
number of samples which can be taken for analysis of hormonal levels.  In the model 
presented here, essentially a large volume of blood can only be taken at an end point in 
order to gain a large enough sample from the mouse without causing undue stress.  
Even in a cannulated mouse, where samples could be taken without restraint, the 
circulating blood volume would still limit the number of samples possible.  Around 
120µL of plasma is needed for each time point to perform a glucagon and corticosterone 
RIA.  In terms of whole blood, this is likely to be around 200µL at each time point, or 
10% of the total circulating blood volume.  2-3 samples of this size would almost 
certainly induce stress related to blood loss.  In the rat and human models, sequential 
samples are routinely taken, and this makes it much more likely that a sample is taken at 
the optimal time point to see a difference in response for a given hormone.  Indeed, 
frequently only one or 2 time points are observed to be significantly different in rodent  
models of hypoglycaemia (Evans et al., 2001, Jacobson et al., 2006a).  It is therefore 
possible that if samples could be taken from a mouse at a different time point, or levels 
could be measured at several time points, an effect might be seen that is not apparent 
here. 
In addition, there is the issue of the stress response of the mouse.  It is widely 
recognised that mice do not acclimatise well to stressful stimuli even with extensive 
habituation.  Previous baseline levels of corticosterone in the mouse have been reported 
as 16.1±1.8 µg/dL (Jacobson et al., 2006a), which aligns closely with the levels found in 
this study (16.9±1.8µg/dL in control animals).  It is still entirely possible that the high 
corticosterone levels measured here could be partially a result of the stressful effects of 
repeated handling, changes to clean cages, fasting, and movement from their home 
room to an experimental room, masking any amelioration of the corticosterone 
response to recurrent hypoglycaemia compared to single hypoglycaemia. 
However, this does not explain the findings for glucagon, as glucagon is not produced in 
response to stress.  The recurrent hypoglycaemia group were not significantly different 




when compared to controls.  However, the levels measured were also not significantly 
different from those seen in the single hypoglycaemia group.  In this case, the most 
striking thing was the variability in glucagon levels for the single hypoglycaemia group.  
Although the mean single hypoglycaemia glucagon response was high, the variation was 
very wide, and the highest glucagon levels were observed in the animal with the highest 
glucose levels in this group, where it might be expected that a lower glucose would 
result in higher glucagon levels. It is not clear why this was the case.  There was not a 
clear correlation between glucose levels and glucagon levels in the mice used for this 
experiment, in either the RH or SH groups (Figure 6.9).  One interesting paper examined 
glucagon levels in response to different degrees of hypoglycaemia in the mouse 
(Malmgren and Ahren, 2015).  They compared the glucagon responses to a graded 
hyperinsulinaemic hypoglycaemic clamp with those observed following a simple i.p 
insulin tolerance test.  There was good correlation between glucose levels and glucagon 
in the graded clamp, but very poor correlation for the ITT.  This fits with the data 
presented here. 
Overall, the RH model appears to require further optimisation.  It is possible that the RIA 
results presented here are simply underpowered.  This seems more likely in the case of 
glucagon, where there was a trend to a return of glucagon levels to baseline in the 
recurrent hypoglycaemia group.  It is also possible that the corticosterone result is 
unclear due to significant noise from the stress of the protocol as a whole.  A chronic 
cannulation approach to allow greater control of blood glucose would be helpful in 
establishing a more reliable model.  In the small body of literature available for mouse 
models of RH, chronic cannulation and intravenous infusion of insulin was able to 
demonstrate reliable blunting of the glucagon and corticosterone response to 
hypoglycaemia in RH mice, although this was still not always the case for the 
epinephrine response (Jacobson et al., 2006b, Jacobson et al., 2006a). 
Finally, it is reasonable to briefly question whether the mouse model of RH will look 
exactly like the rat or human model.  Senthilkumaran and colleagues suggest that there 
has yet to be a valid model of HAAF in the mouse, as no group has been able to show a 
consistent return towards baseline of epinephrine levels in the recurrent hypoglycaemia 
group (Senthilkumaran et al., 2016).  Some of the issues with obtaining valid epinephrine 




levels in a mouse under any scenario were discussed briefly in the introduction to this 
chapter.  We did not attempt to obtain epinephrine levels in this model, as there was no 
realistic prospect of obtaining stress free samples.  Indeed, in some cases the 
epinephrine and norepinephrine levels reported in rat models of HAAF are inconsistent 
(Evans et al., 2001, Orban et al., 2014) or there is a failure to show blunting of the 
glucagon and corticosterone responses, although there is a fall in epinephrine (Tkacs et 
al., 2005).  It is possible that a sufficiently useful mouse model of HAAF could be 
developed that shows consistent reduced levels of glucagon and corticosterone in 
recurrent hypoglycaemia compared to single hypoglycaemia, without necessarily 
causing blunting of epinephrine/norepinephrine levels. 
6.5.4 cfos is increased in CRH neurons in IIH compared to control animals 
cfos expression was increased in 84% of CRH neurons following insulin induced 
hypoglycaemia, compared to 30% of CRH neurons in the control group, a substantial 
increase.  This effect has not been previously been demonstrated in CRH PVN neurons.  
The effect is not merely due to the stress of injection and handling, as the saline controls 
were treated exactly as the insulin receiving animals, and a significant difference 
between the groups is seen.  The increase in cfos expression in the PVN has been 
previously been reported in rats for non-specific neurons after insulin induced 
hypoglycaemia (Niimi et al., 1995).  In addition, this marker of neuronal activation is lost 
after recurrent episodes of hypoglycaemia (Evans et al., 2001). 
It is not possible to make statements of certainty based on this experiment, with regard 
to what is causing the neuronal activation; the insulin directly, the hypoglycaemia 
directly, or indirect activation related to the overall response of the animal.  In order to 
unpick the mechanism further, insulin injection as part of a normoglycaemic clamp could 
be used to test for a direct effect of insulin.  Alternatively, 2,4 deoxyglucose injected 
intracerebroventricularly could be used to induce CNS hypoglycaemia, which would be 
of interest as the whole animal does not experience hypoglycaemia, and there is no use 
of insulin.  However, this would still not answer the question as to whether the 
hypoglycaemia is directly activating the PVN, or whether activation is occurring via a set 
of pathways in the brain as a whole.  For this, in vitro investigations could prove more 
valuable. 




Interestingly, cfos activation was not observed in the most posterior PVN slices.  This 
was surprising as it was predicted that these autonomic projecting areas might show 
strong activation.  It is possible that activation occurred at sub threshold levels that were 
not detected here, or indeed that these neurons, similarly to VMN neurons (Niimi et al., 
1995), are involved in responses to hypoglycaemia, but do not elevate cfos levels. 
As a control experiment, oxytocin and cfos double immunohistochemistry was 
performed looking for evidence of cfos expression in oxytocin neurons in single 
hypoglycaemia mice as compared to control.  There was no evidence of increased cfos in 
oxytocin neurons after single hypoglycaemia.  Interestingly, one study had previously 
reported increases in cfos in oxytocin neurons in a rat model of insulin induced 
hypoglycaemia (Griffond et al 1994).  However, the effect was only seen in around 18% 
of oxytocin neurons, and no other neuronal subtypes were examined.  The data 
presented here fits more consistently with that reported by Niimi et al. (1995), who 
show an increase in cfos following insulin induced hypoglycaemia in the parvocellular 
part of the PVN, with much less cfos in the magnocellular areas. 
The logical extension to this work would be to seek evidence of a reduction in cfos 
expression in RH mice as compared to SH.  However, it would be preferable to examine 
this in an optimised model of HAAF in mice.  The large number of animals that would be 
required to have sufficient power for an effect to be seen would be difficult to put 
through the current protocol in a consistent fashion.  In addition, the stress of the 
recurrent hypoglycaemia procedure would be a confounding factor which could affect 
the cfos levels seen.  A chronic cannulation model of recurrent hypoglycaemia in mice, 
as described by Jacobson and colleagues (Jacobson et al., 2006a), would be less stressful 
and more reliable in inducing hypoglycaemia.  It is also possible that fewer episodes of 
hypoglycaemia could be sufficient.  Just one prior hypoglycaemic episode was sufficient 
to induce a degree of HAAF in some studies in humans, rats and mice (Jacobson et al., 
2006a, Heller and Cryer, 1991, Kang et al., 2008). 




6.5.5 Effects of recurrent hypoglycaemia on the glucose sensing CRH PVN 
neurons 
Slices from mice exposed to recurrent insulin induced hypoglycaemia as compared to 
saline injected controls showed an expansion of the numbers of GI and GE cells 
observed.  This was counter to the hypothesis.  The expectation was that RH would 
cause glucose sensing neurons to shift their threshold for glucose sensing, such that a 
lower level of glucose was required to elicit the same response.  A left shift in threshold 
of activation would result in a contraction of the numbers of glucose sensing neurons 
observed when exposed to the same low glucose step.  This has previously been 
reported for VMN glucose inhibited neurons (Song and Routh, 2006, Kang et al., 2008).  
The expansion reported here might suggest that these neurons are in fact being 
sensitised to low glucose by the previous exposure to hypoglycaemia, which has not 
previously been reported for a glucose sensing population after recurrent 
hypoglycaemia. 
At this point, the potential outflow of glucose sensing CRH PVN neurons should be 
considered.  The implied result of this finding would be that neurons would increase 
their release of CRH (and/or additional neurotransmitters) after hypoglycaemia in the 
context of recurrent hypoglycaemic episodes, compared to the response to a single 
hypoglycaemic episode.  CRH mRNA levels were found to be raised after recurrent 
hypoglycaemia in previous work by Nina Balthasar (unpublished data).  CRH is 
anorexigenic and raised levels of CRH have previously been implicated in the 
development of HAAF (Flanagan et al., 2003).  The mechanism underlying this is unclear.  
CRH is known to cause hyperglycaemia via a brainstem effect, not dependent on either 
the pituitary or the adrenal medulla (adrenalectomy or hypophysectomy has no effect) 
(Brown et al., 1982).  A further paper infused CRH chronically intracerebroventricularly, 
and showed that the effect of CRH waned over time, suggesting that chronic release of 
CRH causes desensitisation of the responsive neurons (Cunningham et al., 1988).  The 
expansion of the glucose sensitive population, in particular the glucose inhibited 
population after RH, could therefore represent a mechanism by which RH could result in 
increased CRH release, and attenuated autonomic responses, contributing to HAAF.  This 
mechanism could operate either via the pre-autonomic or neurosecretory outflow, but 




previous work suggests that the pre-autonomic pathway is more likely (Brown et al., 
1982, Flanagan et al., 2003). 
With regard to the pre-autonomic CRH PVN population, it is not known what other 
neurotransmitter(s) these cells release.  There is some evidence for a glutamatergic CRH 
PVN population (Zhao et al., 2017, Dabrowska et al., 2013).  This would mean that RH 
results in increased release of glutamate as well as CRH in the brainstem, from synapses, 
which could activate the autonomic areas.  This would not fit so well with a mechanism 
for inducing HAAF, unless inhibitory interneurons were involved.  Other 
neurotransmitters have been described as co-released with CRH from the PVN, 
especially in the context of chronic stress, for example oxytocin and vasopressin 
(Dabrowska et al., 2013). 
6.5.6 Summary 
Overall, this chapter discusses the models used for HAAF, and presents a model of 
insulin induced hypoglycaemia in mice, which has been valuable to show evidence of 
PVH CRH neuronal activation after a single episode of hypoglycaemia.  The challenges in 
extending this model to induce recurrent hypoglycaemia and in particular HAAF in the 
mouse are described.  Finally, the effect of recurrent hypoglycaemia on subsequent 
responses to low glucose in acute slices in vitro is presented, followed by an outline of 
potential mechanisms for how this could contribute to the development of HAAF. 
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Chapter 7 General Discussion 
7.1 Summary of findings and their relevance 
This thesis used the CRH-ires-Cre mouse in combination with floxed reporter mice 
(TdTomato and GCaMP6f) and viral vectors including floxed mCherry to investigate the 
neuroanatomy and glucose responsiveness of CRH PVN neurons.  A summary of the key 
findings with reference to the original hypotheses is presented below. 
7.1.1 CRH PVN neurons make direct connections to autonomic areas of the 
brainstem 
Evidence was presented in chapter 3 that this is indeed the case.  A wide range of 
targets for CRH PVN neuronal projections were identified, with particular regions of 
interest including the NTS, DMX and ventrolateral medulla as well as the lateral PBN, the 
VTA, the PAG and sympathetic preganglionic neurons of the thoracic spinal cord.  
Catecholaminergic, serotoninergic and cholinergic neuronal targets were all identified.  
This represents an important and, in most cases, novel set of targets that may be 
engaged by the CRH PVN neurons in in response to a wide range of stressful stimuli 
including hypoglycaemia.  The known reciprocal connections from many of these areas 
onto the PVN are also interesting, as this creates a direct feedback loop between the 
CRH neurons of the PVN and autonomic outflow areas of the brainstem. 
7.1.2 CRH PVN neurons are glucose sensing 
Chapters 4 and 5 present the first evidence of a novel subset of CRH PVN neurons that 
are directly glucose inhibited, with a mechanism which involves glucose metabolism.  
This is the first evidence that these neurons can sense the glycaemic state of the local 
milieu, in addition to receiving inputs from a wide range of other areas sensing glucose 
both locally (VMN, DMN, ARC, LH, PO) and from more distant sites (NTS, PBN via VMN, 
peripheral glucose sensors via the brainstem).  The wide variety of areas which respond 
to a fall in glucose means that there are multiple levels of redundancy in the system- if 
any one glucose sensor fails, the event will still be detected.  The presence of directly 
glucose sensitive neurons in the CRH PVN group, at the top of the HPA axis, further 
increases the biological security of the response to hypoglycaemia.  In addition, the 
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ability to directly sense glucose could enable CRH PVN neurons to alter their intrinsic 
excitability in the context of the local fuel status in the PVN, and thus modulate the 
likelihood that activation and release of neurotransmitters from CRH PVN neurons to 
cause downstream effects will occur, following integration of the multitude of signals 
being received from elsewhere in the CNS and peripherally. 
7.1.3 CRH PVN neurons are activated by hypoglycaemia 
Cfos expression following insulin induced hypoglycaemia suggested that a much larger 
group of CRH PVN neurons (~84%) were activated in this whole animal model of 
hypoglycaemia.  This matches with previous reports examining cfos in the PVN in rat 
models of hypoglycaemia.  However, when compared to  the numbers of CRH PVN 
neurons activated by low glucose in vitro (~10%) the population activated as evidenced 
by cfos expression is much larger.  The two models are not truly comparable, however.  
In vivo hypoglycaemia induced by insulin was prolonged (75% of animals remained 
hypoglycaemic when perfused after 2.5hours) compared to transient hypoglycaemia in 
vitro (low glucose applied for ~400s at a time).  There is a much greater degree of 
connectivity in vivo, and peripheral sensing mechanisms will also feed into the CNS.  In 
addition, the in vivo model would be expected to activate a wide range of stress 
responses, both signalling via hormones and via neuronal activation of additional stress 
responsive regions.  This would be expected to cause a much broader activation of CRH 
neurons of the PVN over time.  The direct effect of insulin in vivo may also have had an 
impact. 
7.1.4 CRH PVN neurons exhibit altered responses to glucose following exposure 
to recurrent hypoglycaemia 
An expansion of the glucose inhibited PVN CRH population was observed following 
exposure of mice to recurrent episodes of hypoglycaemia, compared to control saline 
injected mice.  Based on previous reports in the literature, it was expected that the 
opposite would be observed.  This finding therefore rejects the initial hypothesis.  
However, given the potential for CRH in itself to cause some elements of HAAF, the 
finding becomes more explicable as discussed in chapter 6, section 6.5.5, leading to the 
generation of a new set of hypotheses.  Overall, the expansion of the CRH PVN GI 
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population after RH could represent a novel mechanism whereby the sympatho-adrenal 
system is downregulated by CRH following recurrent hypoglycaemia, contributing to 
HAAF.  A figure summarising the overall effect of the CRH PVN neurons is presented 
below (Figure 7.1).  




Figure 7.1 Proposed role of CRH PVN neurons in glucose sensing and counterregulatory 
response to hypoglycaemia 
CRH PVN neurons, a subset of which directly sense glucose (indicated by inset dark pink 
box), are able to integrate information from a wide range of glucose sensing cells of 
central and peripheral origin, and respond with alterations of outflow both via the 
pituitary-adrenal axis and via modulation of sympathetic brainstem and spinal cord.  
Recurrent hypoglycaemia expands the number of glucose inhibited neurons, which are 
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7.2 Potential future work 
7.2.1 Improvement to the RH model to generate robust activation of HAAF 
As discussed in chapter 6, the RH model described in this thesis was effective in inducing 
recurrent episodes of hypoglycaemia in mice, with limited evidence of development of 
HAAF.  Further optimisation of this model would be of great value in allowing 
investigation of the role of CRH PVN neurons in HAAF.  Simple alterations could include 
lengthening the time course of the hypoglycaemic events to target one hypoglycaemic 
episode per day for 4 days.  This could also potentially allow administration of an 
increased dose of insulin, which would induce hypoglycaemia more reliably.  Use of 
chronic cannulation could also be explored to examine whether this resulted in more 
reliable hypoglycaemic episodes, and to reduce stress when sampling from animals.  
Finally, blood donation could be considered to allow increased sampling from test 
animals over time.   
7.2.2 Anatomy of CRH PVN neuronal projections to the brainstem 
A number of potential avenues to explore present themselves following on from the 
neuronal tracing work described here.  Firstly, it would be of interest to confirm the 
neurotransmitter expression of the projections.  It has been reported that glutamate is 
the main fast neurotransmitter released from CRH PVN neurons, and that GABA 
transmission is not seen in pre-autonomic PVN neurons.  This could be explored further 
using VGAT and VGLUT antibodies in combination with anterograde tracing to examine 
expression of these transmitter specific transporter proteins at CRH PVN synapses in the 
brainstem.  A second experiment would be to examine whether the neurosecretory CRH 
PVN populations and the pre-autonomic CRH PVN populations are overlapping, or 
segregated.  One way to examine this would be to combine i.v fluorogold to label 
neurosecretory neurons (Markakis and Swanson, 1997, Biag et al., 2012) , and a 
retrograde tracing virus injected into known projection targets in the brainstem (for 
example NTS) and examine for overlap in cell bodies in the PVN. 
Finally, the logical next steps would be to further characterise the CRH PVH pre-
autonomic population functionally to assess their importance and role in responses to 
hypoglycaemia.  This could involve in vitro work examining the responses of pre-labelled 
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pre autonomic CRH neurons to low glucose, in vivo imaging, and indeed functional 
manipulation of the labelled population using opto or pharmacogenetic approaches to 
examine the effect of activation or silencing of this neuronal population on whole animal 
physiology, and in particular the counterregulatory response to hypoglycaemia. 
7.2.3 In vitro investigation of CRH PVN neurons 
The calcium imaging technique using GCaMP6f opens a broad range of possible future 
experiments.  Clearly, further investigation of the mechanisms of glucose sensing in the 
CRH neurons would be of interest, in particular to examine whether AMPK, cGMP and 
CFTRs are implicated in GI neurons.  Identifying the synaptic inputs driving GE responses 
would also be interesting, and potentially could be carried out by altering the plane of 
slicing or dissecting out parts of the hypothalamus with potential inputs and examining 
the effect on glucose sensing.  In addition, as mentioned in section 7.2.2, retrograde 
labelling of pre-autonomic CRH neurons with GCaMP6 could enable calcium imaging in 
this population to seek evidence of glucose sensing. 
A potentially further very interesting experiment would be to simultaneously record in 
cell attached mode from CRH neurons whilst imaging their calcium levels.  This would be 
of help to develop knowledge of how a rapidly firing cell behaves with regard to its 
calcium levels, in particular when neuronal activity is reduced. 
A voltage clamp approach could provide valuable clues to the conductances that are 
being activated or inhibited in response to a low glucose step in vitro, which would aid 
further mechanistic investigation.  The electrophysiological phenotypes of CRH PVN cells 
could also be investigated further.  In particular, a closer examination using patch 
clamping to investigate whether pre-autonomic neurons in mice exhibit similar 
properties to those reported in rats would be of interest.  LTS and rebound spiking after 
hyperpolarising pulses could be examined, to compare to the results reported for rats.  
In addition, the cells which maintain wide based spiking in the presence of TTX could be 
investigated further. 
Chapter 7 General Discussion 
251 
 
7.2.4 In vivo investigation of CRH PVN neurons 
A range of potential in vivo investigations could follow on from the experiments 
presented here.  It would be fascinating to implant a Graded index (GRIN) lens and 
image CRH neurons of the PVN responding to a hypoglycaemic event in vivo, either in an 
anaesthetised or an awake mouse.  This could help to improve understanding of the 
discrepancy between the numbers of neurons observed to be activated after in vitro low 
glucose (~10%) and the activation after IIH (~84%).  Additionally, the effect of 
intracerebroventricular 2-DG could be examined as an alternative method of introducing 
local hypoglycaemia without involvement of insulin. 
A follow up experiment to the description of PVN inactivation using lignocaine causing 
defective counter-regulation (Evans et al., 2003) would be to target CRH neurons 
specifically in the PVN with an inhibitory DREADD via a viral vector.  The effect of 
pharmacogenetically silencing this population on counter-regulation could then be 
examined.   
A much more complex experiment would be to identify and functionally modify the 
responses of the specific GI subset of CRH PVN neurons.  A combination of a viral 
injection of a FRT/Cre dependent DREADD (Sciolino et al., 2016) to the PVN of a 
genetically modified mouse with FLP under the control of the CRH promoter (available 
from JAX,  strain no 031559 Crh-ires-FlpO) and Cre recombinase expressed in a activity 
dependent TRAP (Kawashima et al., 2013), combined with an episode of hypoglycaemia 
could be effective in isolating these neurons in a fashion that would allow their 
subsequent pharmacological reactivation.  See figure 7.2 for a detailed summary of this 
proposed experiment. 
7.3 Is HAAF still a relevant clinical problem in need of a solution? 
Given the recent advances in diabetic care, in particular technological developments 
such as closed loop glucose monitoring and insulin pump technologies, it is reasonable 
to question the relevance of HAAF for diabetic patients now and in the future.  Whilst 
insulin pump technology is becoming more widely used in high income countries 
(generally with manual glucose measurement and adjustment by the patient), it is still 
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by no means the default mode of insulin delivery.  Closed loop systems, which 
automatically adjust insulin infusion in response to glucose measurements, have been 
extensively trialled in research settings (Hovorka et al., 2011, Kumareswaran et al., 2014, 
Thabit et al., 2014), but are only now becoming suitable for use in the home (Elleri et al., 
2011, Hovorka, 2011, Hovorka et al., 2011).  Commercially available systems are now 
entering the market.  The first device to be licensed by the FDA, the MiniMed 670G 
(Medtronic, USA) was approved in 2016.  This device has been reported to perform well 
over short periods (up to 3 months (Garg et al., 2017)) and is currently being trialled for 
home use over 6 months in a multicentre Australian study (de Bock et al., 2018, McAuley 
et al., 2018).  These devices are clearly life changing, in particular in increasing the time 
spent in the target blood glucose range and avoiding hypoglycaemia, whilst reducing the 
time spent by patients managing their condition.  However, patients still need to be 
highly motivated, and in particular to be made aware of how to manage the systems in 
cases where their insulin requirements will change, for example during illness, exercise 
and pregnancy.  Not all diabetic patients would be suitable candidates for such devices 
in the near future. 
The other factor that needs to be taken into account is the epidemiology of diabetes 
worldwide.  The diabetes epidemic shows some early signs of plateauing in the USA 
(Gregg, 2017).  However, diabetes continues to increase in prevalence, especially in low 
and middle income countries (Mathers and Loncar, 2006, Patterson et al., 2009).  
Patients are also living longer with diabetes, which makes it more likely that they will 
need insulin to manage their condition, and be at greater risk of developing HAAF.  
Many of these patients lack access to advanced technologies, even given sufficient 
motivation.  Better understanding of the underlying mechanisms of HAAF, with the 
ultimate aim of developing simple pharmacological methods to prevent it, remains a 
potentially valuable research goal. 
   




Figure 7.2 Potential future experiment to identify CRH PVN neurons which are 
activated by hypoglycaemia in vivo, and to target them functionally to investigate 
their effects on counterregulation. 
A 2 transgenic mouse lines are required, i) CRH FLP0 (Jax stock no 031559, no 
publication, developed by B Sabatini, Harvard Medical School) which expresses FLP 
recombinase enzyme in CRH neurons and ii) Rosa-FRT-Lox-hM3Dq (Sciolino et al., 2016).  
The offspring of this cross will express eGFP in CRH neurons, but hM3Dq will remain 
inverted and will not be expressed  
B Third transgene introduced to PVN alone as a viral (AAV) injection of E-SARE-
ERT2CreERT2 (Matsuda and Cepko, 2007, Kawashima et al., 2013) 
C Tamoxifen administered, followed by insulin induced hypoglycaemia.  Cre 
recombinase will be expressed in neurons activated during the ~2.5 hour time course 
following tamoxifen.   
hM3Dq-mcherry will be expressed in neurons which were activated in the PVN AND 
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